CSL Limited  
Annual Report 2010-2011  
CSL Limited ABN 99 051 588 348  
Annual Report 2010-2011  
Financial Calendar  
2
011  
17 August  
Annual profit and final dividend announcement  
1
9 September Shares traded ex-dividend  
3 September Record date for final dividend  
2
1
4 October  
9 October  
Final dividend paid  
1
Annual General Meeting  
31 December Half year ends  
2
012  
2
2 February  
Half year profit and interim dividend announcement  
Shares traded ex-dividend  
1
4 March  
0 March  
3 April  
2
Record date for interim dividend  
Interim dividend paid  
1
3
2
0 June  
Year ends  
2 August  
Annual profit and final dividend announcement  
1
7 September Shares traded ex-dividend  
1 September Record date for final dividend  
2
1
2 October  
7 October  
Final dividend paid  
1
Annual General Meeting  
31 December Half year ends  
Cover: Marcus de Alwis is a corporate counsel  
for CSL and Daria Kurtov is a CSL research  
scientist at the Bio21 Institute. Both work  
in Parkville, Australia.  
Annual General Meeting  
Share Registry  
Wednesday 19 October 2011 at 10:00am  
Function Centre, National Tennis Centre,  
Melbourne Park, Batman Avenue, Melbourne 3000  
Computershare Investor Services Pty Limited  
Yarra Falls, 452 Johnston Street Abbotsford VIC 3067  
Postal Address: GPO Box 2975 Melbourne VIC 3001  
Enquiries within Australia: 1800 646 882  
Enquiries outside Australia: +61 3 9415 4178  
Investor enquiries facsimile: +61 3 9473 2500  
Website: www.investorcentre.com  
AGM Live Webcast  
The CSL Limited Annual General Meeting will be webcast through  
CSL’s website: www.csl.com.au  
Log on to the Home Page of CSL’s website and then click  
on the item called Annual General Meeting webcast.  
Please see inside back cover for legal notice.  
CSL Limited  
1
Annual Report 2010-2011  
Biotherapies for life  
CSL Limited has over 10,000 staff in more than 20 countries.  
We produce life-saving and life-enhancing medicines that  
enable many thousands of people around the world to  
lead normal healthy lives. Our headquarters is in Australia  
and we have substantial manufacturing operations in the  
US, Germany and Switzerland.  
CSL is a global specialty  
We support patient, biomedical  
and local communities by improving  
access to therapies, enhancing  
patients’ quality of life, advancing  
scientific knowledge, supporting  
future medical researchers, and  
engaging our staff in the support  
of local communities. We also  
biopharmaceutical company that  
researches, develops, manufactures  
and markets biotherapies to treat  
and prevent serious and rare medical  
conditions. We produce safe and  
effective therapies for patients who  
rely on them for their quality of life,  
and sometimes for life itself.  
contribute to humanitarian programs  
and relief efforts around the world.  
Innovation is at the heart of  
everything we do. It is reflected  
in our creation of state-of-the-art  
plasma collection and manufacturing  
facilities, our investment in improving  
current therapies, finding new  
indications for existing therapies,  
and innovating new therapeutic  
products for unmet needs.  
Our continuing priority is to develop  
innovative therapies and programs  
that make a real and lasting  
difference to the lives of people  
who use our products, providing  
new medicines for unmet needs  
and continuous improvement  
of our protein-based therapies.  
To achieve this, we invest in life  
cycle management and market  
development for existing products,  
as well as longer term, new product  
development opportunities.  
Contents  
Year in Review  
Our Company  
Financial Report  
Highlights  
3
4
5
Corporate Responsibility  
Directors’ Profiles  
20  
22  
24  
26  
27  
28  
30  
Directors’ Report  
38  
Financial Results  
Year in Review  
Auditor’s Independence Declaration 63  
Executive Management  
CSL Group Business Operations  
Share Information  
Consolidated Statement of  
Comprehensive Income  
64  
65  
Business Features  
Consolidated Balance Sheet  
CSL Behring  
10  
14  
18  
Consolidated Statement  
of Changes in Equity  
Shareholder Information  
Corporate Governance  
66  
CSL Biotherapies  
Consolidated Cash Flow Statement 67  
Research and Development  
Notes to the Financial Statements  
Directors’ Declaration  
68  
126  
127  
Independent Auditor’s Report  
2
About CSL Limited  
Our Businesses  
CSL Behring  
CSL Biotherapies  
Research and Development  
CSL Behring is a global leader  
in biotherapies with the broadest  
range of quality products in our  
industry and substantial markets  
in the US, Europe and Japan.  
CSL Biotherapies provides  
CSL continues to invest in the  
development of protein-based  
medicines to treat serious human  
illnesses. Today, most of our  
licensed medicines are purified  
from human plasma or made  
from traditional sources.  
In addition, CSL is building  
the capabilities required to  
develop future products using  
recombinant DNA technology.  
plasma fractionation services  
in Melbourne under contracts  
with Australia, New Zealand,  
Hong Kong, Malaysia, Singapore  
and Taiwan. We market  
commercial plasma products  
in Asia (excluding Japan) and  
we develop, manufacture and  
market immunohaematology  
products (diagnostic reagents)  
for Australia and Asia Pacific.  
Our therapies are indicated  
for treatment of coagulation  
disorders including haemophilia  
and von Willebrand disease,  
primary immune deficiencies,  
hereditary angioedema and  
inherited respiratory disease.  
Global research and development  
activities support CSL’s licensed  
product businesses and the  
development of new therapies  
focusing on products that align  
with our technical and commercial  
capabilities in immunoglobulins,  
specialty products, haemophilia  
and coagulation, breakthrough  
therapies and licensing.  
CSL Biotherapies manufactures  
and markets vaccines and  
pharmaceutical products in  
Australia and New Zealand  
and is responsible for global  
sales of our influenza vaccines.  
CSL Behring products are  
also used to prevent haemolytic  
disease in newborns, speed  
recovery from heart surgery,  
prevent infection in people  
undergoing solid organ  
transplants, and help victims  
of shock and burns to  
recover faster.  
MARBURG Germany  
CSL Behring  
R&D and Manufacturing  
HATTERSHEIM Germany  
CSL Behring  
CSL Biotherapies  
KING OF PRUSSIA US  
CSL Behring  
Administration, R&D,  
Sales and Distribution  
Sales and Marketing  
BERN Switzerland  
CSL Behring  
R&D, Manufacturing,  
Sales and Distribution  
SCHWALMSTADT  
Germany  
CSL Plasma  
GOETTINGEN  
Germany  
CSL Plasma  
Testing Laboratory  
TOKYO Japan  
KANKAKEE US  
CSL Behring  
R&D and  
CSL Behring  
R&D, Sales and  
Marketing  
CSL Biotherapies  
Sales and Marketing  
EU Logistics Centre  
Manufacturing  
INDIANAPOLIS US  
CSL Plasma  
Logistics Centre  
KNOXVILLE US  
CSL Plasma  
Testing Laboratory  
BOCA RATON US  
CSL Plasma  
Administration  
MELBOURNE Australia  
CSL Limited  
Group Head Office, R&D  
CSL Biotherapies  
R&D, Manufacturing, Sales,  
Warehousing and Distribution  
Regional Sales and Distribution  
CSL Limited  
Annual Report 2010-2011  
Year in Review  
Highlights  
3
Year in Review  
2010-2011 Highlights  
Dear Shareholder,  
CSL achieved international sales growth for our plasma  
products this year in both established and emerging  
markets and continues to build the capacity to develop  
and produce new and improved therapies.  
>
Net profit after tax was $941 million for the twelve months ended  
0 June 2011. This result has been achieved despite an unfavourable  
CSL Group Sales by Region 2010-11  
3
foreign exchange impact of $116 million. On a constant currency basis¹,  
operational net profit after tax was $1,057 million. CSL’s balance sheet  
remains very strong with $479 million cash on hand against borrowings  
of $416 million. Cash flow from operations was $1,018 million.  
North America 41%  
Europe 32%  
Australia 11%  
Asia 9%  
>
>
Our immunoglobulin portfolio achieved an outstanding result as transitions  
Other 7%  
®
®
®
®
continued to Hizentra from Vivaglobin , and to Privigen from Carimune  
®
and Sandoglobulin . Strong sales in our critical care portfolio came from  
®
fibrinogen products Haemocomplettan and RiaSTAP™, and  
®
from Berinert our C1 esterase inhibitor for hereditary angioedema.  
CSL Group Sales by Major Products 2010-11  
Immunoglobulins 40%  
We continue to invest in manufacturing capacity to meet future demand  
for our products. We have expanded facilities in Bern and received  
approval by the US FDA and European regulatory authorities for our 20%  
Plasma-derived  
coagulants 14%  
®
subcutaneous immunoglobulin Hizentra . In addition, capacity expansion  
has been completed in Marburg for several critical care products and  
a capacity upgrade has been initiated in Kankakee (US) for albumin.  
Helixate 12%  
Albumin 10%  
Other 24%  
®
>
>
We are going to build a 15 million gram capacity Privigen facility at  
our Broadmeadows site in Melbourne. Expected to be in place by 2016,  
the facility will enhance operational integration with CSL Behring to  
maximise single platform efficiencies and support global demand.  
We further progressed development of a family of recombinant  
coagulation therapies to treat bleeding disorders, concluded Phase III  
®
clinical trials for Beriplex to arrest bleeding caused by anti-coagulant  
therapy and completed a Phase I safety study supporting the possible  
use of reconstituted high density lipoprotein, a potential additional  
breakthrough product made from human plasma.  
>
Supporting our research and development activities, new facilities have  
been completed in Marburg for the purification and formulation of  
recombinant products, and construction of a new biotechnology facility  
commenced in Melbourne for late stage development of new therapies  
for cancer, bleeding disorders and inflammation.  
¹
Constant currency removes the impact of exchange rate movements to facilitate comparability  
between 2010-11 and the prior year. For further details see page 4.  
4
Financial Results  
Financial highlights for the year ended 30 June 2011  
Dividends to Shareholders  
On 8 April 2011, shareholders received an interim unfranked  
dividend of 35 cents per share. A final dividend of 45 cents per  
share, franked to 2 cents per share, will be paid on 14 October  
2011. Total ordinary dividends for the year were 80 cents per share.  
(1,2)  
Five Year Summary All figures are in $A million unless stated otherwise  
2
010-11  
2010-11  
2009-10  
Reported  
2008-09  
Reported  
2007-08  
Reported  
2006-07  
Reported  
(1)  
(1)  
(1)  
(1)  
(1)  
Constant  
Reported  
(2)  
Currency  
Total revenue  
4,729  
4,584  
344  
4,322  
4,188  
325  
4,627  
4,456  
317  
5,039  
4,622  
312  
3,803  
3,557  
225  
3,313  
3,172  
191  
Sales revenue  
R&D investment  
Profit before income tax expense  
Net profit  
1,340  
1,057  
1,198  
941  
1,379  
1,053  
265  
1,370  
1,146  
286  
952  
774  
702  
539  
Capital investment  
212  
218  
205  
Total assets at 30 June  
Total equity at 30 June  
Net tangible assets per share at 30 June ($)  
5,068  
3,644  
5.20  
541  
5,711  
4,215  
5.93  
7,367  
5,463  
7.43  
4,695  
2,806  
3.44  
550  
4,200  
2,269  
2.44  
548  
(3)  
(3)  
Weighted average number of shares (million)  
567  
595  
(3)  
Basic earnings per share (cents)  
174.0  
80.0  
185.8  
80.0  
192.5  
70.0  
127.6  
46.0  
98.5  
34.7  
(3)  
Dividend per share (cents)  
(1) The Group’s Reported results are reported in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).  
(2) Constant currency removes the impact of exchange rate movements to facilitate comparability by restating the current year’s results at the prior year’s rates. This is done in two parts: 1) by  
converting the current year net profit of entities in the group that have reporting currencies other than Australian Dollars at the rates that were applicable to the prior year (“translation currency  
effect”) and comparing this with the actual profit of those entities for the current year; and 2) by restating material transactions booked by the group that are impacted by exchange rate  
movements at the rate that would have applied to the transaction if it had occurred in the prior year (“transaction currency effect”) and comparing this with the actual transaction recorded in  
the current year. The sum of translation currency effect and transaction currency effect is the amount by which reported net profit is adjusted to calculate the result at constant currency.  
(3) Restated for the year ended 30 June 2007 following the 3 for 1 share split undertaken on 24 October 2007.  
CSL Limited  
Annual Report 2010-2011  
Year in Review  
010-2011  
5
2
Year in Review  
2010-2011  
Elizabeth  
Alexander, AM  
Brian McNamee, AO  
Chief Executive Officer  
and Managing Director  
Chairman  
Dividends and Financial Results  
CSL Behring  
On 8 April 2011, shareholders received  
an interim unfranked dividend of  
Announced on 18 August 2010,  
CSL’s on-market share buyback  
of up to $900 million has been  
completed through our purchase  
of approximately 26.1 million shares.  
The benefit to shareholders is through  
improved investment return ratios,  
such as earnings per share and  
return on equity.  
Increasing demand for CSL Behring’s  
plasma products underpinned sales  
of $3.5 billion, up 10% in constant  
currency. Strong sales in North America  
were well supported by those in both  
Europe and emerging markets.  
3
5 cents per share. A final dividend of  
5 cents per share, franked to 2 cents  
per share, will be paid on 14 October  
011. Total ordinary dividends for  
4
2
the year were 80 cents per share.  
Immunoglobulin sales increased 25%  
in constant currency as transition  
Net profit after tax was $941 million  
for the twelve months ended  
®
continued from Carimune and  
®
30 June 2011. This result included an  
CSL business activities reported  
on here include CSL Behring, CSL  
Biotherapies and our global research  
and development operations.  
Sandoglobulin to Privigen , and  
®
®
unfavourable foreign exchange impact  
of $116 million. On a constant currency  
basis, operational net profit after tax  
was $1,057 million. CSL’s balance sheet  
remains very strong with $479 million  
cash on hand against borrowings  
of $416 million. Cash flow from  
Vivaglobin to Hizentra . We anticipate  
this trend will continue for our  
immunoglobulin portfolio through  
®
increasing sales of Privigen and rolling  
European launches in the next year of  
®
Hizentra , our 20% immunoglobulin  
for subcutaneous administration.  
operations was $1,018 million.  
In our haemophilia product portfolio,  
we continue to maximise opportunities  
®
for Helixate recombinant factor VIII  
and to develop sales of plasma derived  
®
®
coagulation factors Beriate , Haemate  
®
and Mononine in Russia, Brazil and  
other emerging markets.  
6
Year in Review 2010-2011  
continued  
Key highlights in our critical care  
portfolio included very strong  
sales of our fibrinogen products  
Our Marburg facility has expanded  
capacity for haemophilia and  
management system (paperless) has  
been implemented in all collection  
centres improving both the quality and  
efficiency of operations and enhancing  
the donor experience.  
critical care products in anticipation  
of continued strong demand for  
several products. In November 2010,  
CSL Behring also completed a  
®
Haemocomplettan and RiaSTAP™,  
®
and our Berinert C1 esterase inhibitor  
for hereditary angioedema. The  
strongest contribution for albumin  
sales came from our Asian markets.  
Most CSL Behring products are used  
to treat patients with congenital or  
acquired deficiencies of blood proteins  
in order to mitigate serious and  
state-of-the-art biotechnology  
facility in Marburg for use in the  
production of recombinant coagulation  
therapies in the later stages of our  
research and development pipeline.  
To support the strong demand  
®
®
for Privigen , Hizentra and albumin,  
CSL Behring has invested in capacity  
upgrades in our Bern manufacturing  
facility over a number of years. This  
year, we received US and European  
regulatory approvals for two  
life-threatening medical outcomes,  
and most of these deficiencies are  
rare or orphan conditions. Since there  
are few treatment choices for many  
patients, we work on additional  
indications for our products and seek  
to enter new markets so that more  
patients can enjoy improved well-being  
and more fulfilling lives.  
To meet strong demand for  
immunoglobulin and albumin, CSL  
Plasma has increased collections and  
purchases of plasma to meet our  
projected needs. Favourable market  
conditions for plasma recovered from  
whole blood collections also allowed  
us to increase our purchased volumes.  
Every year, we upgrade and expand  
the capacity of a number of our  
existing plasma collection centres.  
In addition to these ongoing  
manufacturing modules which will  
enable us to satisfy demand for a  
number of years. Further capacity  
upgrades in Bern, Kankakee and  
Melbourne manufacturing facilities  
have been initiated to meet prospective  
demand in the second half of  
CSL Behring’s broad product range,  
commercial presence, plasma supply  
and manufacturing infrastructure  
ensure that we remain well placed to  
meet increasing demand. Prospective  
product development activities in our  
research and development portfolio  
enhance this potential.  
this decade. Through operational  
integration with CSL Behring, the  
upgrades, we will open two new  
centres in Florida in the second half  
of 2011. CSL Plasma’s new electronic  
®
new Privigen facility in Melbourne is  
expected to maximise single platform  
efficiencies in such areas as information  
technology systems, product  
dossier management and product  
development programs.  
Treatment for a rare disease  
In May 2011, the National Organization  
for Rare Disorders (NORD) presented  
CSL Behring with a corporate award  
for developing Corifact™ and bringing  
this unique product to the US market.  
The first and only factor XIII approved  
in the US, Corifact™ is for treatment  
of congenital factor XIII deficiency, a  
rare and potentially life-threatening  
bleeding disorder.  
Shown here with the NORD award is  
CSL Behring President, Paul Perreault.  
Representing the teams instrumental  
in bringing Corifact™ to market are  
Marie DiFiore (left) from Marketing  
and Dr Antionette Mangione from  
Clinical R&D.  
CSL Limited  
Annual Report 2010-2011  
Year in Review  
010-2011  
7
2
CSL Biotherapies  
®
CSL Biotherapies delivered sales of  
BIOSTATE 1000 IU is formulated to  
Progress has been made towards  
the close-out of compliance issues  
at CSL Biotherapies’ Parkville site  
following receipt of the FDA’s Warning  
Letter. CSL Biotherapies submitted a  
comprehensive response to the letter  
and met with the FDA to discuss the  
response in detail. Corrective actions  
continue to be implemented in close  
consultation with the FDA. The  
TGA has been closely involved with  
this process, ensuring our approach  
is consistent with Australian  
$735 million this year, a good result  
twice the concentration of the smaller  
(500 and 250 IU) presentations to allow  
dosing in half the infusion volume and  
preparation of fewer vials.  
after taking into account the one-off  
contribution of $235 million from  
pandemic influenza vaccine sales  
in the previous year.  
This year, we manufactured Factor  
VIII/von Willebrand concentrate from  
source plasma (collected by CSL Plasma)  
for supply to commercial markets in  
Asia and South America. Expansion  
of product registrations in Europe  
and other markets will provide strong  
opportunities for future sales.  
CSL Biotherapies is the leading supplier  
of plasma fractionation services and  
plasma-derived products in the Asia  
Pacific region. We continue to expand  
our fractionation capacity to ensure we  
remain positioned to meet demand for  
our plasma fractionation services.  
regulatory requirements.  
As mentioned above, a new  
Demand for our plasma fractionation  
services remains strong and this year  
we renewed our manufacturing  
agreement with the New Zealand  
Blood Service. We also continued to  
provide plasma fractionation services  
from our Broadmeadows facility to  
Hong Kong, Malaysia, Singapore  
and Taiwan.  
The FDA and European regulators  
have approved CSL Biotherapies  
annual strain update and the release  
of CSL Biotherapies seasonal influenza  
vaccine for the 2011-2012 Northern  
Hemisphere influenza season.  
®
Privigen manufacturing facility at  
Broadmeadows in Melbourne was  
approved with the aim of enhancing  
efficiency through operational  
integration with CSL Behring’s global  
plasma products business  
and supporting global demand.  
Our in-licensing business includes  
vaccines and a range of pharmaceutical  
products for distribution in Australia  
and New Zealand. We successfully  
launched Vesicare* for overactive  
bladder treatment following the  
Advancing our immunoglobulin  
®
product portfolio, INTRAGAM 10 NF,  
Our Asian business again grew well  
underpinned by demand for albumin  
in China and by relationships built with  
distributors in the Asian region for  
plasma-derived therapies.  
our high yielding chromatographically  
purified 10% intravenous  
immunoglobulin was approved by the  
Therapeutic Goods Administration  
transfer of distribution rights to CSL in  
February 2011. We also entered into  
distribution agreements with Crucell  
and Novartis for two new vaccines.  
(
TGA) and is under review by the New  
In addition to our ongoing  
Zealand Medicines and Medical Devices  
commitment to Australia, we have  
continued with global plans to  
expand our influenza vaccine market.  
Commercial partners have achieved  
substantial sales in the US, Europe,  
Asia and Latin American countries.  
Safety Authority (MedSafe) for a broad  
®
range of indications. EVOGAM , our  
Australia’s TGA approved registration  
of GARDASIL* for immunisation  
of males aged 9 to 26 years for  
high yielding chromatographically  
purified 16% subcutaneous product,  
is under review in Australia and  
New Zealand.  
prevention of external genital lesions.  
Merck & Co. Inc. remains our exclusive  
licensee for GARDASIL* vaccine with  
global marketing rights. CSL retains  
distribution rights for Australia and  
New Zealand and receives royalties  
from global sales. In the current year,  
CSL received $83 million in royalties  
from international sales of human  
papillomavirus vaccines.  
During the period, CSL Biotherapies  
received a Warning Letter from the  
US Food and Drug Administration  
Following registration by both the  
TGA and MedSafe, we commenced  
manufacture of a 1000 IU presentation  
(
FDA) following an inspection of its  
®
of BIOSTATE , our Factor VIII/von  
influenza vaccine manufacturing  
facilities, processes and procedures  
at the Parkville, Australia site in  
March 2011.  
Willebrand factor concentrate. We have  
®
launched BIOSTATE 1000 IU in New  
Zealand, and will launch it in Australia  
early in 2012.  
*
*
GARDASIL is a trademark of Merck & Co. Inc.  
Vesicare is a trademark of licensor Astellas Pharma Europe  
8
Year in Review 2010-2011  
continued  
In November last year, Professor  
John Shine, AO, received the 2010  
Prime Minister’s Prize for Science,  
Australia’s highest honour for scientific  
achievement. Among his many career  
highlights, John is perhaps best known  
for discovering the importance of a  
sequence of genetic code now known as  
the Shine-Dalgarno sequence. John also  
developed sophisticated gene cloning  
techniques that helped revolutionise  
the world of biotechnology.  
Professor Shine has been on CSL’s Board  
since June 2006 and recently shared  
highlights of his career with scientists  
at our Parkville site. Shown here with  
John are CEO and Managing Director,  
Dr Brian McNamee, AO, and Chief  
Scientist, Dr Andrew Cuthbertson,  
who both attended the presentation.  
Research and Development  
Global research and development  
activities support CSL’s licensed product  
businesses and the development of  
new therapies focusing on products  
that align with our technical  
RiaSTAP™ (human fibrinogen) was  
approved in Europe and Corifact™  
(human factor XIII concentrate) in  
the US for the treatment of patients  
with congenital deficiencies of these  
coagulation factors.  
We completed Phase III clinical trials  
®
for Beriplex to arrest bleeding caused  
by anti-coagulant therapy and expect  
to submit a Biological License  
Application (BLA) to the US FDA  
by the end of 2011.  
and commercial capabilities in  
immunoglobulins, specialty products,  
haemophilia and coagulation,  
Investment in new therapies continued  
with a key focus the development of  
a family of recombinant coagulation  
therapies to treat haemophilia and  
other coagulation disorders. These  
therapies include the extended half-  
life albumin fusion proteins rIX-FP  
(recombinant fusion protein linking  
coagulation factor IX with albumin),  
rVIIa-FP (recombinant fusion protein  
linking coagulation factor VIIa with  
albumin), and a unique single-chain  
rFVIII. Important milestones in the  
past year included commencement  
of clinical trials of rIX-FP and completion  
of preclinical studies to support  
the development of rVIIa-FP  
Developing our capability to take  
recombinant products into the clinic  
and ultimately to patients, construction  
is now well under way of a new state-  
of-the-art biotechnology facility at  
our Broadmeadows site in Melbourne  
(see feature on page 18).  
breakthrough therapies and licensing.  
Achieving licenses for therapies in  
major regulatory jurisdictions is a  
critical objective of our research and  
development programs. During the  
®
year Hizentra , our 20% subcutaneous  
A priority for CSL’s R&D program is  
the development of reconstituted high  
density lipoprotein (rHDL), a potential  
additional breakthrough product  
made from human plasma. We have  
recently completed a Phase I safety  
study supporting possible use in acute  
coronary syndrome.  
immunoglobulin product, was  
approved by the European Commission  
for treating patients in Europe  
diagnosed with Primary Immune  
Deficiency or Secondary Immune  
Deficiency. This follows the approval  
®
of Hizentra by the US Food and Drug  
Administration in March 2010.  
and rFVIII products.  
CSL Limited  
Annual Report 2010-2011  
Year in Review  
010-2011  
9
2
Research and Development Strategy  
Breakthrough  
medicines  
Maintain commitment to  
extracting maximum value  
from existing assets and  
supporting and improving  
current products  
Specialty  
Products  
Immunoglobulins  
Develop new protein-based  
therapies for treating serious  
illnesses focusing on products  
that align with our technical  
and commercial capabilities  
Haemophilia  
Products  
Our Thanks to  
Management and Staff  
During the year our partners  
Investment in research and  
Our commitment to saving lives and  
continued to show confidence in CSL’s  
development remains an important  
improving the quality of life for people  
with serious and rare conditions underpins  
everything we do from developing new and  
improved therapies to their production and  
worldwide distribution, and to the support  
we provide to assist patient communities.  
®
ISCOMATRIX adjuvant as a technology driver for CSL’s future growth. We  
platform that could be used to enable  
now have a high quality and potentially  
the next generation of prophylactic and valuable portfolio of projects in various  
therapeutic vaccines. Additional licenses stages of development. We continue  
have been obtained by our major  
partners covering more than thirty  
fields of interest for research and  
product development.  
to make a balanced investment in the  
life cycle management and market  
development of existing products that  
bring short to mid-term commercial  
benefits, and we make strategic  
investments in longer term, higher  
risk and high opportunity new  
Your Board of Directors understands  
and appreciates the work done by our  
management and staff throughout the  
world to ensure that we deliver on our  
commitment through high operational  
standards and strong business performance.  
Because of the complexity of CSL’s  
biological products we regularly  
undertake research activities as part  
of our commitment as a supplier of safe  
and efficacious products. One example  
which arose in the past year was the  
development and rapid implementation  
of an extensive research program to  
identify the cause of reported febrile  
events associated with influenza  
product development activities.  
Elizabeth Alexander, AM  
Chairman  
vaccine in paediatric patients.  
Investigations are ongoing but the  
preliminary results of this research have  
been communicated to public health  
officials and regulatory agencies.  
Brian McNamee, AO  
Chief Executive Officer  
and Managing Director  
10  
Business Feature  
CSL Behring  
CSL Behring is committed to saving lives and improving  
the quality of life for patients with rare and serious diseases.  
Our product supply capacity, extensive  
research and development activities  
and patient support services are key  
elements in an ongoing commitment  
to people whose lives depend on  
our products. We deliver on our  
commitment with new therapies  
for unmet needs and through  
patient groups and stakeholders  
around the world to advocate for  
patient access to care.  
therapies, cost effective, high yield  
manufacturing processes and  
efficient operations.  
Our therapies are indicated for  
treatment of bleeding disorders  
including haemophilia and von  
Willebrand disease, primary immune  
deficiencies, hereditary angioedema  
and inherited respiratory disease.  
CSL Behring products are also used  
to prevent haemolytic diseases in  
newborns, speed recovery from heart  
surgery, prevent infection in people  
undergoing solid organ transplants,  
and help victims of shock and burns  
to recover faster.  
CSL Behring produces high quality  
products in our state-of-the-art  
facilities using the most sophisticated  
methods available. Because patient  
safety is our first priority, we closely  
monitor every aspect of the  
improvements to help patients  
lead more normal lives.  
manufacturing process.  
We listen carefully to the concerns  
of people with rare, life-threatening  
disorders and work to address  
A global leader in biotherapies  
with substantial markets in the US,  
Europe and Japan, we offer the  
broadest range of quality products  
in our industry.  
their needs. By providing safe and  
effective products and services, we  
help patients to improve their quality  
of life. We continue to develop  
programs and provide educational  
tools that help patients and families  
manage the daily challenges of living  
with chronic conditions. CSL Behring  
is committed to collaboration with  
Headquartered in the US at King of  
Prussia in Pennsylvania, CSL Behring  
operates manufacturing plants  
CSL Behring is well positioned to  
develop its biotherapeutics business  
with a broad portfolio of quality  
products, global marketing that meets  
customer needs, an ongoing pipeline  
of new and improved plasma  
in Kankakee, Illinois (US), Bern in  
Switzerland and Marburg in Germany.  
Regional sales and distribution centres  
are located throughout the world.  
Now able to lead more normal lives  
®
Stacey Monden and her sons  
Gary and Gage are able to lead  
more normal lives since they  
began receiving Privigen®  
treatments in February this  
year for Common Variable  
Immunodeficiency (CVID),  
which is characterised by low  
levels of serum immunoglobulins  
“Privigen allows us to go out  
and enjoy everyday activities  
like everyone else,” says Stacey.  
“We used to go shopping at  
1:00am to avoid excessive  
exposure to people and their  
germs. This therapy allows me to  
be a mum and do things with my  
children that were not possible  
before. Now we can go to the  
mall, church, sporting events,  
movies, and be involved in  
community activities.”  
(antibodies) and increased  
susceptibility to infections.  
CSL Limited  
Annual Report 2010-2011  
Business Feature  
CSL Behring  
11  
Major products marketed by CSL Behring  
HAEMOꢀHꢁLꢁA ANꢂ OꢃHER  
COAꢄꢅLAꢃꢁON ꢂꢁSORꢂERS  
CRꢁꢃꢁCAL CARE  
CONꢂꢁꢃꢁONS  
ꢁMMꢅNE ꢂꢁSORꢂERS  
ANꢂ ꢁMMꢅNE ꢃHERAꢀY  
Coagulation therapies are used to treat  
bleeding disorders such as haemophilia  
and von Willebrand disease.  
Critical care products are used to treat  
shock, sepsis and severe burns, hereditary  
angioedema and haemostasis disorders  
and are used in cardiac surgery.  
Immunoglobulins are used to treat and  
prevent infections, to treat autoimmune  
diseases and to prevent haemolytic  
disease in the newborn.  
Plasma-derived Factor VIII  
and von Willebrand Factor  
Haemostasis Disorders  
Polyvalent Immunoglobulins  
®
®
•ꢀ Privigen®  
•ꢀ Carimune NF  
•ꢀ Sandoglobulin  
•ꢀ Sanglopor  
•ꢀ Beriate ꢀ  
•ꢀ Beriplex ꢀ/N  
®
®
®
•ꢀ MonoclateꢀP  
•ꢀ HumateꢀP  
•ꢀ HaemateꢀP  
•ꢀ Confidex  
®
®
®
•ꢀ Haemocomplettan ꢀ  
®
®
®
•ꢀ Kybernin ꢀ  
•ꢀ RiaSTAP™  
Recombinant Factor VIII  
Subcutaneous Immunoglobulins  
®
Trauma Therapies  
•ꢀ Hizentra®  
®
•ꢀ Vivaglobin  
•ꢀ Helixate FS  
®
•ꢀ Albuminar®  
•ꢀ HumanꢀAlbuminꢀBehringꢀ  
•ꢀ Helixate Nexꢄen  
Plasma-derived Factor IX  
®
Specific Immunoglobulins  
•ꢀ Humanalbin  
®
®
®
•ꢀ Berinin ꢀ  
•ꢀ Mononine  
•ꢀ AlbuRx  
•ꢀ Beriglobin ꢀ  
®
®
•ꢀ Berirab ꢀ  
Other Critical Care  
•ꢀ HepatitisꢀBꢀ  
ꢁmmunoglobulin ꢀ Behring  
Plasma-derived Factor X  
•ꢀ FactorꢀXꢀPꢀBehring  
•ꢀ Berinert®  
•ꢀ Streptase  
®
®
•ꢀ Rhophylac  
®
•ꢀ Tetagam ꢀ  
®
Plasma-derived Factor XIII  
•ꢀ Corifact™  
ꢀ Fibrogammin ꢀ  
WOꢅNꢂ HEALꢁNꢄ  
•ꢀ Varicellon ꢀ  
®
•ꢀ Cytogam  
Wound healing therapies are used  
to facilitate healing.  
®
ALꢀHA 1-ꢀROꢃEꢁNASE  
ꢁNHꢁBꢁꢃOR ꢂEFꢁCꢁENCY  
®
•ꢀ Beriplast ꢀ  
Other Products  
•ꢀ Stimate®  
•ꢀ Octostim*  
•ꢀ CombiSet  
•ꢀ Fibrogammin ꢀ  
•ꢀ Tachocomb*  
For people at risk from life-shortening  
emphysema through a genetic deficiency  
in their synthesis of this protein.  
®
•ꢀ Zemaira®  
*
*
Octostim is a trademark of Ferring GmbH  
Tachocomb is a trademark of Nycomed.  
Forꢀmoreꢀinformationꢀaboutꢀtheseꢀproducts,ꢀseeꢀwww.cslbehring.com  
12  
Business Feature  
CSL Behring continued  
Capacity increased to meet strong patient demand  
In April 2011, the US Food and  
Drug Administration (FDA) granted  
of primary immune deficiency and  
chronic immune thrombocytopenic  
purpura.  
®
approval for expanded Privigen  
®
and Hizentra facilities at our  
®
Hizentra is a 20% liquid  
Bern manufacturing plant.  
immunoglobulin for subcutaneous  
administration for the treatment  
of primary immune deficiency.  
As a result, we have now increased  
the production capacity available  
to meet the growing demand for  
these immunoglobulin products.  
The US demand, European  
authorisation and our increased  
production capacity will enable us  
to serve a wider range of patients  
with these therapies.  
®
Privigen is a 10% liquid  
immunoglobulin for intravenous  
administration for the treatment  
®
Andreas von Gunten in the Hizentra facility.  
New plant for recombinants  
In November 2010, Marburg unveiled  
a new state-of-the-art production  
plant for the purification and  
formulation of recombinant proteins.  
Shown inside the new Marburg  
facility (left to right) are Mario Fischer  
(Deputy Operations Manager), Daniel  
Brigulla (Team Leader), Dr Wilfried  
Freudenberg (Department Head,  
Albumin and Immunoglobulins  
Production) and Dr Klaus-Jûrgen  
Schlitt (Operations Manager).  
Patient and CSL Behring employee  
As an engineering work planner  
at CSL Behring’s manufacturing  
facility in Marburg, Germany,  
Jens Burk knows first-hand the  
importance of his daily efforts  
because he has been managing  
a bleeding disorder throughout  
his life.  
“Easy and convenient, this  
treatment is part of my routine,  
and using a therapy my company  
provides gives me a feeling of  
pride, trust and security,” says Jens.  
My mum and dad were always  
there for me and helped educate  
me about haemophilia but they  
were not overprotective and I  
really appreciate that they allowed  
me to lead a normal life.”  
Since Jens was diagnosed with  
haemophilia A in early childhood,  
he has been treating his condition  
with factor VIII replacement  
therapy. Currently, he manages  
the disorder by self-infusing  
Helixate® NexGen three times  
a week.  
Jens remains active when not  
at work, spending time with his  
family, fishing and playing games  
on his computer.  
CSL Limited  
Annual Report 2010-2011  
Business Feature  
CSL Behring  
13  
Franziska Dahlke takes care of  
a donor at our new CSL Plasma  
collection centre in Goettingen.  
Located in the inner city’s largest  
shopping mall, the centre has 24  
beds and includes operational  
efficiencies to better serve our  
plasma donors.  
The CSL Plasma laboratory in  
Goettingen has new testing  
machines and is designed to  
meet current and future testing  
requirements for our German  
plasma collection centres.  
US STATES AND GERMAN CITIES WITH CSL PLASMA COLLECTION CENTRES  
CSL Plasma  
CSL Behring’s plasma collection  
business, CSL Plasma, has collection  
centres throughout the US and  
Germany, along with plasma testing  
laboratories and logistics centres in  
both countries.  
Millions of donations every year  
provide the plasma used to produce  
life-saving products for critically ill  
patients. CSL Plasma offers a reliable  
and secure source of plasma for those  
essential medications.  
CSL Plasma has its headquarters in  
Boca Raton, Florida (US), a logistics  
centre in Indianapolis, Indiana (US),  
and a plasma-testing laboratory  
in Knoxville, Tennessee (US). Our  
German operations include a plasma-  
testing laboratory in Goettingen and  
a logistics centre in Schwalmstadt.  
ꢅS Headquarters  
Boca Raton, Florida  
ꢅS ꢃesting Laboratory  
Knoxville, Tennessee  
In this stringently regulated industry,  
CSL Behring and CSL Plasma meet  
or exceed international standards,  
use the most sophisticated systems,  
and continue to explore avenues  
of innovation.  
ꢅS Logistics Centre  
Indianapolis, Indiana  
Eꢅ Headquarters  
Marburg, Germany  
Eꢅ ꢃesting Laboratory  
Goettingen, Germany  
Eꢅ Logistics Centre  
Schwalmstadt, Germany  
14  
Business Feature  
CSL Biotherapies  
CSL Biotherapies is committed to serving the health needs of  
patients by providing innovative medicines to treat and prevent a  
range of serious human medical conditions.  
Our unique role includes:  
From our manufacturing facility  
at Broadmeadows in Melbourne  
saved the lives of many children and  
adults by neutralising toxins in the  
bites and stings of Australia’s most  
venomous creatures.  
•ꢀ  
ꢀT heꢀmanufactureꢀofꢀplasma-  
derived therapies under  
(Australia), CSL Biotherapies provides  
plasma fractionation services under  
contracts with Australia’s National  
Blood Authority (NBA), and with the  
Governments or Blood Services of  
New Zealand, Hong Kong, Malaysia,  
Singapore and Taiwan.  
contract for six countries in  
Asia Pacific, and for commercial  
sale in international markets;  
At our Broadmeadows site, we have  
®
a dedicated Q-Vax manufacturing  
®
facility. Q-Vax protects against  
ꢀT heꢀmanufactureꢀandꢀglobalꢀ  
sales of seasonal and pandemic  
influenza vaccines;  
Q-Fever, an occupational disease  
of people working in the meat and  
livestock industry, and is supplied  
under contract to the Australian  
Government.  
CSL Biotherapies’ immunohaematology  
business develops, manufactures  
and distributes diagnostic reagents  
in Australia under contract with the  
NBA and in Asia under commercial  
arrangements with several countries.  
ꢀT heꢀdevelopment,ꢀmanufacture,ꢀ  
marketing and distribution of  
immunohaematology products  
CSL Biotherapies’ plasma-derived  
therapies, immunohaematology  
products, seasonal and pandemic  
influenza vaccines, antivenoms  
(diagnostic reagents) in  
Australia and Asia Pacific;  
•ꢀ  
•ꢀ  
•ꢀ  
ꢀT heꢀmanufactureꢀandꢀ  
distribution of antivenoms  
in Australia and Papua  
New Guinea;  
The CSL Biotherapies Asia head office  
in Hong Kong provides local support to  
our longstanding plasma fractionation  
customers in the region. The Hong  
Kong office also supports the sale and  
distribution of commercial plasma-  
derived therapies manufactured by  
CSL Behring at its facilities located in  
Bern (Switzerland), Marburg (Germany)  
and Kankakee (US), and by CSL  
®
and Q-Fever vaccine underpin our  
ongoing commitment to ensuring that  
Australians have access to products of  
national significance.  
ꢀT heꢀmarketingꢀandꢀdistributionꢀ  
of in-licensed vaccines and  
Our vaccine and pharmaceutical  
product in-licensing business based  
at Parkville provides vaccines and  
pharmaceuticals for distribution in  
Australia and New Zealand. This  
allows CSL Biotherapies to offer a  
broad portfolio of vaccines against  
life threatening infections, and  
pharmaceutical products to treat  
serious medical conditions.  
pharmaceutical products in  
Australia and New Zealand; and  
ꢀA ustralia-wide,ꢀcoldꢀchainꢀ  
distribution services.  
Biotherapies at Broadmeadows  
in Melbourne (Australia).  
Our presence in the People’s Republic  
of China has increased considerably in  
recent years. CSL Biotherapies is the  
leading supplier of albumin in China  
where we now have more than sixty  
staff supporting sales, and offices  
in Shanghai, Guangzhou, Wuhan,  
Chengdu and Beijing.  
In Australia, we provide cold chain  
distribution services through which  
we distribute our plasma-derived  
therapies, immunohaematology  
products, antivenoms, vaccines and  
pharmaceutical products. Leveraging  
the resources and expertise of this  
part of our Australian operation,  
we also offer a national third party  
distribution service under commercial  
arrangements with Australia’s State  
Governments and international  
pharmaceutical companies  
At our manufacturing site at Parkville  
in Melbourne, we manufacture  
seasonal and (as required) pandemic  
influenza vaccines for Australia and  
international markets including the  
US, Europe, Asia and Latin America.  
At Parkville, we also manufacture a  
portfolio of antivenoms that have  
based offshore.  
CSL Limited  
Annual Report 2010-2011  
Business Feature  
CSL Biotherapies  
15  
Plasma fractionation  
specialist, Ryan D’Sousa,  
inspects new state-of-the-art  
chromatography columns  
commissioned this year  
at CSL’s Broadmeadows  
facility in Melbourne. They  
offer double the processing  
capacity of existing columns.  
®
INTRAGAM 10 NF will be  
produced in this facility.  
More convenience  
for patients  
Australia’s HPV vaccination program  
making an impact  
Two new immunoglobulin products that  
have been developed by CSL Biotherapies  
will deliver more convenient treatment  
options for patients.  
The broad scope of Australia’s  
National Human Papillomavirus  
(HPV) Vaccination Program  
In another study, Brotherton et al  
(2011) compared the incidence  
of cervical abnormalities reported  
to the Victorian Cervical Cytology  
Registry before and after the  
vaccination program began. After  
the introduction of the program,  
a reduction in high grade cervical  
abnormalities was observed in  
females less than 18 years. The  
authors note that although  
(females aged 12-26 years) and  
the high uptake of GARDASIL*  
have resulted in Australia being  
the first country to demonstrate  
an impact of an HPV vaccination  
program at a population level.  
Post vaccination program  
®
INTRAGAM 10 NF (developed as an  
®
enhancement to 6% INTRAGAM P) is a  
high-yielding chromatographically purified  
10% intravenous immunoglobulin in a  
higher concentration and smaller volume  
that will reduce the treatment time for  
®
commencement, a significant  
reduction in diagnoses of genital  
warts in females of vaccine eligible  
age was reported by Donovan et  
al (Lancet 2010).  
patients. EVOGAM is a high-yielding  
the study is ecological in nature,  
the observed reductions are likely  
attributable to the impact of the  
vaccination program.  
chromatographically purified 16%  
subcutaneous immunoglobulin suitable  
for self administration by patients at home.  
®
In December 2010, INTRAGAM 10 NF was  
approved by Australia’s Therapeutic Goods  
Administration (TGA) and the regulatory  
dossier is being reviewed by the Medicines  
and Medical Devices Safety Authority  
®
(MedSafe) in New Zealand. The EVOGAM  
regulatory dossier is being reviewed by  
both the TGA and MedSafe.  
The manufacturing facilities required  
for both of these products are in place  
at our Broadmeadows site in Melbourne.  
*GARDASIL is a trademark of Merck & Co. Inc.  
16  
Business Feature  
CSL Biotherapies continued  
Major plasma-derived therapies and diagnostic products manufactured by CSL Biotherapies  
HAEMOꢀHꢁLꢁA ANꢂ OꢃHER  
COAꢄꢅLAꢃꢁON ꢂꢁSORꢂERS  
ꢁMMꢅNE ꢂꢁSORꢂERS  
ANꢂ ꢁMMꢅNE ꢃHERAꢀY  
ꢂꢁAꢄNOSꢃꢁC  
ꢀROꢂꢅCꢃS  
Coagulation therapies are used to treat  
bleeding disorders such as haemophilia and  
von Willebrand disease.  
Immunoglobulins are used to treat  
immunodeficiency, modify the function  
of the immune system, and for protection  
against specific infections.  
Diagnostic products are used in the  
testing of blood to prevent haemolytic  
transfusion reactions and haemolytic  
disease of the foetus and newborn,  
and for snake venom detection.  
•ꢀ BꢁOSꢃAꢃE®  
human coagulation factor VIII/von  
®
(
•ꢀ ꢁNꢃRAꢄAM ꢀ  
(6g liquid intravenous  
immunoglobulin)  
Willbrand Factor Concentrate)  
•ꢀ Reagent Red Blood Cells  
•ꢀ Monoclonal Reagents  
•ꢀ Supplementary Reagents  
®
•ꢀ MonoFIX -VF  
(
human coagulation factor IX)  
•ꢀ NormalꢀImmunoglobulin-VFꢀꢀ  
(human normal immunoglobulin)  
®
•ꢀ PROTHROMBINEX -VF  
(human prothrombin complex)  
•ꢀ Rh(D)ꢀImmunoglobulin-VF  
human Rh (D) immunoglobulin)  
•ꢀ SnakeꢀVenomꢀDetectionꢀProducts  
Used to detect venom in snakebite  
victims and indicate the appropriate  
monovalent antivenom for treatment.  
(
•ꢀ CMVꢀImmunoglobulin-VF  
human cytomegalovirus  
CRꢁꢃꢁCAL CARE CONꢂꢁꢃꢁONS  
(
immunoglobulin)  
Critical care products are used in fluid  
resuscitation, for replacement of albumin,  
and to treat specific factor deficiencies.  
•ꢀ HepatitisꢀBꢀImmunoglobulin-VF  
(human hepatitis B immunoglobulin)  
•ꢀ ALBUMEX®  
human albumin)  
•ꢀ ZosterꢀImmunoglobulin-VF  
human zoster immunoglobulin)  
(
(
®
•ꢀ ꢃHROMBOꢃROL -VF  
•ꢀ TetanusꢀImmunoglobulin-VFꢀ  
human tetanus immunoglobulin)  
(human antithrombin III)  
(
®
RHOꢀHYLAC  
Special Access Scheme  
ꢃoll Fractionation  
®
Rhophylac (human Rh (D) immunoglobulin  
Under Australia’s Special Access Scheme,  
CSL Biotherapies distributes several life-  
saving, plasma-derived therapies for the  
treatment of rare conditions.  
CSL Biotherapies performs plasma  
fractionation for Australia’s National Blood  
Authority, a role pivotal to Australia’s policy  
of self-sufficiency. CSL Biotherapies is also  
the national plasma fractionator of New  
Zealand, Hong Kong, Malaysia, Singapore  
and Taiwan.  
for IV use) is manufactured by CSL  
Behring and distributed in Australia by CSL  
Biotherapies.  
®
RiaSꢃAꢀ  
®
RiaSTAP (fibrinogen concentrate) is  
manufactured by CSL Behring and  
distributed in Australia by CSL Biotherapies.  
BERꢁNER®  
®
Berinert (C1 esterase inhibitor) is  
manufactured by CSL Behring and  
distributed in Australia by CSL Biotherapies.  
CSL Limited  
Annual Report 2010-2011  
Business Feature  
CSL Biotherapies  
17  
Major vaccines and pharmaceutical products marketed by CSL Biotherapies in Australia  
VACCINESꢀ  
FORꢀPREVENTIONꢀOF:  
PHARMACEUTICALSꢀ FORꢀTREATMENTꢀOF:  
•ꢀ Fluvax®  
Influenza  
•ꢀ Advantan*  
•ꢀ Angiomax*ꢀ  
Eczema and psoriasis  
®
P atients undergoing percutaneous  
coronary intervention (PCI).  
•ꢀ Aꢂꢃ Booster  
Diphtheria and Tetanus  
Q-Fever  
•ꢀ Q-Vax®  
•ꢀ Antivenoms  
•ꢀ Benꢀen®  
Envenomation  
Bacterial infections  
Oedema  
•ꢀ Comvax*ꢀ  
H aemophilus influenzae B  
and Hepatitis B infection  
•ꢀ Burinex*ꢀ  
•ꢀ Cervidil*ꢀ  
•ꢀ GARDASIL*ꢀ  
•ꢀ H-B-Vax*ꢀIIꢀ  
•ꢀ JESPECT*ꢀ  
•ꢀ Menjugate*ꢀ  
•ꢀ Menveo*ꢀ  
•ꢀ M-M-R*IIꢀ  
•ꢀ ꢀanvax®  
Cervical cancer and genital warts  
Hepatitis B infection  
C omplications during childbirth  
requiring induced labour  
Japanese encephalitis  
Meningococcal C disease  
Meningicoccal (A,C W-135,Y)  
Measles, mumps and rubella  
Pandemic influenza  
•ꢀ Daivobet*ꢀ  
•ꢀ Daivonex*ꢀ  
•ꢀ Finacea*ꢀ  
Psoriasis  
Psoriasis  
Rosacea  
•ꢀ Flomaxtra*ꢀ  
•ꢀ Fucidin*ꢀ  
Benign prostatic hyperplasia  
Bacterial infections  
•ꢀ Modavigil*ꢀ  
E xcessive daytime sleepiness in  
narcolepsy  
•ꢀ PedvaxHIB*ꢀ  
•ꢀ Pneumovaxꢀ23*ꢀ  
•ꢀ Rabipur*ꢀ  
Haemophilus influenzae B  
Pneumococcal infection  
Rabies infection  
•ꢀ Nebilet*ꢀ  
Congestive heart failure  
•ꢀ Scheriproct*ꢀ  
Haemarrhoids, proctitis and anal fissures  
Actinic keratosis  
•ꢀ RotaTeq*ꢀ  
•ꢀ Vaqta*ꢀ  
Rotavirus-induced gastroentiritis  
Hepatitis A infection  
•ꢀ Solaraze*ꢀ  
Streptase®  
Myocardial infarction  
and arterial thrombosis  
•ꢀ Varivax*ꢀꢀ  
•ꢀ VivotifꢀOral*ꢀ  
Varicella  
Typhoid infection  
•ꢀ Tramal*ꢀ  
•ꢀ Vaniqa*ꢀ  
•ꢀ Vesicare*ꢀ  
Moderate to severe pain  
Unwanted facial hair in women  
Overactive bladder syndrome  
TRADEMARKS  
CSL, Bioplasma and ISCOMATRIX are  
trademarks of the CSL Group  
*
Trademarks of companies other than  
CSL and referred to on this page are  
listed below:  
®
Registered trademark of  
CSL Limited or its affiliates  
Merck & Co. Inc.  
Intendis GmbH  
Intercell AG  
Advantan  
Finacea  
Scheriproct  
Comvax  
GARDASIL H-B-Vax II  
Trademark of CSL Limited or its affiliates  
M-M-R II PedvaxHIB Pneumovax  
RotaTeq  
Almirall  
Vaqta  
Varivax  
JESPECT  
Solaraze  
Vaniqa  
Leo Pharmaceutical  
Products Limited AS  
Burinex  
Daivobet  
Daivonex  
Fucidin  
Astellas  
Flomaxtra  
Vesicare  
Crucell  
Vivotif Oral  
Modavigil  
Novartis  
Menjugate  
Rabipur  
Cephalon Inc.  
Menveo  
Controlled Therapeutics  
Scotland) Limited  
(
Cervidil  
Tramal  
Menorini  
Nebilet  
Grunenthal GmbH  
The Medicine Company  
Angiomax  
18  
Business Feature  
Research and Development  
CSL invests in the development of protein-based medicines that  
save lives by preventing or treating serious human illnesses.  
In July 2010, CSL announced plans  
to build a new R&D biotechnology  
facility at our manufacturing site  
at Broadmeadows in Melbourne,  
Australia. The facility is designed for  
the manufacture of protein medicines  
from engineered mammalian cells  
and will be used to support later stage  
clinical development of new therapies  
for cancer, bleeding disorders  
The facility has been designed to be  
highly flexible and is based on single  
use technology systems, resulting  
in a lower environmental footprint  
compared to traditional manufacturing  
facilities. It will have sufficient capacity  
to meet the planned future needs of  
CSL’s R&D portfolio, be fully compliant  
with local and international regulatory  
agencies and capable of performing  
commercial scale manufacture of new  
biotechnology products.  
and inflammation.  
Construction is scheduled to  
be complete by the third quarter  
of 2012, which will be followed  
by commissioning and validation.  
Manufacturing for clinical trials in  
a fully validated facility is expected  
to commence during the first half of  
This significant project enables CSL  
to build on our existing capabilities  
and research collaborations, further  
develop key biotechnology skills and  
work towards our important goal  
of improving the lives of people  
with life-threatening diseases.  
2013. The facility will build on CSL’s  
core manufacturing skills and enable  
CSL to progress R&D projects through  
Phase III clinical trials, a key step in the  
regulatory approval of new medicines.  
Research and Development Operations  
Plasmaꢀfractionation and associated research and  
development activities are carried out in Melbourne,  
Kankakee, Bern and Marburg.  
Clinicalꢀandꢀregulatoryꢀaffairs teams operate from Melbourne, King of  
Prussia, Bern, Marburg and Tokyo. Global project teams draw together staff  
from different sites depending on the expertise required for a specific project.  
¹
Constant currency removes the impact of exchange rate movements to facilitate comparability between 2010-11 and the prior year. For further details see page 4.  
CSL Limited  
Annual Report 2010-2011  
Business Feature  
19  
Research and Development  
CSL’s Global R&D Pipeline Achievements 2010-2011  
Life cycle management and  
post marketing commitments#  
Research/pre-clinical  
Clinical development Registration/post launch  
Intravenous Immunoglobulin (10% IVIG)  
Subcutaneous Immunoglobulin (20% SCIG) in the US  
FXIII Congenital Deficiency in the US  
Alpha1-Proteinase Inhibitor in the US  
C1 Esterase Inhibitor in the US  
Fibrinogen Concentrate in the US  
Influenza Vaccine in the US  
H5N1 and H1N1 Influenza Vaccine  
Market development  
Subcutaneous Immunoglobulin (20% SCIG) in Europe  
Intravenous Immunoglobulin (10% IVIG) in CIDP in Europe  
Factor VIII/VWF in Europe  
Fibrinogen Concentrate in Europe  
Alpha1-Proteinase Inhibitor in Europe  
Prothrombin Complex Concentrate in the US  
Fibrinogen Concentrate in Aortic Surgery  
Prothrombin Complex Concentrate New Indications  
Fibrinogen Concentrate New Indications  
New product development  
Novel Plasma Proteins  
CSL654 (rIX-FP)  
CSL627 (rFVIII)  
CSL689 (rVIIa-FP)  
Recombinant Coagulation Factors  
CAM3001 GMCSFR mAb in RA – MedImmune*  
CSL112 Reconstituted HDL in ACS  
CSL362 (IL-3R mAb) in AML  
CSL324 (Anti-G-CSFR mAb)  
Discovery Projects  
Core capabilities  
Vaccines – Merck*  
Immunoglobulins  
Partnered Vaccine Programs*  
Vaccines – Merck*  
Haemophilia/Coagulation  
Specialty Products  
Vaccines – Pfizer*  
Breakthrough Medicines  
Vaccines and Licensing  
P. Gingivalis POD – Sanofi*  
*
Partnered projects  
#
Life cycle management projects also address pathogen safety, capacity expansions, yield improvements and new packages and sizes  
2
0
Corporate Responsibility  
At CSL, Corporate Responsibility is our ongoing commitment to  
conduct business ethically and to contribute to the economic, social  
and environmental well-being of our communities.  
Our Corporate Responsibility  
priority areas  
As part of our commitment to providing  
stakeholders with comprehensive  
and balanced information about our  
economic, social and environment  
performance, CSL released its second  
global corporate responsibility report  
on 1 February this year.  
The award acknowledged our leadership  
on ESG issues and our advances in  
sustainability reporting.  
n Researching and developing  
new medicines for unmet  
needs, while continually improving  
our protein-based therapies  
for patients;  
During the year, CSL was also listed on  
the Dow Jones Sustainability Asia Pacific  
Index (DJSI Asia Pacific). This index tracks  
the performance of the top 20% of the  
600 largest Asia Pacific companies in  
the Dow Jones Global Total Stock  
Market Index that leads the field  
Our Corporate Responsibility 2010  
details our challenges and achievements  
across our corporate responsibility  
priority areas in the 2009-2010 financial  
year. It is available in limited print copy  
and on our website www.csl.com.au/  
about/corporate-responsibility.  
n Ensuringꢀourꢀtherapiesꢀareꢀsafeꢀ  
andꢀofꢀtheꢀhighestꢀquality by  
maintaining the highest standards  
throughout all stages of the  
product life cycle;  
in terms of sustainability.  
In addition, over three consecutive  
years to 2010, CSL was included in  
the Carbon Disclosure Project (CDP)  
Australia/New Zealand Leadership  
n Operating responsibly in the  
marketplace by marketing our  
medicines in an ethical manner,  
working with others to improve  
equity of access and sharing our  
financial success;  
CSL continues to improve internal  
reporting systems, taking into  
Index. The index recognises companies  
that provide the most comprehensive  
disclosure of their emissions and climate  
change exposures. Furthermore, CSL  
was one of four Australian companies  
and amongst 175 across the globe that  
participated in the first ever CDP Water  
Disclosure 2010 Project. This initiative  
provides investors with insight into water  
related risks and opportunities including  
associated strategies and plans faced  
by organisations. CSL’s submissions are  
available from the CDP website.  
consideration feedback received from  
stakeholders. We are working towards  
the goal of publishing environmental,  
social and governance (ESG) information  
closer to the applicable reporting period.  
n ꢀroviding a positive working  
environmentꢀforꢀourꢀpeople  
by engendering a culture of mutual  
trust and respect, enabling them to  
do their jobs safely and effectively,  
and rewarding and recognising  
their contributions;  
We have made substantial progress in  
formalising and integrating corporate  
responsibility within the business. In  
recognition of this, CSL was awarded  
the 2010 Sustainable Company of the  
Year by Ethical Investor in Australia.  
n Supporting our patient,  
biomedical and local  
communities by improving  
access to our therapies and  
enhancing the quality of life for  
patients, advancing scientific  
knowledge and supporting future  
medical researchers, and engaging  
our staff in the support of  
local communities;  
CSL Corporate  
Responsibility  
Associate, Patrick  
Castauro, accepts  
our Ethical Investor  
Award for 2010  
Sustainable Company  
of the Year. The  
award acknowledges  
our leadership on  
environmental, social  
and governance  
issues, and advances  
in sustainability  
reporting.  
n Minimising our impacts on  
the environment through the  
responsible management of our  
operations and natural resources,  
without compromising the safety,  
quality and accessibility of  
our therapies.  
Photo courtesy of Ethical Investor  
CSL Limited  
Annual Report 2010-2011  
Our Company  
21  
Corporate Responsibility  
Our stakeholders  
ꢅnderstanding the perceptions and expectations  
ofꢀourꢀstakeholdersꢀprovidesꢀtheꢀbasisꢀforꢀ  
informingꢀourꢀprioritiesꢀandꢀourꢀapproachꢀtoꢀ  
sustainability. We maintain an open dialogue  
with our stakeholders and utilise various methods  
forꢀachievingꢀthisꢀincludingꢀcustomerꢀsurveys,ꢀ  
meetings with government, visits to major  
suppliers, perception studies amongst health  
careꢀprofessionals,ꢀforumsꢀtoꢀbriefꢀourꢀinvestorsꢀ  
andꢀsurveysꢀofꢀemployees.ꢀ  
Supporting local communities in times of emergency  
CSL is committed to supporting  
the CSL group also came to the  
as employee giving and matching  
programs. CSL Behring Japan, on  
behalf of the CSL Group, donated  
US$250,000 to the Japan Red  
communities in times of disaster,  
and never before have we seen  
such great need in areas where we  
immediate aid of Australians  
through payroll giving, fundraising  
events and volunteering, with over  
operate. In early 2011, we witnessed A$70,000 raised from staff and  
Cross which was instrumental in  
establishing relief efforts in regions  
affected by the tsunami which  
resulted from the earthquake.  
a number of devastating natural  
disasters affecting communities  
in Australia and abroad. Extreme  
rainfalls in Queensland and  
matched in full by CSL.  
As rebuilding efforts commenced  
in Australia, a series of other tragic  
natural disasters took the world  
by surprise - the devastating  
Combined with corporate and  
employee donations and the  
matching of staff contributions,  
a total of A$857,982 was raised  
by CSL and staff towards these  
relief efforts.  
Victoria inundated homes and  
businesses with almost three  
quarters of Queensland declared  
a natural disaster zone. A state of  
emergency was also declared in  
regional Victoria in communities  
that endured similar floods a few  
months earlier.  
earthquake in Christchurch,  
New Zealand and the catastrophic  
9.0 magnitude Pacific Ocean  
earthquake near Japan, both  
taking place within weeks of each  
other. The earthquakes were in  
countries where CSL operations  
and permanent staff are located.  
We are fortunate all staff are  
reported safe and well.  
CSL is grateful to all staff who,  
despite difficult circumstances,  
continued to support our operations  
and maintain the supply of our life-  
saving therapies. To them and those  
who contributed financially we are  
most appreciative.  
To assist those affected and to  
support the significant rebuilding  
efforts, CSL made a corporate  
donation of A$250,000 and  
CSL contributed to the New Zealand  
relief efforts with a corporate  
donation of A$50,000 as well  
A$100,000 to Queensland and  
Victorian state-run relief appeals  
respectively. Employees across  
2
2
Directors’ Profiles  
Brian A McNamee, AO  
MBBS, FAꢁCꢂ, FꢃSE - (Age 54)  
INTERNATIONAL PHARMACEUTICAL INDUSTRY,  
MEDICINE (RESIDENT IN VICTORIA)  
ChiefꢀExecutiveꢀOfficerꢀ  
and Managing ꢂirector  
Dr McNamee was appointed to the CSL  
Board in July 1990 and is the Chief Executive  
Officer and Managing Director. Dr McNamee  
is a former Director of the Peter MacCallum  
Cancer Foundation Ltd. Dr McNamee  
completed Bachelor of Medicine and  
Bachelor of Surgery Degrees at the  
University of Melbourne.  
ELIZABETH ALEXANDER  
BRIAN MCNAMEE  
BRUCE BROOK  
JOHN SHINE  
PETER TURNER  
CHRISTINE O’REILLY  
DAVID SIMPSON  
JOHN AKEHURST  
Dr McNamee is a member of the Innovation  
and Development Committee.  
Peter J Turner  
BSc, MBA, MAꢁCꢂ – (Age 62)  
DAVID ANSTICE  
IAN RENARD  
INTERNATIONAL PHARMACEUTICAL INDUSTRY  
(RESIDENT IN PENNSYLVANIA, USA)  
Executive ꢂirector  
Mr Turner was appointed to the CSL Board in  
December 2009. He has more than 40 years  
experience in the biopharmaceutical industry.  
His expertise includes plasma fractionation,  
research and development, production,  
engineering and management. Mr Turner  
contributed to the successful acquisition of  
Aventis Behring to form CSL Behring in 2004  
and served as President of CSL Behring from  
that time until June 2011. He was also Chief  
Operating Officer, CSL Group from December  
MAURICE RENSHAW  
2009 until June 2011.  
Elizabeth A Alexander, AM  
John H Akehurst  
BCom, FCA, FCꢀA, FAꢁCꢂ - (Age 68)  
MA (Oxon), FꢁMechE - (Age 62)  
FINANCE AND RISK MANAGEMENT  
ENGINEERING AND MANAGEMENT  
(RESIDENT IN WESTERN AUSTRALIA)  
(RESIDENT IN VICTORIA)  
Chairman  
Mr Akehurst was appointed to the CSL Board  
in April 2004. He had 30 years’ executive  
experience in the international hydrocarbon  
industry, including seven years as Managing  
Director and CEO of Woodside Petroleum  
Ltd. Mr Akehurst is a member of the Board  
of the Reserve Bank of Australia and is also  
a Director of Origin Energy Limited and of  
Securency International Pty Ltd. He was  
formerly Chairman of Alinta Limited and of  
Coogee Resources Limited and is a former  
Director of Oil Search Limited. Mr Akehurst is  
Chairman of the National Centre for Asbestos  
Related Diseases and the Fortitude Foundation  
and a Director of the University of Western  
Australia’s Business School.  
Miss Alexander was appointed to the CSL  
Board in July 1991 and became Chairman  
in October 2006. She is Chairman of  
the Dexus Wholesale Property Group  
Limited, a Director of the Dexus Property  
Group and of Medibank Private Limited.  
Miss Alexander is a former National  
President of the Australian Society of  
Certified Practising Accountants and  
of the Australian Institute of Company  
Directors. She is Chancellor of the  
University of Melbourne, Chairman  
of the Nossal Institute of Global Health  
and National President of the Winston  
Churchill Fellowship Trust.  
Mr Akehurst is a member of the Human  
Resources and Remuneration Committee.  
Miss Alexander is a member of the Audit  
and Risk Management Committee.  
CSL Limited  
Annual Report 2010-2011  
Our Company  
23  
Directors’ Profiles  
David W Anstice  
Christine E O’Reilly  
John Shine, AO  
BEc - (Age 63)  
BBus (Age 50)  
BSc (Hon), ꢀhꢂ, ꢂSc, FAA - (Age 65)  
INTERNATIONAL PHARMACEUTICAL INDUSTRY  
FINANCE AND INFRASTRUCTURE  
(RESIDENT IN VICTORIA)  
PHARMACEUTICAL INDUSTRY AND MEDICINE  
(RESIDENT IN NSW)  
(RESIDENT IN PENNSYLVANIA, USA)  
Mr Anstice was appointed to the CSL  
Board in September 2008. He was a  
long-time member of the Board of  
Directors and Executive Committee of the  
US Biotechnology Industry Organisation,  
and has over 40 years’ experience in the  
global pharmaceutical industry. Until  
August 2008, Mr Anstice was for many  
years a senior executive of Merck & Co.  
Inc. serving at various times as President  
of Merck Human Health for US/Canada/  
Latin America, Europe, Japan and Asia,  
and as Executive Vice President. He is  
a Director of Alkermes, Inc., in Boston,  
Massachusetts, and a Director  
Ms O’Reilly was appointed to the CSL  
Board in February 2011. She is currently  
Co-Head of Unlisted Infrastructure  
Investments at Colonial First State Global  
Asset Management, a position that she  
has held since July 2007. In this capacity,  
Ms O’Reilly is a Director of the Anglian  
Water Group (UK) and Electricity North  
West (UK). Prior to her position with  
Colonial First State Global Asset  
Management, Ms O’Reilly was the  
Chief Executive Officer of the GasNet  
Australia Group from October 2001  
until December 2006. She is a Director  
of Care Australia.  
Professor Shine was appointed to the  
CSL Board in June 2006. He is Executive  
Director of the Garvan Institute of  
Medical Research and a Board Member  
of the Garvan Research Foundation. He  
is Professor of Molecular Biology and  
Professor of Medicine at the University  
of NSW, and a Director of many scientific  
research and medical bodies throughout  
Australia. Professor Shine was formerly  
Chairman of the National Health  
and Medical Research Council and a  
Member of the Prime Minister’s Science,  
Engineering and Innovation Council. In  
November 2010, he was awarded the  
2010 Prime Minister’s Prize for Science.  
of the United States Studies Centre  
at the University of Sydney.  
Ms O’Reilly is a member of the Audit  
and Risk Management Committee and  
the Human Resources Remuneration  
Committee.  
Professor Shine is a member of the  
Innovation and Development Committee.  
Mr Anstice is a member of the Human  
Resources and Remuneration Committee  
and the Innovation and Development  
Committee.  
David J Simpson  
FCꢀA – (Age 71)  
Ian A Renard  
BA, LLM, LLꢂ (Hon), FAꢁCꢂ - (Age 65)  
FINANCE AND MANAGEMENT  
Bruce R Brook  
(RESIDENT IN VICTORIA)  
LAW (RESIDENT IN VICTORIA)  
BCom, BAcc, FCA, MAꢁCꢂ – (Age 56)  
Mr Simpson was appointed to the CSL  
Board in September 2006. He is a former  
Chairman of Aristocrat Leisure Limited.  
For many years, Mr Simpson was Finance  
Director of Tabcorp Holdings Limited and  
before that Executive General Manager  
Finance of Southcorp Holdings Ltd.  
Mr Renard was appointed to the CSL  
Board in August 1998. For many years  
he practised in company and commercial  
law. Mr Renard is a Director of Hillview  
Quarries Pty Ltd, SP Australia Networks  
FINANCE AND MANAGEMENT  
(RESIDENT IN VICTORIA)  
Mr Brook was appointed to the CSL  
Board in August 2011. He is currently  
Chairman of Programmed Maintenance  
Services Limited and a Director of  
Boart Longyear Limited. Mr Brook has  
previously been Chairman of Energy  
Developments Limited and a Director  
of Lihir Gold Limited and Consolidated  
Minerals Limited. During his executive  
career he was Chief Financial Officer of  
WMC Resources Limited and prior to  
that the Deputy Chief Financial Officer  
of the ANZ Banking Group.  
(Distribution) Ltd and SP Australia  
Networks (Transmission) Ltd. He is the  
Chairman of the University of Melbourne  
Archives Advisory Board and a Trustee of  
the R E Ross Trust.  
Mr Simpson is Chairman of the Human  
Resources and Remuneration Committee  
and a member of the Audit and Risk  
Management Committee.  
Mr Renard is Chairman of the Audit and  
Risk Management Committee.  
Edward H Bailey  
LLB, BCom, FCꢁS - (Age 45)  
Maurice A Renshaw  
Bꢀharm. - (Age 64)  
Company Secretary  
INTERNATIONAL PHARMACEUTICAL INDUSTRY  
(RESIDENT IN NSW)  
Mr Renshaw was appointed to the CSL  
Board in July 2004. Formerly, he was Vice  
President of Pfizer Inc, USA, Executive  
Vice President, Pfizer Global Consumer  
Group and President of Pfizer’s Global  
Consumer Healthcare Division. Prior to  
his positions in Pfizer, Mr Renshaw was  
Vice President of Warner Lambert Co.  
and President of Parke-Davis USA. He has  
had more than 30 years’ experience in  
the international pharmaceutical industry.  
Mr Renshaw is Chairman of the Innovation  
and Development Committee.  
2
4
Executive Management  
Paul Perreault  
President, CSL Behring  
BA ꢀsychology – (Age 54)  
Paul joined a CSL predecessor company  
in 1997. He currently heads CSL Behring  
as President and works with all areas of  
the business. Paul’s previous roles were in  
sales, marketing and operations. He has  
worked in senior leadership roles with  
Wyeth, Centeon, Aventis Behring, Aventis  
Bioservices and CSL. Paul has worked in  
the health care field for 30 years.  
BRIAN MCNAMEE  
ANDREW CUTHBERTSON  
GREG BOSS  
PETER TURNER  
PAUL PERREAULT  
MARY SONTROP  
JILL LEVER  
GORDON NAYLOR  
KAREN ETCHBERGER  
PAUL WALTON  
Gordon Naylor  
Chief Financial Officer  
MBA, BEng (Hons), ꢂipCompSc – (Age 48)  
Gordon was appointed Chief Financial  
Officer in October 2010. He joined CSL  
in 1987 and has held many operational  
and corporate roles in different parts  
of the CSL Group. Prior to his current  
role, Gordon was based in the US and  
responsible for CSL Behring’s global  
supply chain, the supply of plasma  
for CSL Behring and CSL’s global  
information systems.  
JEFF DAVIES  
EDWARD BAILEY  
Andrew Cuthbertson  
R&D Director and  
Chief Scientific Officer  
BMedSci, MBBS, ꢀhꢂ – (Age 56)  
Brian McNamee, AO  
Andrew is responsible for CSL’s  
Chief Executive Officer  
and Managing Director  
MBBS, FAꢁCꢂ, FꢃSE – (Age 54)  
Research and Development strategy and  
the implementation of that strategy. He  
joined CSL in March 1997 as Director of  
Research. Andrew trained in medicine and  
science at the University of Melbourne, the  
Walter and Eliza Hall Institute, the Howard  
Florey Institute and the National Institutes  
of Health in the US. Andrew was then  
a Senior Scientist at Genentech, Inc.  
in San Francisco.  
See the Directors’ Profiles on page 22.  
Peter Turner  
Executive Director  
BSc, MBA, MAꢁCꢂ – (Age 62)  
See the Directors’ Profiles on page 22.  
CSL Limited  
Annual Report 2010-2011  
Our Company  
25  
Executive Management  
Jeff Davies  
Greg Boss  
Jill Lever  
Executive Vice President,  
CSL Biotherapies  
CSL Group General Counsel  
and Executive Vice President,  
CSL Behring  
Senior Vice President,  
Human Capital  
BSc (Hons), ꢀhꢂ – (Age 54)  
BA (Hons) – (Age 55)  
Jꢂ, BS (Hon) – (Age 50)  
Jeff was appointed Executive Vice  
Jill joined CSL Limited as Senior Vice  
President, Human Capital in 2009. She  
heads the Human Resources function  
and works with the Managing Director  
and Board on strategic matters relating  
to talent, succession, organisation culture  
and executive remuneration. Originally  
from the UK, Jill held a number of  
Human Resources roles with the Royal  
Dutch Shell Group in Europe, the Middle  
East, South America and Asia Pacific  
before working in the finance and  
mining sectors in Melbourne.  
President of CSL Biotherapies in January  
Greg was appointed Group General  
Counsel in January 2009 and is  
2010 and is responsible for CSL’s  
Australian and Asia Pacific businesses. He  
served as General Manager and President  
of CSL Bioplasma Asia Pacific from  
responsible for worldwide legal  
operations for all CSL Group companies.  
He joined CSL in 2001, serving as General  
Counsel for CSL Behring, a position he  
continues to hold. In addition, Greg is  
responsible for risk management for the  
Group. Prior to joining CSL, Greg was  
Vice President and Senior Counsel for  
CB Richard Ellis International.  
2008 to 2010, responsible for plasma  
businesses in the region. Jeff has 28 years  
experience at CSL including executive and  
senior management roles in research and  
development in Australia and Switzerland.  
Mary Sontrop  
Edward Bailey  
Executive Vice President,  
CSL Behring Operations  
BAppSc, MBA – (Age 54)  
Paul Walton  
Company Secretary and  
Australian General Counsel  
LLB, BCom, FCꢁS – (Age 45)  
Senior Vice President,  
Corporate Development  
Mary was appointed as Executive  
Vice President, CSL Behring Operations  
in April 2010. She joined CSL as a  
Production Manager in April 1988 and  
has held a broad range of positions in  
manufacturing, quality management  
and general management located in  
Australia, Switzerland and Germany. Prior  
to her current position, Mary was General  
Manager of CSL Biotherapies for Australia  
and New Zealand.  
hꢂ, MS, ꢄMQ, BAppSc – (Age 54)  
Edward was appointed as Company  
Secretary and Australian General Counsel  
in January 2009. Prior to that, he was  
Senior Corporate Counsel and Assistant  
Company Secretary, having joined CSL  
in 2000. Edward works with the Board  
to develop and maintain CSL’s corporate  
governance practices and provides legal  
advice to the Corporate Head Office and  
Australian operations. Prior to joining  
CSL, Edward was a Senior Associate with  
lawyers Arthur Robinson & Hedderwicks.  
Paul was appointed as SVP Corporate  
Development in January 2008. Prior to  
that, he was SVP Business Development  
at CSL Behring, and held senior roles  
in ZLB and JRH Biosciences, having  
joined CSL in 1999. Paul works with the  
Managing Director and the Board on  
corporate growth initiatives, including  
mergers and acquisitions. Prior to joining  
CSL, Paul was Vice President, Marketing,  
Sales and Business Development,  
Diagnostic Systems Laboratories, Inc.,  
Webster, Texas.  
Karen Etchberger  
Executive Vice President,  
Plasma, Supply Chain and  
Information Technology,  
CSL Behring  
hꢂ – (Age 53)  
Karen was appointed as Executive Vice  
President, Plasma, Supply Chain and  
Information Technology in April 2010.  
She joined CSL as Product Manager in  
JRH Biosciences in August 2001 and  
progressed through a number of positions  
in technical services, research and  
development, quality management, and  
was most recently Head of Global Quality  
for CSL Behring. Prior to joining CSL,  
Karen was Director of Developmental  
Research at Endotech Corporation.  
2
6
CSL Group Business Operations  
Regional Sales and Distribution Locations  
CSL Biotherapies  
Australia  
CSL Behring  
Argentina  
Austria  
Belgium  
Brazil  
Adelaide  
Brisbane  
Melbourne  
Perth  
Buenos Aires  
Vienna  
Japan  
Tokyo  
Mexico  
Mexico City  
Breda  
Leuven  
Netherlands  
ꢀortugal  
Sydney  
Sao Paulo  
Ottowa  
Lisbon  
China  
Beijing  
Chengdu  
Guangzhou  
Hong Kong  
Shanghai  
Wuhan  
Canada  
ꢂenmark  
France  
Spain  
Barcelona  
Stockholm  
Bern  
Copenhagen  
Paris  
Sweden  
Switzerland  
ꢅnited States  
UnitedꢀKingdom  
ꢄermany  
ꢄreece  
Hattersheim  
Athens  
King of Prussia  
Haywards Heath  
ꢄermany  
Hattersheim  
Auckland  
NewꢀZealand  
ꢅnited States  
King of Prussia  
ꢁtaly  
Milan  
CSL Limited  
Annual Report 2010-2011  
Our Company  
27  
Share Information  
Share Information  
CSL Limited  
Issued Capital Ordinary Shares:  
The CSL Sale Act 1993 (Cth)  
In accordance with the CSL Act,  
CSL’s Constitution provides that the  
votes attaching to significant foreign  
shareholdings are not to be counted  
when they pertain to the appointment,  
removal or replacement of more than  
one-third of the directors of CSL who  
hold office at any particular time.  
A significant foreign shareholding  
is one where a foreign person has  
a relevant interest in 5% or more  
of CSL’s voting shares.  
amends the CSL Act to impose  
certain restrictions on the voting rights  
of persons having significant foreign  
shareholdings, and certain restrictions  
on the Company itself.  
524,840,532 as at 30 June 2011  
Details of Incorporation  
CSL’s activities were carried on within  
the Commonwealth Department of  
Health until the Commonwealth Serum  
Laboratories Commission was formed  
as a statutory corporation under the  
Commonwealth Serum Laboratories  
Act 1961 (Cth) [the CSL Act] on  
CSL ordinary shares have been traded  
on the Australian Stock Exchange since  
30 May 1994. Melbourne is the  
Home Exchange.  
Substantial Shareholders  
2
November 1961. On 1 April 1991,  
As at 30 June 2011, the Capital Group  
Companies, Inc. was a substantial  
shareholder in CSL.  
Significant Foreign  
Shareholdings  
the Corporation was converted to a  
public company limited by shares under  
the Corporations Law of the Australian  
Capital Territory and it was renamed  
Commonwealth Serum Laboratories  
Limited. These changes were brought  
into effect by the Commonwealth  
Serum Laboratories (Conversion into  
Public Company) Act 1990 (Cth).  
As at 30 June 2011, the Capital Group  
Companies, Inc. was a significant  
foreign shareholder in CSL.  
Voting Rights  
At a general meeting, subject to  
restrictions imposed on significant  
foreign shareholdings and some other  
minor exceptions, on a show of hands  
each shareholder present has one vote.  
On a poll, each shareholder present has  
one vote for each fully paid share held  
in person or by proxy.  
On 7 October 1991, the name of the  
Company was changed to CSL Limited.  
The Commonwealth divested all of its  
shares by public float on 3 June 1994.  
Distribution of Shareholdings as at 30 June 2011  
Range  
Holders  
Shares  
% ꢃotal Shares  
1
- 1,000  
,001 - 5,000  
,001 - 10,000  
0,001 - 100,000  
00,001 and over  
73,563  
29,048  
5,153  
2,278  
91  
28,998,191  
68,357,416  
35,471,386  
41,779,811  
350,233,728  
524,840,532  
5.53  
13.02  
6.76  
1
5
1
7.96  
1
66.73  
100.00  
ꢃotal shareholders  
110,133  
Number of shareholders with less than a marketable parcel  
of 16 shares (based on the share price at 30 June 2011)  
815  
6,257  
2
8
Shareholder Information  
CSL’s Twenty Largest Shareholders as at 30 June 2011  
%
ꢃotal  
Shareholder  
Account  
Shares  
Shares  
1
2
3
4
5
6
7
8
9
HSBC Custody Nominees (Australia) Limited  
123,631,700  
84,687,285  
58,510,734  
25,756,930  
5,318,880  
5,058,715  
4,793,711  
3,486,587  
3,075,172  
2,552,334  
2,499,023  
2,207,202  
2,064,907  
1,278,000  
1,249,502  
1,120,337  
1,110,207  
1,036,980  
903,485  
23.56  
16.14  
11.15  
4.91  
1.01  
0.96  
0.91  
0.66  
0.59  
0.49  
0.48  
0.42  
0.39  
0.24  
0.24  
0.21  
0.21  
0.20  
0.17  
0.16  
J P Morgan Nominees Australia Limited  
National Nominees Limited  
Citicorp Nominees Pty Limited  
J P Morgan Nominees Australia Limited  
Cogent Nominees Pty Limited  
Cash Income A/c  
PIPOOLED A/c  
RBC Dexia Investor Services Australia Nominees Pty Limited  
AMP Life Limited  
UBS Wealth Management Australia Nominees Pty Ltd  
Citicorp Nominees Pty Limited  
10  
BHP Billiton ADR Holders A/c  
BCUST A/c  
1
1
RBC Dexia Investor Services Australia Nominees Pty Limited  
2 Perpetual Trustee Company Limited  
Queensland Investment Corporation  
UBS Nominees Pty Ltd  
1
13  
14  
15  
RBC Dexia Investor Services Australia Nominees Pty Limited  
Argo Investments Limited  
MLCI A/c  
16  
17  
Cogent Nominees Pty Limited  
SMP Accounts  
18  
Australian Reward Investment Alliance  
Citicorp Nominees Pty Limited  
19  
CFSIL CFS WS AUST SHRE A/c  
20  
Dr Brian Anthony McNamee  
835,669  
Topꢀ20ꢀholdersꢀofꢀordinaryꢀandꢀemployeeꢀshares  
Remaining holders balance  
331,177,360  
193,663,172  
524,840,532  
63.10  
36.90  
ꢃotal shares on issue  
100.00  
Inꢀaddition,ꢀasꢀatꢀ30ꢀJuneꢀ2011,ꢀaꢀsubstantialꢀshareholderꢀnoticeꢀhasꢀbeenꢀreceivedꢀfrom:  
ꢃhe Capital ꢄroup Companies, ꢁnc.  
34,827,695  
6.496  
CSL Limited  
Annual Report 2010-2011  
Our Company  
29  
Shareholder Information  
Share Registry  
Shareholders as at 30 June 2011  
Computershare ꢁnvestor  
Services ꢀty Limited  
Shareholders  
Shares  
Yarra Falls, 452 Johnston Street  
Abbotsford VIC 3067  
Australian Capital Territory  
New South Wales  
Northern Territory  
Queensland  
1,973  
30,603  
341  
2,898,219  
289,901,260  
346,281  
Postal Address:  
GPO Box 2975  
Melbourne VIC 3001  
14,498  
6,934  
22,178,226  
12,252,498  
2,121,339  
Enquiries within Australia:  
1
800 646 882  
Enquiries outside Australia:  
1 3 9415 4178  
Investor enquiries facsimile:  
1 3 9473 2500  
South Australia  
Tasmania  
1,659  
6
Victoria  
38,143  
11,745  
4,237  
177,658,972  
11,916,506  
5,567,231  
6
Western Australia  
International Shareholders  
ꢃotal shareholders  
Website:  
www.investorcentre.com  
110,133  
524,840,532  
Email:  
web.queries@computershare.com.au  
Shareholders with enquiries should  
go to www.investorcentre.com where  
most common questions can be  
answered by virtual agent “Penny”.  
Alternatively, shareholders may email,  
telephone or write to the Share  
Registry at the above address.  
Direct payment of dividends into  
a nominated account may be arranged  
with the Share Registry. Shareholders  
are encouraged to use this option  
by providing a payment instruction  
online via the Investor Centre at  
Supporting the environment  
through eTree  
CSL Limited is a participating member  
of eTree and proud to support this  
environmental scheme encouraging  
security holders to register to access  
all their communications electronically.  
Our partnership with eTree is an  
ongoing commitment to driving  
sustainable initiatives that help security  
holders contribute to a greener future.  
www.investorcentre.com or by  
obtaining a direct credit form from the  
Share Registry or by advising the Share  
Registry in writing with particulars.  
Separate shareholdings may be  
consolidated by advising the Share  
Registry in writing or by completing  
a Request to Consolidate Holdings  
form which can be found online  
at the above website.  
The Annual Report is produced for  
your information. The default option  
is an online Annual Report via the  
company’s website. If you opted to  
continue to receive a printed copy and  
you receive more than one or you wish  
to be removed from the mailing list for  
the Annual Report, please advise the  
Share Registry. You will continue to  
receive Notice of Meeting and Proxy.  
For every email address registered at  
www.eTree.com.au/csl, a donation of  
up to $1 is made to Landcare Australia  
towards reforestation projects to help  
restore degraded plant, animal and  
water resources. With your support,  
CSL has registered over 19,200 email  
addresses, which in turn has facilitated  
the planting of more than 55,600 trees  
in Australia and New Zealand.  
Change of address should be  
notified to the Share Registry  
online via the Investor Centre at  
www.investorcentre.com, by  
telephone or in writing without  
delay. Shareholders who are broker  
sponsored on the CHESS sub-register  
must notify their sponsoring broker  
of a change of address.  
The Annual General Meeting will be  
held at the Function Centre, National  
Tennis Centre, Melbourne Park, Batman  
Avenue, Melbourne at 10:00am on  
Wednesday 19 October 2011. There  
is a public car park adjacent to the  
Function Centre which will be available  
to shareholders at no charge.  
We also encourage you to visit eTree  
if your email address has changed  
and you need to update it. For every  
updated registration, $1 dollar will  
be donated to Landcare Australia. To  
register, you will need your Security  
Holder Reference Number (SRN) or  
Holder Identification Number (HIN).  
3
0
Corporate Governance  
CSL’s Board and management maintain high standards of  
corporate governance as part of their commitment to maximise  
shareholder value through promoting effective strategic planning,  
risk management, transparency and corporate responsibility.  
ꢃhis statement outlines the Company’s  
principal corporate governance  
1. The Board of Directors  
set out below. The Board also delegates  
specific responsibilities to ad hoc  
committees from time to time.  
1.1 ꢃhe CSL Board Charter  
practicesꢀinꢀplaceꢀduringꢀtheꢀfinancialꢀ  
year. ꢃhe Board believes that the  
CompanyꢀcompliesꢀwithꢀtheꢀASXꢀ  
Corporate ꢄovernance Council’s  
Corporate ꢄovernance ꢀrinciples and  
Recommendations, released in August  
The Board has a formal charter  
documenting its membership, operating  
procedures and the apportionment of  
responsibilities between the Board  
and management.  
The CSL Board Charter sets guidelines as  
to the desired term of service of non-  
executive directors. This charter recognises  
that whilst board renewal is essential, a  
mixture of skills and differing periods of  
service provides for balance and optimal  
outcomes at a board level. Prior to the  
expiry of a director’s term of office, the  
Board reviews that director’s performance.  
In the event that such performance is  
considered less than adequate, the Board  
may decide that it will not support the  
re-election of that director.  
The Board is responsible for oversight of  
the management of the Company and  
providing strategic direction. It monitors  
operational and financial performance,  
human resources policies and practices  
and approves the Company’s budgets  
and business plans. It is also responsible  
for overseeing the Company’s risk  
management, financial reporting  
2
007 (the Corporate ꢄovernance  
rinciples and Recommendations)  
and the amendments to the  
Corporate ꢄovernance ꢀrinciples and  
Recommendations which applied to  
theꢀfinancialꢀyearꢀendingꢀ30ꢀJuneꢀ2011.  
A checklist summarising the  
Directors are entitled to access independent  
professional advice at the Company’s  
and compliance framework.  
Company’s compliance with the  
Corporate ꢄovernance ꢀrinciples and  
Recommendations is available on the  
Company’s website.  
The Board has delegated the day-to-day  
management of the Company and the  
implementation of approved business plans  
and strategies to the Managing Director,  
who in turn may further delegate to senior  
management. In addition, a detailed  
authorisations policy sets out the decision-  
making powers which may be exercised  
at various levels of management.  
expense to assist them in fulfilling their  
responsibilities. To do so, a director must  
first obtain the approval of the Chairman.  
The director should inform the Chairman of  
the reason for seeking the advice, the name  
of the person from whom the advice is to  
be sought, and the estimated cost of the  
advice. Professional advice obtained in this  
way is made available to the whole Board.  
The Board has delegated specific authority  
to five Board committees that assist  
it in discharging its responsibilities by  
examining various issues and making  
recommendations to the Board.  
Those committees are:  
Details of Board meetings held during the  
year and individual directors’ attendance  
at these meetings can be found on  
page 38 of the Directors’ Report  
attached to the financial report.  
The CSL Board Charter is available on the  
Company’s website.  
n
n
the Nomination Committee;  
the Audit and Risk Management  
Committee;  
1.2ꢀ CompositionꢀofꢀtheꢀBoard  
Throughout the year there were either  
nine or ten directors on the Board. Christine  
O’Reilly was appointed to the Board as  
a non-executive director on 16 February  
2011. On 17 August 2011, an additional  
director, Bruce Brook, was appointed to the  
Board. Two of the current directors – the  
Managing Director and Peter Turner – are  
executive directors. The CSL Board Charter  
provides that a majority of directors should  
be independent. No director acts as a  
nominee or representative of any particular  
n
n
n
the Human Resources and  
Remuneration Committee;  
the Innovation and Development  
Committee; and  
the Securities and Market Disclosure  
Committee.  
Each committee is governed by a  
charter setting out its composition and  
responsibilities. A description of each  
committee and their responsibilities is  
CSL Limited  
Annual Report 2010-2011  
Our Company  
31  
Corporate Governance  
shareholder. A profile of each current  
director, including details of their skills,  
expertise, relevant experience, term of  
office and Board committee memberships  
can be found on pages 22 and 23 of  
this Report.  
executive director to determine whether  
it considers the director to be independent.  
The Board considers that an independent  
director is a director who is independent  
of management and free of any business  
or other relationship that could, or could  
reasonably be perceived to, materially  
interfere with the exercise of their  
to materiality consistent with Australian  
accounting standards.  
If a director has a current or former  
association with a supplier, professional  
adviser or consultant to the CSL Group,  
that supplier, adviser or consultant will  
be considered material:  
The Chairman of the Board, Elizabeth  
Alexander, is an independent, non-  
n
from the Company’s point of view,  
if the annual amount payable by the  
CSL Group to the supplier, adviser  
or consultant exceeds 5% of the  
consolidated expenses of the CSL  
Group; and  
unfettered and independent judgment.  
executive director. She is responsible for  
leadership of the Board, for ensuring that  
the Board functions effectively, and for  
communicating the views of the Board  
to the public. The Chairman sets the  
agenda for Board meetings and manages  
their conduct and facilitates open and  
constructive communication between the  
Board, management, and the public. On  
Information about any such interests or  
relationships, including any related financial  
or other details, is assessed by the Board  
to determine whether the relationship  
could, or could reasonably be perceived  
to, materially interfere with the exercise  
of a director’s unfettered and independent  
judgment. As part of this process the Board  
takes into account a range of relevant  
matters including:  
n
from the director’s point of view,  
if that amount exceeds 5% of the  
supplier’s, adviser’s or consultant’s  
total revenues.  
17 August 2011, the Company announced  
that John Shine would become Chairman  
of the Board upon the conclusion of the  
Similarly, a customer of the CSL Group  
would be considered material for this  
purpose:  
n
information contained in specific  
disclosures made by directors  
pursuant to their obligations under  
the CSL Board Charter and the  
Corporations Act;  
2011 Annual General Meeting.  
n
from the Company’s point of view,  
if the annual amount received by the  
CSL Group from the customer exceeds  
1.3 ꢁndependence  
The Board has determined that all of its  
non-executive directors are independent,  
and were independent for the duration  
of the reporting period.  
5% of the consolidated revenue of the  
n
n
n
any past employment relationship  
between the director and the  
Company;  
CSL Group; and  
n
from the director’s point of view,  
if that amount exceeds 5% of the  
customer’s total expenses.  
All CSL directors are aware of, and adhere  
to, their obligation under the Corporations  
Act to disclose to the Board any interests  
or relationships that they or any associate  
of theirs may have in a matter that relates  
to the affairs of the Company, and  
any shareholding the director or any  
of his or her associates may have in  
the Company;  
In addition to assessing the relationship in  
a quantitative sense, the Board also  
considers qualitative factors, such as the  
nature of the goods or services supplied,  
the period since the director ceased to be  
associated and their general subjective  
assessment of the director.  
any association or former association  
the director may have with a  
professional adviser or consultant  
to the Company;  
any other matter that may affect their  
independence. As required by law, details  
of any related party dealings are set out in  
full in Note 28 of the financial report. All  
directors have agreed to give the Company  
notice of changes to their relevant interests  
in Company shares within five days to  
enable both them and the Company to  
comply with the ASX Listing Rules. If a  
potential conflict of interest exists on a  
matter before the Board then (unless the  
remaining directors determine otherwise),  
the director concerned does not receive the  
relevant briefing papers, and takes no part  
in the Board’s consideration of the matter  
nor exercises any influence over other  
members of the Board.  
n
any other related party transactions  
whether as a supplier or customer of  
the Company or as party to a contract  
with the Company other than as a  
director of the Company;  
1.4 Nomination Committee  
The functions and responsibilities of the  
Nomination Committee are documented  
in a formal charter approved by the Board.  
The Nomination Committee comprises  
all of the independent non executive  
directors. The Committee is chaired  
by the Board Chairman.  
n
n
any other directorships held by  
the director;  
any family or other relationships  
a director may have with another  
person having a relevant relationship  
or interest; and  
The Committee is responsible for  
reviewing the Board’s membership  
and making recommendations on  
n
length of service.  
In determining whether an interest or  
relationship is considered to interfere with  
a director’s independence, the Board has  
regard to the materiality of the interest  
or relationship. For this purpose, the  
Board adopts a conservative approach  
any new appointments. In making  
recommendations for new directors, the  
Committee seeks to ensure that any new  
director will complement or maintain the  
skills, experience, expertise and diversity of  
the Board necessary to enable it to oversee  
In addition to considering issues that may  
arise from disclosure by directors from time  
to time under these obligations, the Board  
makes an annual assessment of each non-  
32  
Corporate Governance continued  
the delivery of the Company’s objectives  
and strategy. The Committee is also  
responsible for:  
The Company provides an induction  
program to assist new directors to gain  
an understanding of:  
2. Audit and Risk Management  
2
.1 ꢁntegrity in Financial Reporting  
and Regulatory Compliance  
n
setting and following the procedure  
for the selection of new directors  
for nomination;  
n
the Company’s financial, strategic,  
operational and risk management  
position;  
The Board is committed to ensuring  
the integrity and quality of its financial  
reporting, risk management and  
compliance systems.  
n
conducting regular reviews of the  
Board’s succession plans to enable it to  
maintain an appropriate mix of skills,  
experience, expertise and diversity;  
n
n
n
the culture and values of the  
Company;  
Prior to giving their directors’ declaration  
in respect of the annual and half-year  
financial statements, the Board requires  
the Managing Director and the Chief  
Financial Officer to sign written  
the rights, duties and responsibilities  
of the directors;  
n
n
regularly reviewing the membership  
of Board committees; and  
the roles and responsibilities of  
senior executives;  
conducting annual performance  
reviews of the Board, individual  
directors, and the Board committees.  
declarations to the Board that:  
n
n
n
the role of the Board committees;  
meeting arrangements; and  
n
the financial statements and  
associated notes comply with IFRS  
Accounting Standards as required  
by the Corporations Act, the  
Corporations Regulations and the  
CSL Group Accounting Policies;  
director interaction with each  
other, senior executives and other  
stakeholders.  
Details of Committee meetings held  
during the year and individual directors’  
attendance at these meetings can be  
found on page 38 of the Directors’  
Report attached to the financial report.  
In addition to the briefing papers, agenda  
and related information regularly supplied  
to directors, the Board has an ongoing  
education program designed to give  
directors further insight into the operation  
of the Company’s business. The program  
includes education on key developments  
in the Company and in the industry and  
environment within which it operates.  
As part of this program, directors have  
the opportunity to visit Company facilities,  
including all major operating sites in the  
US, Europe and Australia, and to attend  
meetings and information sessions with  
the Company’s local management  
n
the financial statements and  
associated notes give a true and  
fair view of the financial position  
as at the relevant balance date and  
performance of the Company for the  
year then ended as required by the  
Corporations Act;  
The Nomination Committee Charter  
is available on the Company’s website.  
1.5 ꢂirector Appointments  
One new director was appointed to the  
Board during the financial year. Christine  
O’Reilly was appointed as of 16 February  
n
in their opinion there are reasonable  
grounds to believe that the Company  
will be able to pay its debts as and  
when they become due and payable;  
and  
2011 and will be eligible for election at the  
2011 Annual General Meeting. In addition,  
another new director, Bruce Brook, was  
appointed to the Board on 17 August  
2011 and will also be eligible for election  
n
they have established and maintained  
an adequate risk management and  
internal compliance and control  
system to facilitate the preparation  
of a reliable financial report which in  
all material respects implements the  
policies adopted by the Board and the  
statements made above are based on  
that system.  
at the 2011 Annual General Meeting. One  
director retired from the Board during  
the financial year. Antoni Cipa retired as  
Finance Director as of the conclusion of  
the 2010 Annual General Meeting.  
and employees.  
1.6ꢀ PerformanceꢀEvaluation  
As mentioned above, the Nomination  
Committee meets annually to review the  
Board’s performance. The Chairman also  
holds discussions with individual directors  
to facilitate peer review. The Nomination  
Committee is responsible for evaluating  
the performance of the Managing Director,  
who in turn evaluates the performance  
of all other senior executives and makes  
recommendations in respect of their  
remuneration. These evaluations are  
based on specific criteria including the  
Company’s business performance, whether  
the long term strategic objectives are  
being achieved and the achievement of  
individual performance objectives. These  
performance evaluations took place in  
accordance with these processes during  
the last financial year.  
Peter Turner was elected and John  
Akehurst, David Anstice and Ian Renard  
were each re-elected as directors at the  
2010 Annual General Meeting.  
These written declarations were received  
by the Board in respect of the financial year  
ended 30 June 2011.  
Before their nomination for election or  
re-election, it is the Company’s policy to  
ask directors to acknowledge to the Board  
that they have sufficient time to meet the  
Company’s expectations of them. The  
Board requires that all of its members  
devote the time necessary to ensure that  
their contribution to the Company is of the  
highest possible quality. The CSL Board  
Charter sets out procedures relating to the  
removal of a director whose contribution  
is found to be inadequate.  
2.2 Audit and Risk Management  
Committee  
The Audit and Risk Management  
Committee is responsible for assisting the  
Board in fulfilling its financial reporting,  
risk management and compliance  
responsibilities. The functions and  
responsibilities of the Committee are set  
out in a charter. Broadly, the Committee is  
responsible for:  
n
overseeing the Company’s system of  
financial reporting and safeguarding  
its integrity;  
CSL Limited  
Our Company  
33  
Annual Report 2010-2011  
Corporate Governance  
n
overseeing risk management and  
compliance systems and the internal  
control framework (other than the  
management of risk associated  
with research and development  
projects which is the responsibility  
of the Innovation and Development  
Committee);  
2.3 Risk Framework  
were appointed by shareholders at  
the 2002 Annual General Meeting.  
A description of the procedure followed  
in appointing Ernst & Young is set out  
in the notice of the 2002 Annual  
General Meeting.  
The Company has adopted and follows a  
detailed and structured Risk Framework  
to ensure that risks in the CSL Group  
are identified, evaluated, monitored and  
managed. This Risk Framework sets out  
the risk management process, the roles  
and responsibilities for different levels  
of management, the risk tolerance of  
the Company, the matrix of risk impact  
and likelihood for assessing risk, and risk  
management reporting requirements.  
The Committee has established guidelines  
to ensure the independence of the external  
auditor. The external audit partner is  
to be rotated at least every five years,  
and the auditor is required to make an  
independence declaration annually.  
Information about the total remuneration  
of the external auditor, including details  
of remuneration for any non-audit  
services, can be found in Note 30  
of the financial report.  
n
n
monitoring the activities and  
effectiveness of the internal audit  
function;  
monitoring the activities and  
performance of the external auditor  
and coordinating its operation with  
the internal audit function; and  
As part of the Risk Framework, a  
Corporate Risk Management Committee  
of responsible executives reports to the  
Audit and Risk Management Committee  
on a quarterly basis, including as to  
the effectiveness of the Company’s  
management of material risks. Its task is  
to implement, coordinate and facilitate  
the risk management process across the  
CSL Group. This includes quantifying  
and monitoring certain business risks  
identified and evaluated as part of the  
risk management process, including  
those relating to operating systems, the  
environment, health and safety, product  
quality, physical assets, security, disaster  
recovery, insurance and compliance. Each  
business unit and manufacturing site in  
the Group has its own Risk Management  
Committee which reports to the  
n
providing full reports to the Board on  
all matters relevant to the Committee’s  
responsibilities.  
The Committee is satisfied that the  
provision of those non-audit services by  
the external auditor was consistent with  
auditor independence.  
The roles and responsibilities of the  
Committee are reviewed annually.  
The Committee currently comprises  
four independent non-executive directors.  
Details of the Committee’s current  
The external auditor attends each Annual  
General Meeting to be available to answer  
questions from shareholders.  
members, including their qualifications  
and experience, are set out in the directors’  
profiles on pages 22 and 23 of this  
Report. The Committee’s charter provides  
that a majority of the Committee must  
be independent directors, and that the  
Committee Chair must be an independent  
director who is not also Chairman of the  
Board. Executive directors may not be  
members of the Committee. Members are  
chosen having regard to their qualifications  
and training to ensure that each is capable  
of considering and contributing to the  
matters for which the Committee  
3. Human Resources  
and Remuneration  
3.1 ꢀC ompetitivenessꢀofꢀRemunerationꢀ  
and Human Resources  
The Company is committed to ensuring  
that it has competitive remuneration and  
human resources policies and practices  
that offer appropriate and fair rewards and  
incentives to employees in the countries in  
which they are employed. The Company  
also seeks to align the interests of senior  
management and shareholders.  
Corporate Risk Management Committee  
on a quarterly basis, and the Group has  
a Global Risk and Insurance Manager  
who is responsible for monitoring and  
coordinating the implementation of  
the Risk Framework throughout the  
CSL Group.  
is responsible.  
The Committee meets at least four times  
a year, and senior executives and internal  
and external auditors frequently attend  
meetings on invitation by the Committee.  
The Committee holds regular meetings  
with both the internal and external  
auditors without management or executive  
directors present. Details of Committee  
meetings held during the year and  
individual directors’ attendance at these  
meetings can be found on page 38 of  
the Directors’ Report attached to the  
financial report.  
In addition, the oversight of risk  
3.2 Remuneration Report  
management associated with research  
and development projects is one of the  
responsibilities of the Innovation and  
Development Committee (see below). The  
research and development operations have  
a number of management committees  
that report into the Innovation and  
Development Committee.  
Details on the Company’s remuneration  
policies and practices are set out in the  
Remuneration Report on pages 44 to 62  
of the Director’s Report attached to the  
financial report. The Remuneration Report  
includes details of the remuneration of  
directors and other key management  
personnel of the consolidated entity  
and the Company, and details of the  
Company’s long-term incentive plans.  
Risk assessment and management policies  
are reviewed periodically, including by the  
CSL Group’s internal audit function.  
3.3 Human Resources and  
Remuneration Committee  
2
.4 External Auditor  
The Audit and Risk Management  
Committee Charter is available on the  
Company’s website.  
One of the chief functions of the Audit  
and Risk Management Committee is to  
review and monitor the performance and  
independence of the external auditor.  
The Company’s external auditor for the  
financial year was Ernst & Young, who  
The Human Resources and Remuneration  
Committee is responsible for assisting  
the Board in fulfilling its responsibilities  
with respect to human resources and  
remuneration matters. Details of the  
Human Resources and Remuneration  
3
4
Corporate Governance continued  
Committee and its charter are set out in  
the Remuneration Report on pages 44 to  
other director may attend any meeting of  
the Committee in an ex officio capacity.  
Details of Committee meetings held  
during the year and individual directors’  
attendance at these meetings can be  
found on page 38 of the Directors’  
Report attached to the financial report.  
obligations and miscellaneous securities  
related issues. It comprises a minimum of  
any two directors, one of whom must be  
an independent director. The Committee  
has authority to:  
62 of the Directors’ Report attached to  
the financial report. Details of Committee  
meetings held during the year and  
individual directors’ attendance at these  
meetings can be found on page 38 of  
the Directors’ Report attached to the  
financial report.  
n
approve the form and substance of  
any disclosure to be made by the  
Company to the ASX in fulfilment of  
its continuous disclosure obligations;  
The Innovation and Development  
Committee Charter is available on  
the Company’s website.  
The Human Resources and Remuneration  
Committee Charter is available on the  
Company’s website.  
n
n
approve the allotment and issue, and  
registration of transfers of securities;  
5. Market Disclosure  
make determinations on matters  
relating to the location of the share  
register; and  
5.1 Communications and External  
4. Innovation and Development  
ꢂisclosure  
4
.1ꢀ ꢀG overnanceꢀofꢀInnovationꢀandꢀ  
n
effect compliance with other  
formalities which may be urgently  
required in relation to matters  
affecting the share capital.  
The Company has a Communications  
and External Disclosure Policy. This policy  
is available on the Company’s website,  
and operates in conjunction with the  
Company’s more detailed internal  
continuous disclosure policy. Together,  
these policies are designed to facilitate the  
Company’s compliance with its obligations  
under the ASX Listing Rules by:  
ꢂevelopment  
The Board is committed to ensuring that  
the Company’s investments in innovation,  
research and development are undertaken  
in ways that are most likely to create long  
term value for shareholders.  
From time to time, the Committee may  
also be specifically authorised by the  
Board to approve minor amendments to  
significant ASX announcements following  
full Board approval.  
4
.2 ꢁnnovation and ꢂevelopment  
Committee  
n
providing guidance as to the types  
of information that may require  
disclosure, including examples of  
practical application of the rules;  
Details of Committee meetings held  
during the year and individual directors’  
attendance at these meetings can be  
found on page 38 of the Directors’  
Report attached to the financial report.  
The Innovation and Development  
Committee is responsible for providing  
the Board with oversight of CSL’s  
technology, research and product  
development opportunities. The functions  
and responsibilities of the Innovation and  
Development Committee are documented  
in a formal charter approved by the Board.  
The Committee is authorised by the  
Board to:  
n
n
providing practical guidance for  
dealing with market analysts and  
the media;  
The Securities and Market Disclosure  
Committee Charter is available on the  
Company’s website.  
identifying the correct channels for  
passing on potentially market-sensitive  
information as soon as it comes  
to hand;  
5.3 Shareholder Communication  
In addition to its formal disclosure  
obligations under the ASX Listing Rules,  
the Board uses a number of additional  
means of communicating with  
n
monitor the strategic direction of  
CSL’s technology, research and  
product development programs;  
n
establishing regular occasions at  
which senior executives and directors  
are actively prompted to consider  
whether there is any potentially  
market-sensitive information which  
may require disclosure; and  
n
provide guidance on issues and  
priorities, additions to the research and  
development pipeline and significant  
development milestones; and  
shareholders. These include:  
n
n
the half-year and annual report and  
shareholder review;  
posting media releases, public  
announcements, notices of general  
meetings and voting results, and other  
investor related information on the  
Company’s website; and  
n
allocating responsibility for approving  
the substance and form of any public  
disclosure and communications  
with investors.  
n
oversee the management of risk  
associated with the research and  
development projects.  
The Committee generally meets at least  
four times a year. The Committee currently  
comprises four members, being three  
independent non-executive directors and  
the Managing Director. Details of the  
Committee’s current members, including  
their qualifications and experience, are  
set out in the directors’ profiles on pages  
5.2 Securities and Market ꢂisclosure  
n
annual general meetings,  
including webcasting which permits  
shareholders worldwide to view  
proceedings.  
Committee  
Significant ASX announcements (such as  
announcements of financial results, market  
guidance or major transactions) are the  
subject of full Board approval. The Board  
has also delegated authority to a Securities  
and Market Disclosure Committee that  
may be convened at short notice to enable  
the Company to comply with urgent  
The Company has a dedicated Governance  
page on the Company’s website which  
supplements the communication to  
shareholders in the annual report regarding  
the Company’s corporate governance  
policies and practices. That web page  
22 and 23 of this Report. The Company’s  
Chief Scientific Officer is a required  
attendee. The Board Chairman or any  
or less significant continuous disclosure  
CSL Limited  
Our Company  
35  
Annual Report 2010-2011  
Corporate Governance  
also contains copies of many of the  
Company’s governance-related documents,  
policies and information.  
breach of the law and the securities trading  
policy. Acquisitions of securities under  
the employee share and option plans are  
exempt from the prohibition under the  
Corporations Act.  
n
n
the safety and quality of products,  
including statements on bioethics  
(including animal ethics) and human  
rights principles;  
The Board is committed to monitoring  
ongoing developments that may enhance  
communication with shareholders,  
including technological developments,  
regulatory changes and the continuing  
development of “best practice” in the  
market, and to implementing changes to  
the Company’s communications strategies  
whenever reasonably practicable to  
reflect any such developments.  
maintaining a safe, fair and rewarding  
workplace, which covers many  
employee relations issues such as:  
A procedure of internal notification  
and approval applies to directors and  
designated senior employees wishing to  
buy or sell Company securities or exercise  
options over Company shares. Directors  
and designated senior employees are  
forbidden from making such transactions  
without the prior approval of the Chairman  
labour standards;  
equal employment opportunity/  
workplace harassment;  
learning and development;  
occupational health and safety;  
professional behaviour;  
(in the case of directors) and the Company  
A copy of the Company’s Communications  
and External Disclosure Policy is available  
on the Company’s website.  
Secretary (in the case of designated  
senior employees). Directors also have  
specific disclosure obligations under the  
Corporations Act and the corresponding  
ASX Listing Rules.  
employee counselling;  
recruitment and selection;  
6. Securities Trading  
recognition of employee  
contribution;  
By promoting director and employee  
ownership of shares, the Board hopes to  
encourage directors and employees to  
become long-term holders of Company  
securities, aligning their interests with  
those of the Company. It does not  
condone short-term or speculative  
trading in its securities by directors and  
employees, nor does it permit directors  
or employees to enter into any price  
protection arrangements with third  
parties to hedge such securities or  
margin loan arrangements in relation  
to Company securities. The Company  
has a comprehensive securities trading  
policy which applies to all directors  
and employees and is available on the  
Company’s website. The policy aims  
to inform directors and employees  
of the law relating to insider trading,  
and provide them with practical guidance  
for avoiding unlawful transactions in  
Company securities.  
A copy of the Company’s Securities Dealing  
Policy is available on the Company’s  
website and has also been lodged with the  
ASX in accordance with Listing Rule 12.9.  
rehabilitation; and  
reporting and management of  
incidents;  
n
n
the community, incorporating policy  
statements on charitable donations;  
and  
7. Corporate Responsibility  
The Company’s approach to Corporate  
Responsibility is guided by its Group Values,  
Code of Responsible Business Practice and  
related policies.  
environmental management.  
In accordance with the Code, the Company  
is committed to ensuring that employees,  
contractors, suppliers and partners are  
able to raise concerns regarding any  
illegal conduct or malpractice and to have  
such concerns properly investigated. This  
commitment is implemented through the  
Company’s internal Whistleblower Policy,  
which sets out the mechanism by which  
employees, contractors, suppliers and  
partners can confidently, and anonymously  
if they wish, voice such concerns in  
7.1ꢀ ꢀG roupꢀValues  
The Company has developed a set of values  
common to the diverse business units  
that form the CSL Group. The CSL Group  
Values, endorsed by the Board, serve as the  
foundation for every day decision-making.  
These values are superior performance,  
innovation, integrity, collaboration and  
customer focus.  
a responsible manner without being  
subject to victimisation, harassment  
or discriminatory treatment.  
7.2ꢀ ꢀC odeꢀofꢀResponsibleꢀ  
Business ꢀractice  
The policy prohibits directors and  
employees from buying or selling securities  
in the Company when they are in  
The Board has adopted a Code of  
A copy of the Code has been distributed  
to all employees and an enhanced training  
program has been implemented across the  
CSL Group.  
Responsible Business Practice (the Code).  
Based upon the CSL Group Values and  
guiding principles, the Code outlines  
CSL’s commitment to responsible business  
practices and ethical standards. The Code  
replaced the previous CSL Limited Code  
of Conduct and sets out the rights and  
obligations that all employees have in the  
conduct of the Company’s business.  
These rights and obligations relate to:  
possession of price sensitive information  
which is not generally available to the  
market. In addition, the policy identifies  
certain “blackout periods” during which no  
directors or employees are allowed to trade  
in Company securities (unless exceptional  
circumstances apply, the person has no  
inside information, and special approval  
is obtained to sell (but not buy) Company  
securities). Directors and employees are  
reminded that procuring others to trade  
in Company securities when in possession  
of price sensitive information is also a  
The Company expects its contractors and  
suppliers to comply not only with the laws  
of the countries in which they operate,  
but also with internationally accepted  
best practice. It therefore expects that  
contractors and suppliers also observe  
the principles set out in the Code.  
n
business integrity, including  
statements relating to compliance with  
applicable laws and standards, ethical  
and transparent business practices,  
privacy and political donations;  
A copy of the Code can be accessed in  
11 languages on the Company’s website.  
3
6
Corporate Governance continued  
7
.3 ꢂiversity  
n
Introduce an annual review by the  
Board of trends and results across a  
range of metrics by gender, including:  
gender profile at all levels, recruitment,  
promotion, departures, inclusion  
in talent and succession processes  
and remuneration. Metrics will be  
reviewed both globally and by country  
of employment and will include  
of work being undertaken in many areas  
of the Company’s operations to ensure that  
the Company is acting with Integrity (one  
of CSL’s core values) at all times.  
The Company recognises its talented and  
diverse workforce as a key competitive  
advantage. CSL’s business success is a  
reflection of the quality and skill of its  
people. CSL is committed to seeking out  
and retaining the best talent to ensure  
strong business growth and performance.  
A copy of the Company’s Anti-Bribery and  
Anti-Corruption Policy is available on the  
Company’s website.  
7.5 Supporting ꢀolicies  
Diversity benefits individuals, teams, CSL as  
a whole and our customers. CSL recognises  
that each employee brings their own  
capabilities, experiences and characteristics  
to their work. Diversity is valued at all levels  
within the Company.  
benchmark data where available;  
A review of the CSL policy framework  
was conducted in conjunction with the  
introduction of the Code in December  
2008. The framework provides for three  
levels of policy making within the CSL  
Group as follows:  
n
Implement further enhancements  
to our Global talent identification  
process to ensure all employees are  
consistently assessed against  
objective criteria; both the process  
and outcomes to be reviewed  
annually by the Board; and  
In the area of gender diversity, CSL has a  
long history of implementing programs  
and policies supporting women in the  
workplace. As at June 2011, there are two  
female directors on the CSL Board (one  
being the Chairman) and 27% of the most  
senior roles in the Company (that is, “Vice  
President level” and above) are held by  
women. CSL believes it has a culture of  
inclusiveness across the organisation.  
n
Board Policies cover any operational  
issue of strategic importance that  
applies to all CSL Group business units  
and all CSL Group employees and  
are approved by the Board;  
n
Require that individual development  
actions are recorded for all employees  
at Vice President level and above levels  
and employees who are considered  
to have the potential to reach Vice  
President level or above levels.  
n
Global Policies cover issues of an  
operational nature requiring consistent  
implementation across all CSL Group  
business units and are approved  
by a member of the Executive  
The Company will report against these  
measurable objectives in its 2012 Annual  
Report.  
Further evidence of CSL’s inclusive culture  
was provided in the CSL Employee Opinion  
survey results published in 2010 in which  
Management Group or the Chair of a  
CSL Global Functional Committee; and  
In addition to these CSL Group-wide  
measurable objectives, CSL management  
in each of the 25 countries in which we  
operate are encouraged to implement  
diversity related initiatives consistent with  
local laws, practice and culture. Examples  
of recent site specific diversity initiatives  
include, in Australia, where CSL will be  
opening a childcare centre on the Parkville  
site in September 2011 and, in Japan,  
where a recently initiated program is  
supporting female sales representatives  
to return to work from maternity leave by  
providing flexible working hours. The CSL  
Board will consistently review site/business  
specific initiatives on diversity during  
regular Board visits to sites/businesses.  
7
3% of female respondents agreed  
or strongly agreed with the statement  
working hours are flexible enough to  
n
Local Policies cover issues that apply  
to a particular CSL Group business unit  
or a part of a particular CSL Group  
business unit and are approved by  
the appropriate site leader or  
functional leader.  
meet family or personal needs”. Benchmark  
data indicate this result places CSL above  
European, Australian and United States  
comparators.  
The framework ensures that policy  
issues are reviewed and approved at the  
appropriate level within the CSL Group and  
that the principles outlined in the Code are  
properly implemented.  
The CSL Board adopted a formal Diversity  
Policy (including gender diversity) in June  
2011. Under this Diversity Policy, the CSL  
Board is required to establish measurable  
objectives in relation to gender diversity  
and, on at least an annual basis, assess  
and renew these objectives. The CSL Board  
will also measure progress against these  
objectives annually. Our current focus is to  
ensure that CSL continues to build strong  
and consistent systems and processes to  
further support women in the workplace.  
Communication of the revised CSL policy  
framework has been undertaken to  
ensure that all employees have a clear  
understanding of the policy structure  
and decision making processes within  
the CSL Group.  
A copy of the Company’s Diversity Policy  
is available on the Company’s website.  
7.6 Ongoing ꢀolicy Review and New  
7
.4 Anti-Bribery and Anti-Corruption  
ꢀolicy ꢂevelopment  
The measurable objectives that the  
CSL Board has set for the financial year  
commencing 1 July 2011 are:  
The Code provides a high level policy  
statement on preventing bribery and  
inducements. The CSL Board also considers  
that it is appropriate to have a clear stand-  
alone policy which sets out the Company’s  
policy against bribery and corruption.  
The Board and management remain  
committed to continuing to review  
the Company’s corporate governance  
practices in response to changes in market  
conditions or recognised best practices,  
including the implementation of any  
changes to the Corporate Governance  
Principles and Recommendations or  
ASX Listing Rules.  
n
Review of sourcing, recruitment and  
selection processes, throughout the  
CSL Group to ensure that consistent  
processes exist to support gender  
diversity principles;  
The Board therefore adopted an Anti-  
Bribery and Anti-Corruption Policy in July  
011. This Policy builds on the current  
2
policy statement in the Code. This Policy  
also supports the considerable amount  
CSL Limited  
Financial Report 2010-2011  
Contents  
Directors’ Report  
38  
63  
Auditor’s Independence Declaration  
Consolidated Statement of Comprehensive Income  
Consolidated Balance Sheet  
64  
65  
Consolidated Statement of Changes in Equity  
Consolidated Cash Flow Statement  
Notes to the Financial Statements  
Directors’ Declaration  
66  
67  
68  
126  
127  
Independent Auditor’s Report  
3
8
Directors’ Report  
The Board of Directors of CSL Limited has pleasure in presenting their  
report on the consolidated entity for the year ended 30 June 2011.  
1.  
Directors  
2. Company Secretary  
The following persons were Directors of CSL Limited during  
the whole of the year and up to the date of this report:  
Mr E H Bailey, B.Com/LLB, FCIS, was appointed to the  
position of Company Secretary on 1 January 2009 and  
continues in office at the date of this report. Mr Bailey  
joined CSL Limited in 2000 and had occupied the role of  
Assistant Company Secretary from 2001. Before joining  
CSL Limited, Mr Bailey was a Senior Associate with Arthur  
Robinson & Hedderwicks. On 16 August 2011, Mr J Levy,  
CPA, was appointed as Assistant Company Secretary,  
following the retirement of Mr P R Turvey from the position.  
Mr Levy has held a number of senior finance positions  
within the CSL Group since joining CSL Limited in 1989.  
Miss E A Alexander, AM (Chairman)  
Dr B A McNamee, AO (Managing Director)  
Mr J H Akehurst  
Mr D W Anstice  
Mr I A Renard  
Mr M A Renshaw  
Professor J Shine, AO  
Mr D J Simpson  
3. Directors’ Attendances at Meetings  
Mr P J Turner  
The table below shows the number of directors’ meetings  
held (including meetings of Board Committees) and  
number of meetings attended by each of the directors of  
the Company during the year. In addition, on two separate  
occasions last year, the directors visited various of the  
Company’s operations in each of the US and Europe and  
met with local management.  
Ms C E O’Reilly was appointed Director on 16 February  
2
011 and continues in office at the date of this report.  
Mr A M Cipa retired at the Annual General Meeting held  
on 13 October 2010.  
Particulars of the directors’ qualifications, experience, all  
directorships of public companies held for the past three  
years, special responsibilities, ages and the period for  
which each has been a director are set out in the Directors’  
Profiles section of the Annual Report.  
Securities  
Human  
Audit and Risk  
Management  
Committee  
and Market  
Disclosure  
Committee  
Resources &  
Remuneration  
Committee  
Innovation and  
Development  
Committee  
Board of  
Directors  
Nomination  
Committee  
A
7
7
7
7
3
2
7
7
7
7
7
B
7
7
7
7
3
2
7
7
7
7
7
A
B
4
4
A
6
6
A
B
A
B
4
4
A
1
1
E A Alexander  
B A McNamee  
J H Akehurst  
D W Anstice  
A M Cipa  
4
4
3
5
2
2
2
4
5
4
3
1
5
5
5
2
5
5
5
4
2
1
1
1
4
1
1
C O’Reilly  
1
2
2
5
5
5
5
I A Renard  
M A Renshaw  
J Shine  
4
4
3
3
4
4
2
1
4
1
D J Simpson  
P J Turner  
4
5
5
3
1
1
A Number of meetings (including meetings of Board Committees) attended during the period.  
B
Maximum number of meetings that could have been attended during the period.  
1
Attended for at least part in ex officio capacity  
Attended for at least part by invitation  
2
CSL Limited  
Annual Report 2010-2011  
Financial Report  
Directors’ Report  
39  
Directors’ Report  
continued  
4
.
.
Principal Activities  
7. Review of Operations  
The principal activities of the consolidated entity during  
the financial year were the research, development,  
manufacture, marketing and distribution of  
biopharmaceutical and allied products.  
CSL Behring sales of US$3.4 billion grew 10% on a  
constant currency basis when compared to the twelve  
months ended 30 June 2010. Sales contribution from  
the immunoglobulins and specialty products portfolios  
underpinned this growth.  
5
Operating Results  
Immunoglobulins grew 25% in constant currency terms.  
Volume growth for intravenous immunoglobulins, lead by  
The Group announced a net profit after tax of $941  
million for the twelve months ended 30 June 2011,  
down $112 million or 11% when compared to the prior  
comparable period. This result included an unfavourable  
foreign exchange impact of $116 million. On a constant  
®
Privigen , was strong. The balance of growth arose from  
a product mix shift in demand towards subcutaneous  
immunoglobulin, largely Hizentra , and sales arising from  
the withdrawal of a competitor from the market place.  
This competitor has since returned to certain markets and  
is expected to increasingly compete for sales during the  
coming year.  
®
1
currency basis, operational net profit after tax grew 14%  
after excluding a one-off contribution from the sale of  
pandemic influenza vaccine (H N ) in the prior period. Sales  
revenue $4.2 billion, up 9% on an underlying basis when  
compared to the twelve months ended 30 June 2010, with  
research and development expenditure of $325 million up  
1
1
2
3
The Critical Care segment, including Asian sales , grew  
9
% in constant currency terms underpinned by strong  
®
demand for specialty products Haemocomplettan P/  
9
$
% at constant currency. Cash flow from operations was  
1,018 million.  
®
RiaSTAP (fibrinogen concentrate) particularly in peri-  
®
operative bleeding management and Berinert P (C-1  
esterase inhibitor), following growth in US patient  
numbers. Growth in albumin sales continues with  
ongoing demand from China.  
6
.
Dividends  
The following dividends have been paid or declared since  
the end of the preceding financial year:  
Haemophilia product sales declined 1% in constant currency  
terms. Volume growth for plasma derived FVIII, led by  
2009-2010 An interim dividend of 35 cents per share,  
®
unfranked, was paid on 9 April 2010. An unfranked final  
dividend of 45 cents per ordinary share, franked to 5.28  
cents per share, for the year ended 30 June 2010 was paid  
on 8 October 2010.  
Beriate , was approximately 8%. Typically, however, these  
sales are in new lower priced markets. Including sale of  
product manufactured at the Broadmeadows facility, volume  
growth in plasma derived FVIII was 9%.  
2
010-2011 An interim dividend of 35 cents per share,  
During the period, CSL Behring recorded an expense of $25  
million relating to losses on receivables in Southern European  
countries. The majority of these losses arose from the sale of  
Greek Government bonds at a discount to their face value.  
These bonds were issued to CSL Behring in settlement of  
long standing Greek Government hospital receivables.  
unfranked, was paid on 8 April 2011. The Company’s  
Directors have declared a final dividend of 45 cents per  
ordinary share, franked to 2 cents per share, for the year  
ended 30 June 2011.  
In accordance with determinations by the Directors, the  
Company’s dividend reinvestment plan remains suspended.  
Other Human Health (CSL Biotherapies) sales of $735  
million grew 4% on an underlying basis when compared to  
the twelve months ended 30 June 2010. The prior period  
included a one-off contribution of $235 million from novel  
A (H N ) influenza (swine flu) vaccine sales.  
Total dividends for the 2010-2011 year are:  
On Ordinary shares  
1
1
$
000  
Underlying growth during the period was driven by the  
Australian plasma therapies business following an increase in  
plasma collections by the Australian Red Cross Blood Service.  
Interim dividend paid 8 April 2011  
188,393  
236,178  
Final dividend payable on 14 October 2011  
1
Constant currency removes the impact of exchange rate movements to facilitate comparability by restating the current year result at the prior year’s rates. This is  
done in two parts: 1) by converting the current year net profit of entities in the group that have reporting currencies other than Australian Dollars at the rates that  
were applicable to the prior year (“translation currency effect”) and comparing this with the actual profit of those entities for the current year; and 2) by restating  
material transactions booked by the group that are impacted by exchange rate movements at the rate that would have applied to the transaction if it had occurred  
in the prior year (“transaction currency effect”) and comparing this with the actual transaction recorded in the current year. The sum of translation currency effect  
and transaction currency effect is the amount by which reported net profit is adjusted to calculate the result at constant currency.  
2
3
Excludes the one-off contribution from the sale of pandemic influenza vaccine (H N ) in the prior comparable period and the impact of foreign exchange  
movements in the period under review.  
1
1
Adjusted to include CSL Behring critical care products sold in Asia by CSL Biotherapies.  
4
0
Directors’ Report  
continued  
®
Biostate (Human coagulation factor VIII and human von  
Willebrand factor (VWF) complex) sales were particularly  
strong, arising from demand for Immune Tolerance  
Therapy and von Willebrand disease treatments.  
financial years of the consolidated entity, are contained  
in the Year in Review in the Annual Report and in section  
7 of this Directors’ Report. Additional information of  
this nature can be found on the Company’s website,  
www.csl.com.au. Any further information of this nature  
has been omitted as it would unreasonably prejudice the  
interests of the Company to refer further to such matters.  
This growth was offset by the conclusion of a Gardasil*  
Human Papillomavirus vaccine) catch-up program in  
New Zealand drawing to an end and the normalisation of  
Pneumovax* (Pneumococcal vaccine) sales following the  
booster program in fiscal 2010. Influenza sales of $125  
million were up 5% on a constant currency basis.  
(
1
1. Health, Safety and  
Environmental Performance  
The Company continues to operate a global Health,  
Safety and Environment Management System that  
ensures its facilities operate to internationally recognized  
standards. These standards include strict compliance  
with government regulations and a commitment to  
minimising the impact of operations on the environment.  
The Company also maintains certifications to relevant  
external Health, Safety and Environment management  
systems including EMAS III certification and certification  
to AS/NZ4801 (AS/NZ4801:2001 Occupational health and  
safety management systems - Specification with guidance  
for use).  
Intellectual Property Licensing revenue of $96 million  
was down 10% on a constant currency basis. Royalty  
contribution from Human Papillomavirus Vaccines largely  
accounts for the decline, with receipts this year of $83  
million.  
8
.
Significant changes in the State of Affairs  
On 18 August 2010, the Company announced its  
intention to conduct a further on-market buyback of up  
to $900 million, representing approximately 5% of shares  
then on issue. During the financial year, the Company  
completed this announced share buyback of 26,063,169  
shares returning $900 million to shareholders.  
The Company’s global Health, Safety and Environment  
Management System ensures the consolidated entity  
continuously reviews its health, safety and environmental  
responsibilities, including regulatory compliance, and  
seeks to continuously improve its approach to health,  
safety and environmental management.  
There were no other significant changes in the state of  
affairs of the consolidated entity during the financial year  
not otherwise disclosed in this report or the financial  
statements.  
Lost time injury frequency rate (LTIFR) and medical  
9
.
Significant events after year end  
treatment injury frequency rate (MTIFR) continue to record  
improved performance. For our Australian operations,  
the Safety, Rehabilitation and Compensation Commission  
granted an extension to the CSL Limited self-insurance  
licence until 30 June 2015 with tier 3 status maintained.  
Other than as disclosed in the financial statements,  
the Directors are not aware of any other matter or  
circumstance which has arisen since the end of the  
financial year which has significantly affected or may  
significantly affect the operations of the consolidated  
entity, results of those operations or the state of affairs of  
the consolidated entity in subsequent financial years.  
The consolidated entity’s environmental obligations and  
waste discharge quotas are regulated under applicable  
Australian and foreign laws. Environmental regulatory  
performance is monitored by the Board and subjected  
from time to time to government agency audits and  
site inspections. Throughout the Company’s operations,  
environmental leadership groups continue to refine data  
collection systems and processes to ensure the Company  
is well prepared for new regulatory requirements.  
10. Likely Developments, Business Strategies  
and Future Prospects  
In the medium term the Company expects to continue to  
grow through developing differentiated plasma products,  
expanding flu vaccine sales internationally, receiving royalty  
flows from the exploitation of the Human Papillomavirus  
Vaccine by Merck & Co, Inc, and the commercialisation  
of the Company’s technology. Over the longer term the  
Company intends to develop new products which are  
protected by its own intellectual property and which are  
high margin human health medicines marketed and sold  
by the Company’s global operations. Further comments  
on likely developments and expected results of certain  
aspects of the operations of the consolidated entity  
and on the business strategies and prospects for future  
No environmental breaches have been notified by  
the Environmental Protection Authority in Victoria,  
Australia, or by any other equivalent interstate or  
foreign government agency in relation to the Company’s  
Australian, European, North American or Asia Pacific  
operations during the year ended 30 June 2011.  
The consolidated group has undertaken a number of  
studies to assess the risks that climate change poses to  
the Company and its operations. The studies indicate that  
climate change and measures introduced or announced  
*Gardasil and Pneumovax are trademarks of Merck & Co. Inc.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
Directors’ Report  
41  
Directors’ Report  
continued  
by various governments to address climate change do  
15. Indemnification of Directors and Officers  
not pose any significant risks or significant financial  
impact to its operations in the short to medium term.  
Climate change risk and control measures continue  
to be monitored and acted upon by the Company to  
ensure compliance to new and emerging regulatory  
requirements.  
During the financial year, the insurance and indemnity  
arrangements discussed below were in place concerning  
directors and officers of the consolidated entity:  
The Company has entered into a Director’s Deed  
with each director regarding access to Board papers,  
indemnity and insurance. Each deed provides:  
As part of compliance and continuous improvement in  
environmental reporting, both regulatory and voluntary,  
the Company continues to report on key environmental  
issues including energy consumption, emissions,  
water use and management of waste as part of its  
Corporate Responsibility Report - 2010. Other reporting  
included reporting under the Australian Government’s  
National Greenhouse Energy Reporting Act (2007).  
The Company’s Australian operations did not exceed  
thresholds for NGER data publication for the 2010  
reporting year.  
(
a) an ongoing and unlimited indemnity to the relevant  
director against liability incurred by that director  
in or arising out of the conduct of the business of  
the Company or of a subsidiary (as defined in the  
Corporations Act) or in or arising out of the discharge  
of the duties of that director. The indemnity is given to  
the extent permitted by law and to the extent and for  
the amount that the relevant director is not otherwise  
entitled to be, and is not actually, indemnified by  
another person or out of the assets of a corporation,  
where the liability is incurred in or arising out of the  
conduct of the business of that corporation or in the  
discharge of the duties of the director in relation to  
that corporation;  
1
2. Directors’ Shareholdings and Interests  
At the date of this report, the interests of the directors  
who held office at 30 June 2011 in the shares, options  
and performance rights of the Company are set out  
in Note 28(g) of the Financial Report. It is contrary to  
Board policy for key management personnel to limit  
exposure to risk in relation to these securities. From time  
to time the Company Secretary makes inquiries of key  
management personnel as to their compliance with this  
policy.  
(
(
b) that the Company will maintain, for the term of each  
director’s appointment and for seven years following  
cessation of office, an insurance policy for the benefit  
of each director which insures the director against  
liability for acts or omissions of that director in the  
director’s capacity or former capacity as a director;  
and  
c) the relevant director with a right of access to Board  
papers relating to the director’s period of appointment  
as a director for a period of seven years following  
that director’s cessation of office. Access is permitted  
where the director is, or may be, defending legal  
proceedings or appearing before an inquiry or hearing  
of a government agency or an external administrator,  
where the proceedings, inquiry or hearing relates to  
an act or omission of the director in performing the  
director’s duties to the Company during the director’s  
period of appointment.  
1
3. Directors’ Interests in Contracts  
Section 15 of this Report sets out particulars of the  
Directors Deed entered into by the Company with each  
director in relation to Board paper access (indemnity and  
insurance matters).  
1
4. Share Options  
As at the date of this report, the number of unissued  
ordinary shares in the Company under options and under  
performance rights are set out in Note 27 of the Financial  
Statements.  
In addition to the Director’s Deeds, Rule 146 of the  
Company’s constitution requires the Company to  
indemnify each “officer” of the Company and of each  
wholly owned subsidiary of the Company out of the  
assets of the Company “to the relevant extent” against  
any liability incurred by the officer in the conduct of  
the business of the Company or in the conduct of  
the business of such wholly owned subsidiary of the  
Company or in the discharge of the duties of the officer  
unless incurred in circumstances which the Board resolves  
do not justify indemnification.  
Holders of options or performance rights do not have  
any right, by virtue of the options or performance rights,  
to participate in any share issue by the Company or any  
other body corporate or in any interest issued by any  
registered managed investment scheme.  
The number of options and performance rights exercised  
during the financial year and the exercise price paid to  
acquire fully paid ordinary shares in the Company is set  
out in Note 27 (c) and (d) of the Financial Statements.  
Since the end of the financial year, no shares were issued  
under the Company’s Performance Rights Plan.  
4
2
Directors’ Report  
continued  
For this purpose, “officer” includes a director, executive  
not compromise the auditor independence requirements  
of the Corporations Act 2001 for the following reasons:  
officer, secretary, agent, auditor or other officer of the  
Company. The indemnity only applies to the extent the  
Company is not precluded by law from doing so, and to  
the extent that the officer is not otherwise entitled to be  
or is actually indemnified by another person, including  
under any insurance policy, or out of the assets of a  
corporation, where the liability is incurred in or arising  
out of the conduct of the business of that corporation or  
in the discharge of the duties of the officer in relation to  
that corporation.  
ꢀa llꢀnon-auditꢀservicesꢀhaveꢀbeenꢀreviewedꢀbyꢀ  
the Audit and Risk Management Committee to  
ensure that they do not impact the impartiality and  
objectivity of the auditor; and  
ꢀn oneꢀofꢀtheꢀservicesꢀundermineꢀtheꢀgeneralꢀ  
principles relating to auditor independence as set  
out in Professional Statement F1, including reviewing  
or auditing the auditor’s own work, acting in a  
management or a decision making capacity for the  
Company, acting as an advocate for the Company or  
jointly sharing economic risks and rewards.  
The Company paid insurance premiums of $1,313,940  
in respect of a contract insuring each individual director  
of the Company and each full time executive officer,  
director and secretary of the Company and its controlled  
entities, against certain liabilities and expenses (including  
liability for certain legal costs) arising as a result of work  
performed in their respective capacities, to the extent  
permitted by law.  
A copy of the auditors’ independence declaration as  
required under section 307C of the Corporations Act  
2
001 accompanies this Report.  
Ernst & Young and its related practices received or are  
due to receive the following amounts for the provision of  
non-audit services in respect to the year ended 30 June  
2011:  
1
6. Auditor independence  
and non-audit services  
$
The Company may decide to employ the auditor on  
assignments additional to their statutory audit duties  
where the auditor’s expertise and experience with the  
Company and/or the consolidated entity are important.  
Due diligence and completion audits  
Compliance and other services  
-
120,696  
120,696  
Details of the amounts paid or payable to the entity’s  
auditor, Ernst & Young for non-audit services provided  
during the year are set out below. The directors, in  
accordance with the advice received from the Audit and  
Risk Management Committee, are satisfied that the  
provision of non-audit services is compatible with the  
general standard of independence for auditors imposed  
by the Corporations Act 2001. The directors are satisfied  
that the provision of non-audit services by the auditor did  
Total fee paid for non-audit services  
1
7. Rounding  
The amounts contained in this report and in the financial  
report have been rounded to the nearest $1,000  
where rounding is applicable) unless specifically stated  
(
otherwise under the relief available to the Company  
under ASIC Class Order 98/0100. The Company is an  
entity to which the Class Order applies.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
43  
Directors’ Report  
Remuneration Report  
Directors’ Report  
continued  
Message from the Board  
The CSL Board has this year adapted the style and content of this report with the intention of adding clarity and  
transparency. We appreciate feedback from CSL’s shareholders on our communication of remuneration matters.  
Our remuneration philosophy is underpinned by a rigorous approach to performance management which is applied to  
senior executives and throughout the organisation.  
CSL is a global company in terms of ownership, operations and employees. The CSL Board considers the reasonable  
expectations of shareholders, noting that nearly 40% of CSL’s shares were held outside Australia as at 30 June 2011. We  
are also mindful of the need to attract, retain and reward executives in the many geographic locations in which they are  
employed. We believe that we have addressed these considerations in a balanced way.  
In 2010-2011, we implemented the outcomes of an in-depth review of long term incentives, the main conclusions of  
which were published in last year’s remuneration report. Long term incentives in the form of equity (performance rights  
and performance options) are now available only to the most senior executives.  
In October 2010 we introduced a new element into our remuneration mix in the form of (three year) deferred cash  
incentives for a number of executives. More details are contained in this report. Our intention in this was to improve our  
overall market remuneration position in order to maximise retention of key executives while continuing to align executive  
reward and shareholder returns.  
We have reviewed and increased the number of senior executives who are defined as Key Management Personnel (KMP).  
Previously this was limited to those direct reports to the Managing Director who met the KMP criteria. In this and future  
reports, we will additionally include Executive Vice President positions reporting into the President CSL Behring, of which  
we currently have three based in the United States.  
During 2011 the Company’s growth in sales revenue and in NPAT at constant currency was 9% and 14% respectively  
(
after removing the sales and NPAT impact of H N vaccines in 2010). This continued strong performance was taken into  
1 1  
account in the Executive KMP short term incentive awards.  
Understanding the remuneration landscape in the markets within which we operate is an important input to  
remuneration decisions. For support with providing market data and analysis for the 2011 Senior Executive remuneration  
review we have appointed Guerdon Associates who are contracted by the Human Resources and Remuneration  
Committee (HRRC) and report directly to them.  
The HRRC and Board Charters were amended in July 2011 to include new responsibilities relating to diversity. The CSL  
Diversity Policy and measurable objectives have been set and are described in the Corporate Governance Statement  
within CSL’s Annual Report. We look forward to following through and reporting on these objectives in next year’s report.  
David Simpson  
Chairman  
Elizabeth Alexander  
Chairman  
HR and Remuneration Committee  
CSL Limited  
This page does not form part of the audited Remuneration Report.  
4
4
Directors’ Report  
continued  
18. Remuneration Report  
Remuneration Framework  
Through an effective remuneration framework the Company  
aims to:  
Introduction  
This Remuneration Report sets out the Company’s  
remuneration framework and practices and the  
remuneration arrangements for the 2011 financial  
year. This report has been prepared in accordance  
with the requirements of the Corporations Act  
ꢀ provideꢀfairꢀandꢀequitableꢀrewards;  
•ꢀ ꢀa lignꢀrewardsꢀtoꢀbusinessꢀoutcomesꢀthatꢀcreateꢀvalueꢀforꢀ  
shareholders;  
ꢀd riveꢀaꢀhighꢀperformanceꢀcultureꢀbyꢀrewardingꢀtheꢀ  
2
001 and the Corporations Regulations 2001. It has  
achievement of strategic and business objectives;  
been audited pursuant to section 308(3C) of the  
Corporations Act 2001.  
•ꢀ attract,ꢀretainꢀandꢀmotivateꢀhighꢀcalibreꢀemployees;ꢀand  
ꢀe nsureꢀremunerationꢀisꢀcompetitiveꢀinꢀeachꢀofꢀourꢀ  
international employment markets.  
Key Management Personnel  
Key Management Personnel (“KMP”) in this report are  
those individuals having authority and responsibility for  
planning, directing and controlling the major activities  
of the Company during the financial year. They include  
Non-Executive Directors, Executive Directors and  
Executive KMP. All are listed below:  
Non-Executive Directors  
Ms Elizabeth Alexander  
Mr John Akehurst  
Position  
Executive KMP including  
Executive Directors  
Position  
Chairman  
Dr Brian McNamee  
Managing Director  
Executive Director  
Non-Executive Director  
Non-Executive Director  
Non-Executive Director  
Non-Executive Director  
Non-Executive Director  
Non-Executive Director  
Non-Executive Director  
2
Mr Peter Turner  
Mr David Anstice  
3
Mr Paul Perreault  
President CSL Behring  
Chief Financial Officer  
Chief Scientific Officer  
Mr Ian Renard  
Mr Gordon Naylor  
Mr Maurice Renshaw  
Professor John Shine  
Mr David Simpson  
Dr Andrew Cuthbertson  
Executive Vice President,  
CSL Biotherapies  
Dr Jeff Davies  
Mr Greg Boss  
1
Ms Christine O’Reilly  
Group General Counsel  
1
4
Executive Vice President  
Operations  
Appointed Non-Executive Director from 16 Feb 2011.  
Ms Mary Sontrop  
2
President CSL Behring throughout the year. Became a CSL Limited Director  
in December 2009.  
Executive Vice President  
Plasma, Supply Chain and IT  
3
Ms Karen Etchberger  
Mr Edward Bailey  
Ms Jill Lever  
5
Executive KMP for the full year in the role of Executive Vice President  
Commercial Operations. Appointed as President, CSL Behring (Designate)  
on 29 March 2011 and assumed the role on 1 July 2011.  
Company Secretary  
4
5
6
Relocated to the US in the role of Executive Vice President Operations CSL  
Behring from 1 April 2010.  
Senior Vice President,  
Human Capital  
Executive KMP at CSL Behring in the role of Executive Vice President  
Plasma, Supply Chain & IT.  
6
Ceased to be an Executive Director and KMP from 13 October 2010 and  
employment ceased 31 March 2011.  
Mr Tony Cipa  
Finance Director  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
45  
Directors’ Report  
Remuneration Report  
Directors’ Report  
continued  
Human Resource and Remuneration Framework  
Responsibilities  
The HRRC is responsible for approving human resources  
initiatives of the CSL Group generally. The HRRC’s  
responsibilities include:  
The Board and its Human Resources and Remuneration  
Committee (HRRC) have various responsibilities in relation  
to the CSL Group’s human resource and remuneration  
framework.  
(a) recommending to the Board a framework or policy for  
setting the remuneration of the Managing Director and  
the CSL Group’s executives. The policy should aim to set  
remuneration outcomes which:  
The full Board has responsibility for:  
(
i) are competitive, equitable and designed to attract  
and retain high quality executives;  
(
(
(
a) approving any framework or policy for setting the  
remuneration of the Managing Director and the  
Company’s executives;  
(ii) motivate executives to pursue the long-term growth  
of the CSL Group; and  
b) appointing and, where appropriate, removing the  
Managing Director, approving other key executive  
appointments, and planning for executive succession;  
(iii) establish a clear relationship between executive  
performance and remuneration;  
c) overseeing and evaluating the performance of the  
Managing Director and other senior executives who  
report to the Managing Director in the context of the  
company’s strategies and objectives;  
(b) reviewing and recommending to the Board the design  
of any share, performance option, performance rights,  
retention and deferred cash incentive plans including  
performance measures and any amendments to such  
schemes or plans;  
(
d) reviewing and approving the remuneration of the  
Managing Director and those senior executives who  
report to the Managing Director, inclusive of fixed pay  
and short and long term incentive components (subject  
to any approval of shareholders in General Meeting  
for executive directors to acquire securities under an  
employee incentive scheme);  
(c) reviewing and recommending to the Board proposals  
from the Managing Director for allocations under share,  
performance option, performance rights, retention and  
deferred cash incentive plans;  
(
d) reviewing, approving and monitoring the implementation  
of the Company’s Human Resources Strategic Plan, and  
Performance Management Systems;  
(
(
e) approving the establishment of or any amendment to  
employee share, performance option, performance rights  
and deferred cash incentive plans;  
(
e) reviewing and recommending to the Board the total  
individual remuneration package of the Managing  
Director and of all senior executives who report to the  
Managing Director;  
f) reviewing and approving remuneration and other  
benefits to be paid to non-executive directors (subject to  
any maximum sum for remuneration of non-executive  
directors approved by shareholders in General Meeting);  
(
(
f) reviewing the CSL Group’s executive succession plan;  
g) reviewing and recommending to the Board the  
remuneration and other benefits of the Non-Executive  
Directors;  
(
(
g) on an annual basis, approving measurable objectives  
for achieving gender diversity and assessing progress  
towards achieving them; and  
(
h) engaging on behalf of the Company and interacting  
directly with any remuneration consultant required to  
assist the HRRC in matters related to the design of the  
CSL Group’s key management personnel remuneration  
system and the implementation of appropriate  
h) Board succession planning to ensure an appropriate mix  
of skills, experience, expertise and diversity (subject to  
the power of shareholders in General Meeting to elect or  
re-elect directors).  
remuneration levels within the agreed system;  
(
(
i)  
overseeing the establishment of and regular review  
of the CSL Group’s diversity policy and reviewing and  
recommending to the Board measurable objectives for  
achieving gender diversity;  
j)  
reviewing and reporting to the Board at least annually  
on the relative proportion of women and men within the  
CSL Group and of the remuneration by gender of CSL  
Group employees at all levels;  
(
(
k) reviewing bi-annually the Company’s global health,  
safety and environmental performance; and  
l)  
reporting to the Board the findings and  
recommendations of the HRRC after each meeting.  
4
6
Directors’ Report  
continued  
The HRRC comprises four independent Non-Executive  
The Chairperson of the Board does not receive any additional  
fees for committee responsibilities.  
Directors, namely David Simpson (Chairman), John Akehurst,  
David Anstice and Christine O’Reilly (from 1 May 2011). Jill  
Lever, Senior Vice President – Human Capital, acts as the  
secretary of the HRRC. The Board Chairperson may attend any  
meeting of the HRRC in an ex officio capacity. The Managing  
Director, Senior Executives and professional advisors retained  
by the HRRC attend meetings by invitation.  
Non-Executive Directors participate in the Non-Executive  
Directors’ Share Plan approved by shareholders at the 2002  
annual general meeting, as amended. The Non-Executive  
Directors’ Share Plan requires that each Non-Executive  
Director takes at least 20% of their after tax director’s base  
fee (excluding superannuation guarantee contributions) in the  
form of shares in CSL Limited.  
The HRRC meets at the conclusion of the performance  
management process, at the conclusion of the succession  
planning process, prior to the allocation of long-term  
incentives and at other times as are required to discharge its  
responsibilities. Information about the HRRC meetings held  
during the year and individual Directors’ attendance at these  
meetings can be found in section 3 of this Directors’ Report.  
Shares are purchased by Directors on-market at prevailing  
share prices, twice yearly, after the announcement of the  
Company’s half and full year results.  
The Board terminated the Non-Executive Director retirement  
plan as at 31 December 2003 and froze the retirement  
allowance as at that date. The Non-Executive Directors who  
remain entitled to a retirement allowance at the level frozen in  
Non-Executive Directors’ Remuneration  
2
003 are Elizabeth Alexander and Ian Renard.  
A remuneration pool of up to $2,500,000 for the payment  
of Non-Executive Directors was approved by shareholders on  
Directors may be reimbursed for reasonable expenses incurred  
by them in the course of discharging their duties.  
1
3 October 2010. This limit applied from 1 July 2010 and any  
increases to the limit are subject to shareholder approval at a  
general meeting.  
Table 10 shows remuneration paid to Non-Executive Directors  
in respect to the 2010 and 2011 years.  
The Board believes that the fee structure approved for Non-  
Executive Directors must:  
 ꢀe nableꢀtheꢀCompanyꢀtoꢀattractꢀandꢀretainꢀsuitablyꢀqualifiedꢀ  
directors with appropriate experience and expertise; and  
 ꢀh aveꢀregardꢀtoꢀdirectors’ꢀBoardꢀresponsibilitiesꢀandꢀtheirꢀ  
activities on Board committees.  
Table 1 below sets out annual Non-Executive Director Board  
and committee fees which became effective 1 July 2010. The  
fees are inclusive of superannuation.  
Table 1 – Annual Non-Executive Director Board and Committee Fees  
Human  
Resources &  
Remuneration  
Committee  
Securities &  
Market  
Disclosure  
Committee  
Audit & Risk  
Management  
Committee  
Innovation &  
Development  
Committee  
Nomination  
Committee  
Role  
Board Base Fee  
Chairman  
550,000  
40,000  
20,000  
30,000  
15,000  
-
-
-
-
30,000  
15,000  
Members  
180,000  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
47  
Directors’ Report  
Remuneration Report  
Directors’ Report  
continued  
Structure of Executive KMP Remuneration  
Executive KMP remuneration details prepared in accordance with statutory requirements and accounting standards are  
contained in Table 11 of this report.  
The diagram below outlines the Company’s remuneration structure for the Executive KMP covered in this report.  
TOTAL POTEꢀTIAL REꢁARD  
Long Term Incentive (LTI)  
Total Fixed  
Short Term Incentive  
being performance rights,  
performance options and  
deferred cash incentives  
Remuneration (Cash  
salary and Benefits)  
Total Potential Reward  
=
+
+
(STI)  
FIxED  
VARIABLE  
Table 2 below shows the key elements of Total Reward in 2011 as the cash elements actually available to Executive KMP in  
the 2011 year as well as the value of equity from former years that vested in 2011 and which was originally reported under  
accounting standards in the year it was granted.  
Table 2  
Executive KMP including  
Executive Directors  
Total 2011 Fixed  
Remuneration  
STI Applicable  
to the 2011 year  
Total Reward  
(received or available)  
LTI Vested in 2011*  
Dr Brian McNamee  
$2,517,900  
$1,071,414  
$480,992  
$851,481  
$702,441  
$514,382  
$476,792  
$480,928  
$378,285  
$390,600  
$422,280  
$750,784  
$1,359,666  
$538,053  
$243,989  
$361,879  
$316,098  
$167,174  
$219,570  
$231,590  
$172,298  
$117,180  
$168,912  
-
$1,614,786  
$584,753  
$274,788  
$188,035  
$333,033  
$205,387  
$185,228  
$206,260  
$161,008  
$55,959  
n/a  
$5,492,352  
$2,194,220  
$999,769  
$1,401,395  
$1,351,572  
$886,943  
$881,590  
$918,778  
$711,591  
$563,739  
$591,192  
$1,335,569  
#
Mr Peter Turner  
#
Mr Paul Perreault  
Mr Gordon Naylor  
Dr Andrew Cuthbertson  
Dr Jeffrey Davies  
#
Mr Gregory Boss  
#
Ms Mary Sontrop  
#
Ms Karen Etchberger  
Mr Edward Bailey  
Ms Jill Lever  
Mr Tony Cipaº  
$584,785  
Dr McNamee is entitled to an additional Deferred STI payment of $679,833 applicable to the 2011 year in accordance with the terms outlined on page 48-49.  
Number of Options (excluding exercise price) and rights vested during the year multiplied by the share price of $32.20 at the date of vesting.  
Ms Lever commenced employment on 1 June 2009 i.e. after the award date of the grants which vested during the 2011 year.  
*
º Mr Cipa’s fixed remuneration until cessation of employment on 31 March 2011. Mr. Cipa ceased to be a Director on 13 October 2010.  
#
2011 Fixed remuneration and STI paid in USD converted to AUD using 2011 average exchange rate.  
4
8
Directors’ Report  
continued  
Total Fixed Remuneration (TFR)  
management of operating expenses, customer service,  
behaviour that is consistent with the CSL Group values, risk  
management (including Health, Safety and Environment  
objectives) and portfolio management.  
TFR is set based on a combination of an internal assessment  
of job weight (through a global job evaluation system), review  
of market data for comparable roles and the incumbent’s  
qualifications and experience. The rate of TFR progression  
is influenced by annual reviews of performance against  
objectives and changes in the remuneration market data  
which is provided by Guerdon Associates. TFR is delivered as  
cash or benefits.  
A formal review of each Executive KMP’s progress against his  
or her specific objectives is conducted twice annually by the  
Managing Director, with the full year performance review  
discussed by the HRRC and confirmed by the Board.  
Managing Director’s Deferred Short Term Incentive  
Short-term Incentives (STI)  
A deferred cash incentive arrangement has been in place for  
the Managing Director since 2008. It operates as follows:  
The STI is a variable reward paid annually in cash to Executives  
who meet or exceed agreed objectives based on their annual  
performance evaluated under CSL’s performance management  
system. Table 3 below shows the bonus opportunity of each  
KMP and the outcome of the STI review for 2011.  
 ꢀi fꢀatꢀtheꢀendꢀofꢀtheꢀfinancialꢀyear,ꢀtheꢀManagingꢀDirector’sꢀ  
performance generates an entitlement to a cash settled  
STI then it also generates an entitlement to an additional  
deferred cash amount;  
The Board approves the Managing Director’s performance  
objectives, ensures that they are consistent with Board  
approved corporate objectives, plans and budgets after  
removing the impact of currency and reviews performance  
against objectives regularly throughout the year. The  
Managing Director sets the performance objectives of his  
direct reports, with those objectives subject to HRRC review.  
Performance objectives include a blend of financial, corporate  
and individual objectives and typically include targets in  
relation to contribution to earnings in the respective operating  
currency, the successful implementation of strategic initiatives,  
 ꢀt heꢀadditionalꢀdeferredꢀcashꢀrewardꢀisꢀequalꢀtoꢀ50%ꢀofꢀtheꢀ  
STI awarded for performance during that financial year. The  
amount is then divided by CSL Limited’s volume weighted  
share price during the last week of the entitlement year to  
give a number (‘A’); and  
•ꢀ ꢀ3 ꢀyearsꢀfromꢀtheꢀendꢀofꢀtheꢀentitlementꢀyearꢀ(orꢀearlierꢀatꢀ  
the Board’s discretion), the Managing Director is entitled to  
the payment of a cash amount equivalent to ‘A’ multiplied  
by CSL Limited’s volume weighted share price during the last  
week immediately prior to the end of that 3 year period (or  
such earlier periods as the Board may determine).  
Table 3 – Executive KMP Short Term Bonus Opportunity and Actual 2011 Bonus  
Bonus Potential Maximum %  
Executive KMP including  
Executive Directors  
of 2011 Fixed Remuneration  
at 30 June 2011  
STI Awarded as a % of  
Potential in 2011  
Actual Bonus Award in 2011  
$
Dr Brian McNamee*  
Mr Peter Turner  
Mr Paul Perreault  
Mr Gordon Naylor  
Dr Andrew Cuthbertson  
Dr Jeff Davies  
90%  
50%  
50%  
50%  
50%  
50%  
50%  
50%  
50%  
40%  
40%  
50%  
90%  
100%  
100%  
85%  
90%  
65%  
90%  
95%  
90%  
75%  
100%  
0
$2,039,499  
$538,053  
$243,989  
$361,879  
$316,098  
$167,174  
$219,570  
$231,590  
$172,298  
$117,180  
$168,912  
n/a  
Mr Greg Boss  
Ms Mary Sontrop  
Ms Karen Etchberger  
Mr Edward Bailey  
Ms Jill Lever  
Mr Tony Cipa  
*One-third of Dr. McNamee’s awarded STI bonus is deferred in accordance with the terms outlined on page 48-49.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
49  
Directors’ Report  
Remuneration Report  
Directors’ Report  
continued  
The Managing Director receives a cash payment upon the  
expiry of the relevant 3 year period (or earlier at the Board’s  
discretion). In the event of the Managing Director leaving the  
Company the earned but deferred STI is payable in full either  
at the end of the original 3 year period or earlier at the Board’s  
discretion.  
entitlement year to give a number (‘A’). Three years from the  
end of the entitlement year the Executive is entitled to the  
payment of a cash amount equivalent to ‘A’ multiplied by the  
volume weighted share price during the last week immediately  
prior to the end of that 3 year period.  
To qualify for the cash payment, Executive KMP must achieve  
at least a ‘good’ rating under CSL’s performance management  
system and must remain in employment for the full three year  
period.  
In 2011 the Managing Director became entitled to a further  
deferred STI.  
Executive Deferred Cash Incentives  
A “Good Leaver” policy applies to the EDIP. This policy allows  
the Board in its absolute discretion, to determine that any  
or all of the performance rights and performance options  
will not lapse upon cessation of employment in the case of  
voluntary retirement, bona fide redundancy, death or total and  
permanent disablement or any other reason as determined  
by the Board in its discretion. Those phantom shares which  
do not lapse will generally be calculated on a pro-rated basis  
between the grant date and the employment end date. The  
pro-rated grants will be subject to the ongoing application of  
the vesting and expiry provisions of the EDIP.  
Deferred Cash Incentives may be offered at the discretion of  
the Board under the Executive Deferred Incentive Plan (EDIP)  
in the form of Phantom Shares which are converted to cash  
at the end of a 3 year vesting period (based on CSL Limited’s  
volume weighted average share price during the 5 trading  
days immediately preceding the vesting date).  
The Board approved an allocation of phantom shares for  
Executive KMP in 2011 under the EDIP. This was done primarily  
to reduce the risk of loss of executives in roles that are: key  
to the delivery of operating or strategic objectives; manage  
critical activities; or undertake functions requiring skills that are  
in short supply and are actively sought in the market.  
In the event of a Change in Control, the Board may determine  
the manner in which Phantom Share Awards will be dealt with  
so that each participant remains in a financial position which is  
as near as possible to that which existed immediately prior to  
the Change of Control Event occurring.  
In 2011 the face value of such awards to Executive KMP was  
between 30% and 80% of the individual’s awarded STI bonus.  
The face value (refer to Table 4) was divided by CSL Limited’s  
volume weighted share price during the last week of the  
The allocation of phantom shares for Executive KMP in 2011  
was as follows:  
Table 4 – Executive KMP Deferred Cash Awards in 2011  
Executive KMP including Executive Directors  
Mr Peter Turner  
Number of Phantom Shares  
Face Value at Grant Date *$  
296,033  
8,850  
6,000  
3,300  
4,900  
4,750  
4,150  
4,950  
2,400  
1,300  
1,200  
Mr Paul Perreault  
200,700  
Mr Gordon Naylor  
110,385  
Dr Andrew Cuthbertson  
Dr Jeff Davies  
163,905  
158,888  
Mr Greg Boss  
138,818  
Ms Mary Sontrop  
165,578  
Ms Karen Etchberger  
Mr Edward Bailey  
80,280  
43,485  
Ms Jill Lever  
40,140  
*Volume weighted share price during the 5 days immediately preceding grant date multiplied by the number of phantom shares  
5
0
Directors’ Report  
continued  
Long-term Incentives - Performance Rights  
and Performance Options  
and Performance Options. Where the applicable performance  
hurdles are met, the tranche vests and the underlying  
instruments become exercisable until their expiry date. Any  
vested but unexercised Performance Rights and Performance  
Options expire seven years from the date of their initial grant.  
When performance hurdles have not been met, then the  
particular tranche of Performance Rights or Performance  
Options can be carried over to the next anniversary and  
retested. Any Performance Rights and Performance Options  
that have not vested at the retest opportunity then lapse. The  
key characteristics and terms and conditions of Performance  
Rights and Performance Options granted in 2011 are explained  
in Table 7.  
Long-term incentives are offered each year at the discretion of  
the Board in the form of Performance Rights and Performance  
Options delivered under the CSL Performance Rights Plan (the  
PRP”) which has been operating since 2003 with periodic  
changes to the PRP Rules.  
Performance Rights are issued for nil cash consideration and  
entitle the holder to subscribe for one share in CSL Limited for  
nil consideration when they vest. Performance Options are also  
issued for nil consideration and, when they vest, they entitle  
the holder to acquire one share in CSL Limited at a purchase  
price equivalent to CSL Limited’s volume weighted average  
share price in the week immediately prior to the date of grant.  
The terms and conditions and key characteristics of  
Performance Rights and Performance Options changed at  
the October 2010 grant. The characteristics of grants made  
between 2006 and 2009 are summarised in Table 15.  
A grant of Performance Rights and Performance Options is  
split into tranches, with each tranche having a different vesting  
period. At the end of a vesting period, an assessment is made  
as to whether or not the performance hurdles attaching to  
the particular tranche have been met. Both EPS and TSR  
performance hurdles are applied to both Performance Rights  
During 2011, a number of tranches of Performance Rights  
and Performance Options granted between 2006 and 2009  
reached the test date for vesting. The outcomes are shown in  
Table 5.  
Table 5 – 2011 Vesting Outcomes (Performance Rights and Performance Options granted 2006-2009)  
Performance Rights  
Grant Date  
October 2006  
October 2007  
April 2008  
Tranche  
Tranche 3  
Tranche 2  
Tranche 2  
Tranche 1  
Tranche 1  
Vest Date  
October 2010  
October 2010  
April 2011  
Relative TSR Percentile Ranking  
th  
96.7  
th  
82.8  
th  
72.8  
October 2008  
April 2009  
Did not vest  
Did not vest  
-
-
Performance Options  
Grant Date  
October 2006  
October 2007  
April 2008  
Tranche  
Tranche 3  
Tranche 2  
Tranche 2  
Tranche 1  
Tranche 1  
Vest Date  
October 2010  
October 2010  
April 2011  
Compound Annual EPS Growth  
26.4%  
18.6%  
18.6%  
13.5%  
13.5%  
October 2008  
April 2009  
October 2010  
April 2011  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
51  
Directors’ Report  
Remuneration Report  
Directors’ Report  
continued  
In 2010 the Board completed a comprehensive review of the  
PRP with independent advice provided by Ernst and Young  
and made a number of changes to the PRP design. Long term  
incentives in the form of Performance Rights and Performance  
Options were offered in the 2011 year to all Executive KMP  
and to 13 other Senior Executives at the level of Senior Vice  
President and above. The grant of Performance Rights and  
Options to Executive Directors is in accordance with the  
resolution approved by shareholders at the 2010 annual  
general meeting.  
Key features of the October 2010 grant under the PRP include:  
 ꢀS ubjectꢀtoꢀperformanceꢀhurdlesꢀbeingꢀsatisfied,ꢀvestingꢀ  
of 50% of the LTI award will occur after 3 years, with the  
remaining 50% vesting after the 4th anniversary of the  
award date;  
 ꢀT heꢀmixꢀofꢀlong-termꢀincentivesꢀisꢀ80%ꢀPerformanceꢀRightsꢀ  
and 20% Performance Options;  
 ꢀB othꢀEPSꢀandꢀTSRꢀmeasuresꢀ(seeꢀTableꢀ7)ꢀareꢀappliedꢀtoꢀ  
both Performance Rights and Performance Options;  
The Board determined a maximum allocation value for  
Executive KMP and 13 other Senior Executives of $9.4 million  
in 2010/2011 for LTI equity awards comprising performance  
rights and performance options. The value which may  
ultimately be realised from these awards is dependent upon  
CSL’s performance and its future share price. In accordance  
with Board Policy, Executive KMP are not permitted, either by  
hedging or any other method, to limit their exposure to risk in  
relation to any share based equity rewards. From time to time,  
the Company Secretary makes inquiries of Executive KMP as to  
their compliance with this policy.  
 ꢀE achꢀtrancheꢀofꢀPerformanceꢀRightsꢀandꢀPerformanceꢀ  
Options will have one retest opportunity in the event that  
performance hurdles are not met at the first testing date. If  
the performance hurdles are not met on the retest dates the  
instruments lapse;  
 ꢀT heꢀ“GoodꢀLeaver”ꢀpolicyꢀallowsꢀtheꢀBoardꢀinꢀitsꢀ  
absolute discretion, to determine that any or all of the  
Performance Rights and Performance Options will not lapse  
upon cessation of employment in the case of voluntary  
retirement, bona fide redundancy, death or total and  
permanent disablement or any other reason as determined  
by the Board in its discretion. Those Performance Rights  
and Performance Options which do not lapse will generally  
be calculated on a pro-rated basis between the grant date  
and the employment end date. The pro-rated grants will be  
subject to the ongoing application of the vesting and expiry  
provisions of the PRP Rules; and  
The grant of long term incentives to Executive KMP including  
Executive Directors in 2011 is based on a percentage of fixed  
remuneration rising with job weight as noted in Table 6 below.  
Table 6 – Executive KMP – Long Term Incentive in 2011  
Executive KMP including  
Executive Directors  
Rights and Options* as a % of  
Fixed Remuneration  
 ꢀI nꢀtheꢀeventꢀofꢀaꢀChangeꢀinꢀControl,ꢀtheꢀBoardꢀmayꢀ  
determine the manner in which Performance Rights and  
Performance Options will be dealt with so that each  
participant remains in a financial position which is as near  
as possible to that which existed immediately prior to the  
Change of Control Event occurring.  
Dr Brian McNamee  
Mr Peter Turner  
80%  
75%  
75%  
75%  
75%  
70%  
75%  
70%  
70%  
60%  
60%  
Mr Paul Perreault  
Mr Gordon Naylor  
Dr Andrew Cuthbertson  
Dr Jeff Davies  
The key characteristics and terms and conditions of  
Performance Rights and Performance Options granted in 2011  
are summarised in Table 7.  
Mr Gregory Boss  
Ms Mary Sontrop  
Ms Karen Etchberger  
Mr Edward Bailey  
Ms Jill Lever  
*
The number of performance rights and performance options are  
calculated based on an assessment of the fair market value of the  
instruments in accordance with the accounting standards (refer Note 27 in  
the Financial Statements).  
5
2
Directors’ Report  
continued  
LTI Business Performance Hurdles  
(ii) Basic Earnings per Share (EPS)  
Two types of quantitative performance hurdles are used to  
assess whether or not performance rights and performance  
options vest at the relevant testing dates. The use of these  
performance hurdles results in an alignment of long-term  
incentive rewards/outcomes with corporate performance  
and returns to shareholders. They increase the market  
competitiveness of Executive KMP remuneration and facilitate  
the attraction and retention of high calibre executives.  
Performance Rights and Performance Options subject to an  
EPS hurdle only vest where CSL Limited achieves a compound  
EPS growth per annum of 10% or greater. This is measured  
from 30 June in the financial year preceding a grant of  
Performance Rights or Performance Options until 30 June in  
the financial year prior to the relevant test date. The Board  
may use its discretion to adjust the EPS used for performance  
measurement purposes to exclude the profit and loss impact  
attributable to significant events or transactions. In the past  
this has been done in respect of the contingent payment  
relating to the acquisition of Aventis Behring and profit after  
tax upon disposal of JRH Biosciences, the cancelled Talecris  
acquisition and the sales of H N vaccines.  
(i) Relative Total Shareholder Return (TSR)  
A company’s TSR is measured by reference to increases in  
share price between grant date and vesting date (or retest date  
where applicable) and by reference to dividends paid during  
those dates. Performance Rights and Performance Options  
subject to a TSR hurdle only start to vest when CSL’s TSR places  
it at or above the 50th percentile of relative TSR performance  
as compared against a peer group. The peer group is the  
ASX top 100 companies by market capitalisation (excluding  
commercial banks, oil and gas and metals and mining). The  
peer group of companies whose TSR performance is compared  
to CSL’s is fixed at the date when a grant of rights and options  
is made. If on a test date, a de-listing occurs of companies  
in the peer group on grant date because of a merger into a  
new entity, the merged entities, both pre and post merger are  
excluded from the peer group.  
1
1
Table 7 – Key Characteristics of Performance Rights and Options granted 2011  
Applicable performance  
hurdle  
Tranche comprises  
Proportion  
of Grant  
Performance Performance Performance Performance  
Vesting  
Period years opportunities  
Re-test  
LTI Grant year Tranche  
Options  
Rights  
Options  
Rights  
1
50%  
50%  
20%  
80%  
3
4
1
1
2
011  
50% EPS / 50% TSR  
2
20%  
80%  
LTI Grant year  
Level of performance at the expiration of the vesting period  
Amount of grant which vests  
5
5
0% of options and rights granted  
0% of options and rights granted  
EPS growth = or >10% compound  
100%  
Below the 50th percentile in relative  
TSR performance  
0%  
At the 50th percentile in relative TSR  
performance  
50%  
2011  
Between the 50th and 75th percentile  
in relative TSR performance  
Straight line vesting from 50%  
to 100%  
Above the 75th percentile in relative  
TSR performance  
100%  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
53  
Directors’ Report  
Remuneration Report  
Directors’ Report  
continued  
Cap on Issue of Equity to Employees  
The creation of shareholder value is reflected in the Company’s  
earnings per share (EPS) and Total Shareholder Return (TSR).  
The PRP Rules approved by shareholders at the 2003 Annual  
General Meeting require that, at any point in time, the  
aggregate number of CSL shares that:  
The payment of long-term equity rewards in the form of  
performance rights and performance options is linked to  
compound EPS (adjusted for significant one off events) and  
relative TSR. This is explained further on page 52.  
 ꢀh aveꢀpreviouslyꢀbeenꢀissuedꢀtoꢀemployeesꢀunderꢀtheꢀ  
Company’s employee equity plans and which remain subject  
to the rules of the relevant plan (e.g. a disposal restriction);  
and  
The company’s EPS over the last five years is displayed in the  
graph below.  
 ꢀw ouldꢀbeꢀissuedꢀifꢀallꢀoutstandingꢀshareꢀoptionsꢀunderꢀ  
such plans (whether or not vested at the time) were to be  
exercised,  
Basic earnings per share  
(
cents)*  
must not exceed 7.5% of the total number of CSL shares on  
issue at that time.  
As at 30 June 2011 the aggregate number of CSL shares  
under (a) and (b) above was 0.99% of the total number of CSL  
shares on issue.  
2
00  
1
50  
In addition, to satisfy a condition of the exemption granted by  
the Australian Securities and Investments Commission from  
certain prospectus and licensing laws, CSL must ensure that,  
at the time of each offer of shares or share options under an  
employee equity plan, the aggregate number of CSL shares  
which are:  
1
00  
50  
0
 ꢀt heꢀsubjectꢀofꢀoutstandingꢀoffersꢀofꢀsharesꢀorꢀshareꢀoptionsꢀ  
to, or outstanding share options held by employees in  
Australia; and  
0
6-07  
07-08  
08-09  
09-10  
10-11  
 ꢀi ssuedꢀtoꢀemployeesꢀinꢀAustraliaꢀunderꢀtheꢀCompany’sꢀ  
equity plans in the 5 year period preceding the offer,  
* In the above graph, the EPS used for performance management purposes  
has been adjusted to exclude the profit and loss impact attributable to the  
following significant events and transactions:  
in each case, after disregarding offers to or holdings of exempt  
offer recipients, must not exceed 5% of the total number of  
CSL shares on issue at the time of the offer.  
•ꢀ ꢀ2 009ꢀfinancialꢀyearꢀexcludedꢀtheꢀfavourableꢀNPATꢀimpactꢀofꢀ$79mꢀ  
(
or 13.3 cents per share) arising from the termination of the Talecris  
acquisition; and  
 ꢀ2 010ꢀfinancialꢀyearꢀexcludedꢀtheꢀfavourableꢀNPATꢀimpactꢀofꢀ$122mꢀ  
(
or 21.5 cents per share) attributable to H N pandemic influenza sales.  
1 1  
Relationship between Company Performance and  
Executive KMP Remuneration  
The Company’s remuneration framework aims to incentivise  
Executive KMP towards growth and long-term sustainability of  
the business, and the creation of shareholder value.  
Performance objectives for short term incentive awards include  
a blend of financial, corporate and individual objectives  
and typically include targets in relation to contribution to  
earnings (in the respective operating currency), the successful  
implementation of strategic initiatives, management of  
operating expenses, customer service, behaviour that is  
consistent with the CSL Group values, risk management  
(
including Health, Safety and Environment objectives) and  
portfolio management.  
5
4
Directors’ Report  
continued  
Table 8 below illustrates the Company’s annual compound  
Executive KMP (including Executive Directors)  
growth in basic EPS in respect of performance options granted  
in 2007, 2008, 2009 and 2010 respectively.  
Executive KMP are employed under individual service  
contracts. The service contract outlines terms of employment  
including fixed remuneration. The potential short-term  
incentive may be stipulated in the contract or be governed by  
the Company’s remuneration policy which sets out the level  
applicable to various seniority levels. The award of short or  
long term incentives remains at the discretion of the Board.  
Table 8 – Annual Compound Growth in Basic EPS  
Compound EPS growth  
to end of financial year  
Year of Grant  
2008  
2009  
35%  
41%  
2010  
19%  
13%  
-8%  
2011  
15%  
11%  
-1%  
6%  
Employment contracts for Executive KMP do not have a fixed  
term. The contracts may be terminated by the Company or  
the Executive by giving 6 months notice. An Executive KMP’s  
employment may be terminated without notice and without  
payment in lieu in the event of serious misconduct and/or  
breach of contract. On termination by the Company for other  
reasons, including redundancy, an Executive KMP is entitled  
to 6 months notice and to receive12 months salary (excluding  
non-cash benefits). New contracts from November 2009  
contain provisions which explicitly limit termination payments  
in accordance with the changes implemented by the Australian  
Government in 2009 unless shareholder approval is sought to  
exceed those limits.  
2007  
2008  
2009  
2010  
30%  
The company’s TSR performance over the relevant performance  
periods up to 30 June 2011 in respect of as yet unvested  
performance rights shown in Table 9 below is indicative and  
for information purposes. The formal TSR calculations will be  
undertaken at the vesting date.  
Advisers to the HRRC  
Table 9 – Relative TSR Performance from Grant Date to 30 June 2011  
The Board and HRRC engage the services of independent  
consultants for the provision of market remuneration data  
and to advise on the remuneration of Non-Executive Directors,  
Executive Directors and Executive Key Management Personnel.  
During 2010/2011, remuneration consulting services were  
provided by Guerdon Associates. Ernst & Young assisted in  
the design of a revised long-term incentive scheme which was  
introduced from 1 October 2010.  
Indicative Relative  
TSR Percentile Ranking  
Performance Right Issue  
October 2007  
April 2008  
77.2%  
68.6%  
October 2008  
April 2009  
40.9%  
17.7%  
In 2011, Guerdon Associates was appointed as principal  
advisers on executive remuneration contracted by and  
reporting directly to the HRRC.  
October 2009  
October 2010  
54.6%  
52.3%  
Remuneration for Australia based Executive KMP was primarily  
compared with: matched executives from an ASX 50 peer  
group comprising 18 ASX50 companies either side of CSL in  
market capitalisation such that CSL approximated to the 50th  
percentile.  
Employment Contracts  
Non-Executive Directors  
There are no specific employment contracts with Non-Executive  
Directors. Non-Executive Directors are appointed under a  
letter of appointment and are subject to ordinary election and  
rotation requirements as stipulated in the ASX Listing Rules and  
CSL Limited’s constitution.  
Remuneration for US based Executive KMP was primarily  
compared with 14 international biomedical and  
pharmaceutical companies where CSL approximated to the  
5
0th percentile on market capitalisation.  
The comparison with relevant market data is an important  
input to the positioning of Executive KMP remuneration.  
In determining appropriate Executive KMP remuneration,  
the Board also take into consideration internal relativities,  
experience and performance.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
55  
Directors’ Report  
Remuneration Report  
Directors’ Report  
continued  
Remuneration Tables  
Remuneration Tables and additional Remuneration Disclosures are  
outlined in the following section of this report.  
Table 10 – Executive and Non-Executive Directors Remuneration  
Directors  
Year  
Short-term benefits  
Post employment  
Other long-term  
Long  
Share Based Payments  
Cash  
Settled  
Non-  
Cash monetary  
bonus benefits annuation  
Cash salary  
and fees1  
Super- Retirement Termination  
service  
leave  
Deferred Performance Performance Deferred  
Incentive  
$
2 2  
options Payment5  
benefits  
Payments  
rights  
Total  
$
$
$
$
$
$
$
$
$
$
$
Executive Directors  
Dr Brian McNamee  
Managing Director  
2011 2,503,863 1,359,666  
-
49,999  
50,000  
-
-
-
-
-
-
-
168,630 679,833  
865,915  
862,939  
985,329  
-
6,490,845  
6,083,365  
2010 2,195,406 1,260,000  
-
-
110,918 630,000  
851,712  
380,123  
338,256  
22,948  
93,968  
-
Mr Peter Turner  
Executive Director  
Mr Tony Cipa3  
2011 1,094,863  
538,053 16,127 243,231  
-
80,896  
88,077  
18,773  
98,327  
-
375,124 68,742 2,797,159  
2010 1,115,605  
593,866 13,330 247,735  
-
500,523  
-
-
-
-
415,303  
33,842  
14,969  
-
-
-
2,812,172  
1,361,634  
1,514,590  
2011  
764,477  
-
-
21,071  
Finance Director  
2010  
937,292  
350,366  
-
19,668  
Non-executive Directors  
Ms Elizabeth Alexander 2011  
527,294  
440,894  
178,899  
175,138  
192,661  
185,138  
201,835  
195,138  
192,661  
185,138  
178,899  
175,138  
211,009  
200,138  
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
22,706  
29,106  
16,101  
15,762  
17,339  
16,662  
18,165  
17,562  
17,339  
16,662  
16,101  
15,762  
18,991  
18,012  
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
550,000  
470,000  
195,000  
190,900  
210,000  
201,800  
220,000  
212,700  
210,000  
201,800  
195,000  
190,900  
230,000  
218,150  
Chairman  
2010  
2011  
2010  
2011  
2010  
2011  
2010  
2011  
2010  
2011  
2010  
2011  
2010  
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Mr John Akehurst  
Non-executive director  
Mr David Anstice  
Non-executive director  
Mr Ian Renard  
Non-executive director  
Mr Maurice Renshaw  
Non-executive director  
Professor J Shine  
Non-executive director  
D J Simpson  
Non-executive director  
Ms Christine O’Reilly4  
Non-executive Director  
2
2
011  
67,278  
-
-
6,055  
-
-
-
-
-
-
-
73,333  
011 6,113,739 1,897,719 16,127 447,098  
010 5,805,025 2,204,232 13,330 446,931  
-
500,523 268,299 679,833 1,268,986 1,271,905 68,742 12,532,971  
297,322 630,000 1,283,936 1,415,601 12,096,377  
Total of all Directors  
2
-
-
-
1
As disclosed in the section titled “Non-Executive Director Remuneration”, Non-Executive Directors participate in the NED Share Plan under which Non-Executive Directors  
are required to take at least 20% of their after-tax base fees (excluding superannuation guarantee contributions) in the form of shares in the Company which are purchased  
on-market at prevailing share prices. The value of this remuneration element is included in cash, salary and fees. Cash salary and fees and cash bonuses paid in foreign  
currency in respect to Mr P Turner who was based overseas have been converted to Australian dollars at an average exchange rate for the year. Both the amount of  
remuneration and any movement in comparison to prior years may be influenced by changes in the respective currency exchange rates.  
2
3
The options and rights have been valued using a combination of the Binomial and Black Scholes option valuation methodologies as at the grant date adjusted for the  
probability of performance hurdles being achieved. This valuation was undertaken by PricewaterhouseCoopers. The amounts disclosed in remuneration have been  
determined by allocating the value of the options and performance rights evenly over the period from grant date to vesting date in accordance with applicable accounting  
standards. As a result, the current year includes options that were granted in prior years.  
As announced to the ASX in December 2009, Mr Cipa resigned from his positions as Chief Financial Officer and Executive Director at the conclusion of the Annual General  
Meeting in October 2010. He was available to the Company in an advisory capacity until 31 March 2011 at which time he received entitlements due under his contract.  
4
5
Ms C O’Reilly was appointed Director from 16 February 2011 and her remuneration is referrable to services rendered from that date until 30 June 2011.  
The fair value of the cash settled deferred payment (EDIP) has been measured by reference to the CSL share price at reporting date, adjusted for the dividend yield and the  
number of days left in the vesting period.  
5
6
Directors’ Report  
continued  
Table 11 – Non director executive key management personnel and other executive remuneration  
Executives  
Year  
Short-term benefits  
Cash  
Post employment Share Based Payments  
Other long-term  
Non-  
Cash Settled  
Deferred  
salary and  
fees1  
Cash monetary  
bonus1 benefits1 annuation  
Super- Retirement Termination Long Service Deferred Performance Performance  
1
2
2
options  
6
benefits  
$
Payments  
$
Leave Incentive  
rights  
Payment  
Total  
$
$
$
$
$
$
$
$
$
$
Key Management Personnel  
Mr Paul Perreault3  
2011 491,796 243,989 19,286  
President CSL Behring 2010 500,955 252,467 21,889  
20,431  
-
-
-
-
-
-
-
-
-
-
-
-
-
207,867  
192,564  
240,480  
149,426  
223,915  
46,605 1,253,889  
20,832  
17,576  
22,109  
-
249,460  
221,795  
222,863  
-
25,633  
-
1,238,167  
1,930,766  
1,229,624  
Mr Gordon Naylor  
2011 898,684 361,879 11,956  
152,763  
Chief Financial Officer  
2010 507,545 222,328 39,868  
65,485  
Dr Andrew  
Cuthbertson  
Chief Scientific Officer  
2
011 713,045 316,098  
-
24,252  
-
-
32,687  
-
206,758  
195,958  
38,060 1,526,858  
1,432,604  
2
010 625,063 311,831  
2,458  
36,137  
-
-
45,681  
-
192,344  
219,090  
-
Dr Jeff Davies  
Executive VP, CSL  
Biotherapies  
2
011 430,268 167,174  
-
119,882  
-
-
33,408  
-
177,641  
188,058  
36,895 1,153,326  
1,178,571  
32,235 1,126,308  
1,043,791  
38,449 1,337,883  
2
010 429,639 226,233  
-
135,396  
-
-
50,385  
-
135,301  
201,617  
-
Mr Greg Boss  
Group General Counsel  
2011 494,107 219,570 19,285  
19,119  
-
-
-
-
172,261  
169,731  
2
010 462,257 244,701 21,397  
21,218  
-
-
-
-
118,166  
176,052  
-
Ms Mary Sontrop4  
Executive VP,  
Operations  
2
011 507,597 231,590 11,872 131,901  
010 375,374 236,618 1,035 144,963  
-
-
45,843  
-
181,140  
189,491  
2
-
-
25,781  
-
136,087  
202,910  
-
1,122,768  
Ms Karen Etchberger5  
Executive VP, Plasma,  
Supply Chain & IT  
2011 378,196 172,298 26,591  
2011 388,386 117,180  
22,697  
-
-
-
-
123,724  
121,201  
18,642  
863,349  
Mr Edward Bailey  
-
16,400  
-
-
33,717  
-
79,178  
61,366  
10,098  
706,325  
Company Secretary  
2010 298,592 104,160  
6,595  
26,876  
-
-
11,405  
-
40,361  
49,834  
-
537,823  
Ms Jill Lever  
Senior VP, Human  
Capital  
2
011 365,570 168,912  
-
34,569  
-
-
11,730  
-
72,713  
60,070  
9,321  
722,885  
2
010 331,680 108,800  
-
28,073  
-
-
7,798  
-
25,584  
37,648  
-
539,583  
Total KMP  
remuneration  
2011 4,667,649 1,998,690 88,990 406,827  
010 3,531,105 1,707,138 93,242 435,604  
-
-
310,148  
-
1,461,762 1,431,585  
255,938 10,621,589  
8,322,931  
2
-
-
206,535  
-
989,833 1,359,474  
-
1
Cash salary and fees, cash bonuses and superannuation paid in foreign currency in respect to executives based overseas have been converted to Australian dollars at an  
average exchange rate for the year. Both the amount of remuneration and any movement in comparison to prior years may be influenced by changes in the respective  
currency exchange rates. The remuneration amounts disclosed in respect of Mr Perreault, Mr Boss, Ms Sontrop and Ms Etchberger are impacted by the AUD/USD  
exchange rate. All other executives listed in Table 11 receive remuneration which is solely denominated in Australian dollars.  
2
The options and rights have been valued using a combination of the Binomial and Black Scholes option valuation methodologies as at the grant date adjusted for the  
probability of hurdles being achieved. This valuation was undertaken by PricewaterhouseCoopers. The amounts disclosed have been determined by allocating the value  
of the options and performance rights evenly over the period from grant date to vesting date in accordance with applicable accounting standards. As a result, the  
current year includes options that were granted in prior years.  
3
4
Mr Perreault’s appointment as President CSL Behring Designate was announced to the ASX in March 2011. He assumed the role on 1 July 2011. The 2010 remuneration  
report disclosed his remuneration as he was one of the top five remunerated executives in that year. His total remuneration disclosed for the 2011 is attributable to a 12  
month period rather than solely to the period subsequent to his appointment to his present role.  
Ms Sontrop relocated to the US to assume the role of Executive Vice President Operations CSL Behring from 1 April 2010. Her 2010 remuneration represents her  
remuneration for a 12 month period ending 30 June 2010.  
5
6
Ms Etchberger is the Executive Vice President Plasma, Supply Chain and IT and is an Executive KMP.  
The fair value of the cash settled deferred payment (EDIP) has been measured by reference to the CSL share price at reporting date, adjusted for the dividend yield and  
the number of days left in the vesting period.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
57  
Directors’ Report  
Remuneration Report  
Directors’ Report  
continued  
Executive Key Management Personnel  
Fixed and Performance Remuneration Components  
Table 12 – Executive key management personnel remuneration components in the 2011 financial year  
Variable Remuneration  
Share Based Payments  
Remuneration Components  
as a Proportion of  
Total Remuneration  
Cash Settled  
Deferred  
Payment  
Fixed  
Cash Based  
Bonuses  
Performance  
rights  
Performance  
options  
Total  
(100%)  
Remuneration1  
2
Total  
Executive Directors  
Dr Brian McNamee  
Mr Peter Turner  
42%  
51%  
96%  
32%  
19%  
-
13%  
14%  
2%  
13%  
13%  
2%  
-
3%  
-
58%  
49%  
4%  
100%  
100%  
100%  
Mr Tony Cipa  
Other executives  
Mr Paul Perreault  
Mr Gordon Naylor  
Dr Andrew Cuthbertson  
Dr Jeff Davies  
42%  
56%  
50%  
51%  
47%  
52%  
50%  
62%  
57%  
19%  
18%  
20%  
15%  
20%  
17%  
20%  
17%  
23%  
17%  
13%  
14%  
15%  
15%  
14%  
14%  
11%  
10%  
18%  
12%  
13%  
16%  
15%  
14%  
14%  
9%  
4%  
1%  
3%  
3%  
3%  
3%  
2%  
1%  
1%  
58%  
44%  
50%  
49%  
53%  
48%  
50%  
38%  
43%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
Mr Greg Boss  
Ms Mary Sontrop  
Ms Karen Etchberger  
Mr Edward Bailey  
Ms Jill Lever  
9%  
1
Fixed remuneration comprises cash salary, superannuation and non monetary benefits.  
Cash based bonuses include amounts awarded which are due and payable shortly after the conclusion of the financial year as well as that component of  
Dr McNamee’s entitlement which is subject to deferred settlement terms.  
2
5
8
Directors’ Report  
continued  
Table 13 – Executive KMP performance remuneration components in the 2011 financial year  
Grant date  
value of Reporting  
options date value  
& rights  
granted  
during  
2011  
Value of  
options  
& rights  
exercised  
Remuneration  
consisting of  
Share Based  
Payments  
of EDIP  
Accounting Values being amortised in respect  
granted during 2011  
Key management  
person  
of the 2011 Share Based Payment grants in  
during  
at exercise  
Cash incentives1  
future years  
2
2011  
3
date  
4
Maximum  
short-term  
incentive Percentage  
Percentage  
Not  
Awarded1  
2012  
$
2013  
$
2014  
$
2015  
$
potential  
Awarded1  
%
$
$
$
Executive Directors  
Dr Brian McNamee  
Mr Peter Turner  
90%  
50%  
50%  
90%  
100%  
-
10%  
0%  
-
589,194  
355,720  
-
587,584  
354,748  
-
336,370  
173,524  
-
63,445  
28,344  
-
26% 2,014,464  
-
276,736  
-
8,021,027  
1,227,654  
7,326,118  
30%  
4%  
899,960  
-
Mr Tony Cipa  
Other executives  
Mr Paul Perreault  
Mr Gordon Naylor  
Dr Andrew Cuthbertson  
Dr Jeff Davies  
50%  
50%  
50%  
50%  
50%  
50%  
50%  
40%  
40%  
100%  
85%  
90%  
65%  
90%  
95%  
90%  
75%  
100%  
0%  
15%  
10%  
35%  
10%  
5%  
181,484  
221,252  
205,316  
154,914  
162,148  
162,191  
112,020  
82,140  
180,988  
220,647  
204,755  
154,491  
161,705  
161,748  
111,714  
81,916  
83,571  
115,292  
100,850  
72,577  
78,710  
76,063  
55,937  
42,552  
39,973  
12,790  
20,111  
16,594  
11,335  
12,790  
11,894  
9,361  
39%  
26%  
30%  
34%  
33%  
31%  
30%  
21%  
20%  
406,088  
638,539  
526,879  
359,913  
406,088  
377,646  
297,235  
234,383  
220,513  
187,618  
103,190  
153,221  
148,531  
129,769  
154,785  
75,047  
810,615  
599,139  
1,194,647  
-
Mr Greg Boss  
357,420  
129,372  
98,496  
142,733  
-
Ms Mary Sontrop  
Ms Karen Etchberger  
Mr Edward Bailey  
Ms Jill Lever  
10%  
25%  
0%  
7,382  
40,651  
77,038  
76,828  
6,945  
37,524  
1
Cash incentives awarded and not awarded relate to the period ended 30 June 2011. All cash incentive amounts are payable in full shortly after the conclusion of the  
0 June 2011 financial year with the exception of that component of Dr McNamee’s cash incentive that is subject to deferred settlement.  
3
The extent to which executives meet and exceed their annual performance objectives determines the level of award received. To be awarded 100% of the potential  
short-term incentive, the executive is required to have exceeded all performance objectives.  
The value of performance rights and performance options is determined at grant date and is then amortised over the applicable vesting period. The amounts  
included in the table above are consistent with this amortisation amount for 2011.  
The value of the EDIP was re-calculated at reporting date and then amortised over the applicable vesting period. The amounts included in the table above are  
consistent with this amortisation amount for 2011.  
The value at exercise date has been determined by the share price at the close of business on exercise date less the option/right exercise price (if any) multiplied by  
the number of options/rights exercised during 2011.  
2
3
4
CSL Limited  
Annual Report 2010-2011  
Financial Report  
59  
Directors’ Report  
Remuneration Report  
Directors’ Report  
continued  
Executive Key Management Personnel  
Options and Rights Holdings  
Table 14 - Executive KMP performance right holdings  
Balance at 30 June 2011  
Number  
Lapsed /  
Forfeited  
Balance at  
1 July 2010  
Number  
Granted  
Number  
Exercised  
Balance at  
30 June 2011  
Number Vested  
during the year  
Vested and  
exercisable  
Key management person  
Executive Directors  
Mr Brian McNamee  
Mr Peter Turner  
Unvested  
119,240  
35,289  
61,020  
27,260  
-
61,356  
10,077  
-
-
118,904  
52,472  
-
27,189  
10,077  
10,077  
-
-
-
118,904  
52,472  
-
Mr Tony Cipa  
186,060  
172,668  
13,392  
Other executives  
Mr Paul Perreault  
Mr Gordon Naylor  
Mr Andrew Cuthbertson  
Dr Jeff Davies  
20,846  
18,362  
23,480  
31,710  
14,767  
16,830  
10,972  
6,740  
12,300  
19,340  
15,960  
10,900  
12,300  
11,440  
9,000  
5,322  
3,702  
10,512  
-
-
27,824  
34,000  
28,928  
42,610  
23,764  
24,532  
17,092  
13,840  
10,300  
394,266  
5,322  
3,702  
5,772  
3,696  
3,303  
3,738  
2,880  
1,125  
-
-
27,824  
34,000  
28,928  
23,944  
23,764  
24,532  
17,092  
11,308  
10,300  
373,068  
-
-
-
-
-
18,666  
Mr Greg Boss  
3,303  
3,738  
2,880  
-
-
-
Ms Mary Sontrop  
Ms Karen Etchberger  
Mr Edward Bailey  
Ms Jill Lever  
-
-
-
-
2,532  
-
7,100  
-
-
3,620  
6,680  
-
Total  
487,916  
193,300  
273,558  
13,392  
76,881  
21,198  
The number of ordinary shares issued on exercise of performance rights is equivalent to the number of performance rights exercised. No amounts are payable  
on exercise of performance rights.  
Table 15 - A summary of the key characteristics applicable to performance rights and performance options granted between 2006 and 2009  
Applicable performance  
Tranche comprises  
hurdle  
Proportion  
of Grant  
Performance Performance Performance Performance Vesting Period  
Re-test  
opportunities  
LTI Grant year Tranche  
Options  
Rights  
Options and  
EPS / TSR  
Rights  
years  
2006-2009  
1
2
3
25%  
35%  
40%  
60%  
60%  
60%  
40%  
40%  
40%  
2
3
4
3
2
1
Level of performance at the expiration of the vesting period  
(or later period where applicable)  
LTI Grant year  
Amount of grant which vests  
Options  
Rights  
EPS growth>10% compound  
100%  
2006-2009  
At or above 50th percentile in relative  
TSR performance  
100%  
6
0
Directors’ Report  
continued  
Table 16 - The terms and conditions of the performance rights granted to Executive KMP in the 2010 and 2011 financial years  
Terms and Conditions for Performance right grants during 2010 and 2011  
Value per Right  
Grant Date  
Tranche  
at Grant Date  
First Exercise Date  
30 September 2011  
30 September 2012  
30 September 2013  
30 September 2013  
30 September 2014  
Last Exercise Date  
30 September 2014  
30 September 2014  
30 September 2014  
30 September 2015  
30 September 2015  
1
1
1
1
1
October 2009  
October 2009  
October 2009  
October 2010  
October 2010  
1
2
3
1
2
28.91  
27.72  
26.31  
26.59  
26.23  
Table 17 - Shares issued to Executive KMP on exercise of performance rights during 2011  
Executive  
Date Performance Rights Granted  
Number of shares issued  
46,920  
14,436  
6,864  
2
1
2
1
October 2006  
Dr Brian McNamee  
October 2007  
October 2006  
October 2007  
1 March 2004  
Mr Peter Turner  
3,213  
3
60,000  
45,000  
45,000  
17,160  
5,508  
7
June 2005  
Mr Tony Cipa  
20 December 2005  
2
1
2
1
2
1
2
1
2
1
2
1
2
1
October 2006  
October 2007  
October 2006  
October 2007  
October 2006  
October 2007  
October 2006  
October 2007  
October 2006  
October 2007  
October 2006  
October 2007  
October 2006  
October 2007  
3,096  
Mr Paul Perreault  
Mr Gordon Naylor  
Dr Andrew Cuthbertson  
Mr Greg Boss  
2,226  
2,232  
1,470  
7,200  
3,312  
2,232  
1,071  
2,520  
Ms Mary Sontrop  
Ms Karen Etchberger  
1,218  
1,872  
1,008  
No amount is payable on exercise of performance rights. One ordinary share is issued on the exercise of each performance right.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
61  
Directors’ Report  
Remuneration Report  
Directors’ Report  
continued  
Table 18 - Executive KMP option holdings  
Balance at 30 June 2011  
Number  
Lapsed /  
Exercised Forfeited 30 June 2011 during the year  
Balance at  
1 July 2010  
Number  
Granted  
Number  
Balance at Number Vested  
Vested and  
exercisable Unvested  
Key management person  
Executive Directors  
Dr Brian McNamee  
Mr Peter Turner  
Mr Tony Cipa  
411,740  
131,216  
121,560  
46,420  
20,740  
-
158,760  
23,256  
58,140  
-
-
299,400  
128,700  
-
109,398  
42,081  
42,081  
65,304  
26,250  
-
234,096  
102,450  
-
63,420  
Other executives  
Mr Paul Perreault  
Mr Gordon Naylor  
Dr Andrew Cuthbertson  
Dr Jeff Davies  
87,400  
75,160  
81,230  
74,620  
54,744  
62,296  
41,012  
19,420  
13,660  
1,174,058  
9,360  
14,720  
12,140  
8,300  
19,620  
-
77,140  
75,660  
68,980  
82,920  
56,520  
70,996  
47,872  
20,500  
18,740  
947,428  
22,400  
17,126  
23,434  
16,902  
14,809  
17,049  
12,033  
3,060  
17,051  
12,947  
14,866  
32,361  
9,700  
60,089  
62,713  
54,114  
50,559  
46,820  
51,127  
33,499  
18,613  
18,740  
732,820  
14,220  
-
24,390  
-
-
-
Mr Greg Boss  
9,360  
7,584  
-
Ms Mary Sontrop  
Ms Karen Etchberger  
Mr Edward Bailey  
Ms Jill Lever  
8,700  
-
-
19,869  
14,373  
1,887  
6,860  
-
4,320  
-
-
5,400  
-
-
5,080  
-
-
Total  
147,080  
310,290  
63,420  
320,373  
214,608  
6
2
Directors’ Report  
continued  
Table 19 - Terms and conditions of the options granted to Executive KMP (amongst others) during 2010 and 2011  
Terms and Conditions for Options grant during 2010 and 2011  
Value per Option  
Grant Date  
Tranche  
at Grant Date  
First Exercise Date  
30 September 2011  
30 September 2012  
30 September 2013  
30 September 2013  
30 September 2014  
Last Exercise Date  
30 September 2014  
30 September 2014  
30 September 2014  
30 September 2015  
30 September 2015  
1
1
1
1
1
October 2009  
October 2009  
October 2009  
October 2010  
October 2010  
1
2
3
1
2
10.34  
10.87  
11.36  
8.46  
8.90  
Table 20 - Shares issued to Executive KMP on exercise of options during 2011  
Number of  
$ amount  
$ amount  
Executive  
Date Options Granted  
2 October 2006  
2 October 2006  
2 October 2006  
2 October 2006  
2 October 2006  
2 October 2006  
2 October 2006  
2 October 2006  
shares issued  
158,760  
23,256  
58,140  
19,620  
14,220  
24,390  
7,584  
paid per share  
unpaid per share  
Dr Brian McNamee  
Mr Peter Turner  
Mr Tony Cipa  
17.48  
-
-
-
-
-
-
-
-
17.48  
17.48  
Mr Paul Perreault  
Mr Gordon Naylor  
Dr Andrew Cuthbertson  
Mr Greg Boss  
17.48  
17.48  
17.48  
17.48  
Mr Edward Bailey  
4,320  
17.48  
One ordinary share is issued on the exercise of each option.  
This report has been made in accordance with  
a resolution of directors.  
Elizabeth Alexander, AM (Director)  
Brian A McNamee, AO (Director)  
Melbourne  
17 August 2011  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
63  
Auditor’s Independence Declaration  
Auditor’s Independence Declaration  
to the Directors of CSL Limited  
In relation to our audit of the financial report of CSL Limited for the financial year ended 30 June 2011,  
to the best of my knowledge and belief, there have been no contraventions of the auditor independence  
requirements of the Corporations Act 2001 or any applicable code of professional conduct.  
Ernst & Young  
Glenn Carmody  
Partner  
17 August 2011  
6
4
CSL Limited  
Consolidated Statement of Comprehensive Income  
for the year ended 30 June 2011  
Consolidated Group  
2
$000  
011  
2010  
$000  
Notes  
Continuing operations  
Sales revenue  
3
4,187,554  
(2,128,873)  
2,058,681  
134,014  
4,455,821  
(2,184,850)  
2,270,971  
171,123  
Cost of sales  
Gross profit  
Other revenues  
3
Research and development expenses  
Selling and marketing expenses  
General and administration expenses  
Finance costs  
(325,146)  
(440,091)  
(214,858)  
(14,481)  
(316,722)  
(489,399)  
(238,361)  
(18,157)  
3
3
Profit before income tax expense  
Income tax expense  
1,198,119  
(257,518)  
940,601  
1,379,455  
(326,554)  
1,052,901  
4
Profit attributable to members of the parent company  
22  
Other comprehensive income  
Exchange differences on translation of foreign operations, net of hedges  
on foreign investments  
21  
(193,438)  
(276,237)  
Actuarial gains/(losses) on defined benefit plans, net of tax  
Mark to Market adjustment on available-for-sale financial assets  
Total of other comprehensive income/(expenses)  
22  
21  
(11,201)  
(913)  
7,667  
-
(205,552)  
(268,570)  
Total comprehensive income for the period  
24  
5
735,049  
784,331  
Earnings per share  
Cents  
174.01  
173.60  
Cents  
185.77  
185.19  
Basic earnings per share  
Diluted earnings per share  
The above consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
65  
CSL Limited  
Consolidated Balance Sheet  
As at 30 June 2011  
Consolidated Group  
011  
$000  
2
2010  
$000  
Notes  
CURRENT ASSETS  
Cash and cash equivalents  
Trade and other receivables  
Inventories  
6
479,403  
808,651  
1,001,059  
883,002  
1,454,616  
479  
7
8
9
1,455,995  
17,993  
Other financial assets  
Total Current Assets  
2,762,042  
3,339,156  
NON-CURRENT ASSETS  
Trade and other receivables  
Other financial assets  
Property, plant and equipment  
Deferred tax assets  
7
4,544  
2,280  
7,570  
4,589  
9
10  
11  
12  
13  
1,207,288  
174,206  
915,049  
2,588  
1,207,839  
191,410  
955,513  
4,967  
Intangible assets  
Retirement benefit assets  
Total Non-Current Assets  
TOTAL ASSETS  
2,305,955  
5,067,997  
2,371,888  
5,711,044  
CURRENT LIABILITIES  
Trade and other payables  
Interest-bearing liabilities and borrowings  
Current tax liabilities  
Provisions  
14  
15  
16  
17  
18  
19  
493,506  
226,214  
131,729  
88,620  
995  
485,403  
25,984  
176,809  
95,697  
995  
Deferred government grants  
Derivative financial instruments  
Total Current Liabilities  
NON-CURRENT LIABILITIES  
Trade and other payables  
Interest-bearing liabilities and borrowings  
Deferred tax liabilities  
Provisions  
5,054  
1,991  
946,118  
786,879  
14  
15  
11  
17  
18  
13  
3,983  
190,030  
122,202  
28,470  
-
436,219  
114,822  
30,924  
Deferred government grants  
Retirement benefit liabilities  
Total Non-Current Liabilities  
TOTAL LIABILITIES  
18,910  
10,605  
113,924  
477,519  
1,423,637  
3,644,360  
116,401  
708,971  
1,495,850  
4,215,194  
NET ASSETS  
EQUITY  
Contributed equity  
20  
21  
22  
24  
253,896  
(421,635)  
3,812,099  
3,644,360  
1,139,228  
(242,615)  
3,318,581  
4,215,194  
Reserves  
Retained earnings  
TOTAL EQUITY  
The above consolidated balance sheet should be read in conjunction with the accompanying notes.  
6
6
CSL Limited  
Consolidated Statement of Changes in Equity  
for the year ended 30 June 2011  
Foreign  
currency  
translation  
reserve  
Available-  
for-sale  
investment  
reserve  
Share based  
payment  
reserve  
Ordinary  
shares  
Retained  
earnings  
Total  
$000  
Consolidated Group  
Notes  
$000  
$000  
$000  
$000  
$000  
At 1 July 2010  
1,139,228  
(326,778)  
84,163  
-
3,318,581  
4,215,194  
Profit for the period  
-
-
-
-
-
-
-
940,601  
(11,201)  
929,400  
940,601  
(205,552)  
735,049  
Other comprehensive income  
(193,438)  
(193,438)  
(913)  
(913)  
Total comprehensive income  
for the full year  
Transactions with owners  
in their capacity as owners  
Share based payments  
Dividends  
21  
23  
20  
-
-
-
-
-
15,331  
-
-
-
-
(435,882)  
-
15,331  
(435,882)  
(900,000)  
-
-
Share buy back  
Share issues  
(900,000)  
-
Employee share scheme  
20  
14,668  
-
-
-
-
14,668  
Balance as at 30 June 2011  
253,896  
(520,216)  
99,494  
(913)  
3,812,099  
3,644,360  
At 1 July 2009  
2,760,207  
(50,541)  
65,739  
-
2,687,490  
5,462,895  
Profit for the period  
-
-
-
-
(276,237)  
(276,237)  
-
-
-
-
-
-
1,052,901  
7,667  
1,052,901  
(268,570)  
784,331  
Other comprehensive income  
Total comprehensive income  
for the full year  
1,060,568  
Transactions with owners  
in their capacity as owners  
Share based payments  
Dividends  
21  
23  
20  
20  
-
-
-
-
-
-
18,424  
-
-
-
-
-
18,424  
(429,477)  
(1,640,584)  
9,341  
-
-
-
(429,477)  
Share buy back  
(1,640,584)  
9,341  
-
-
Capital raising tax benefit  
Share issues  
-
Employee share scheme  
20  
10,264  
-
-
-
-
-
10,264  
Balance as at 30 June 2010  
1,139,228  
(326,778)  
84,163  
3,318,581  
4,215,194  
The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
67  
CSL Limited  
Consolidated Cash Flow Statement  
for the year ended 30 June 2011  
Consolidated Group  
011  
2
2010  
$000  
Notes  
$000  
Cash flows from Operating Activities  
Receipts from customers  
4,302,820  
(3,012,454)  
1,290,366  
(288,651)  
30,399  
4,543,363  
(3,213,925)  
1,329,438  
(179,822)  
39,210  
Payments to suppliers and employees  
Cash generated from operations  
Income taxes paid  
Interest received  
Finance costs paid  
(13,995)  
(20,334)  
Net cash inflow from operating activities  
25  
1,018,119  
1,168,492  
Cash flows from Investing Activities  
Proceeds from sale of property, plant and equipment  
Payments for property, plant and equipment  
Payments for intangible assets  
320  
(198,472)  
(13,738)  
2,248  
641  
(244,288)  
(51,926)  
2,619  
Receipts from other financial assets  
Net cash outflow from investing activities  
(209,642)  
(292,954)  
Cash flows from Financing Activities  
Proceeds from issue of shares  
Dividends paid  
16,626  
(435,882)  
49,256  
13,194  
(429,477)  
-
23  
Proceeds from borrowings  
Repayment of borrowings  
(18,292)  
(900,000)  
(302)  
(214,821)  
(1,721,317)  
(126)  
Payment for shares bought back  
Payment for settlement of finance hedges  
Net cash outflow from financing activities  
(1,288,594)  
(2,352,547)  
Net increase/(decrease) in cash and cash equivalents  
(480,117)  
(1,477,009)  
Cash and cash equivalents at the beginning of the financial year  
Exchange rate variations on foreign cash and cash equivalent balances  
Cash at the end of the financial year  
994,505  
(35,569)  
478,819  
2,522,192  
(50,678)  
994,505  
25  
For non-cash financing activities refer to note 25.  
The above consolidated cash flow statement should be read in conjunction with the accompanying notes.  
6
8
CSL Limited and its Controlled Entities  
Notes to the Financial Statements  
for the year ended 30 June 2011  
1
Corporate information  
CSL Limited is a company incorporated and domiciled in Australia and limited by shares publicly traded on the Australian Securities  
Exchange. This financial report covers the financial statements for the consolidated entity consisting of CSL Limited and its subsidiaries  
(together referred to as the Group). The financial report was authorised for issue in accordance with a resolution of the directors on 17  
August 2011.  
A description of the nature of the Group’s operations and its principal activities is included in the directors’ report.  
Summary of significant accounting policies  
The principal accounting policies adopted in the preparation of the financial report are set out below. These policies have been consistently  
applied to all the years presented unless otherwise stated.  
(a) Basis of preparation  
This general purpose financial report has been prepared in accordance with Australian Accounting Standards, other authoritative  
pronouncements of the Australian Accounting Standards Board and the Corporations Act 2001. The financial report also complies with  
International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. The financial report has  
been prepared under the historical cost convention, except for “available-for-sale” and “at fair value through profit or loss” financial  
assets and liabilities (including derivative instruments), that have been measured at fair value.  
Critical accounting estimates  
The preparation of a financial report in conformity with Australian Accounting Standards requires the use of certain critical accounting  
estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. The areas  
involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial report  
are disclosed in note 1(ee).  
Rounding of amounts  
The Company is of a kind referred to in Class Order 98/0100, issued by the Australian Securities and Investments Commission, relating  
to ‘rounding off’ of amounts in the financial report. Amounts in the financial report have been rounded off in accordance with that  
Class Order to the nearest thousand dollars.  
Adoption of accounting standards  
The group has adopted the following accounting standards that became effective during the year: AASB 2009-5, AASB 2009-8, AASB  
2009-10 and AASB 2010-3. The major changes that affect the Group are in the classification of leases for land, classification of cash  
flows, share based payments expense and classification of financial instruments. Since many of the amendments mandated accounting  
policies that had historically been applied by the Group the introduction of these standards did not result in a material change in the  
Group’s financial result or the extent of disclosures in the financial report.  
(
b) Principles of consolidation  
i. Subsidiaries  
The consolidated financial statements comprise the financial statements of CSL Limited and its subsidiaries. Subsidiaries are all of those  
entities over which the Group has the power to govern the financial and operating policies so as to obtain benefits from their activities.  
The financial statements of the subsidiaries are prepared using consistent accounting policies and for the same reporting period as the  
Parent Company.  
In preparing the consolidated financial statements, all intercompany balances and transactions have been eliminated in full. Subsidiaries  
are fully consolidated from the date on which control is obtained by the Group and cease to be consolidated from the date on which  
control is transferred out of the Group.  
The acquisition of subsidiaries is accounted for using the purchase method of accounting. The purchase method of accounting involves  
allocating the cost of the business combination to the fair value of assets acquired and the liabilities and contingent liabilities assumed at  
the date of the acquisition.  
ii. Employee share trust  
The Group has formed a trust to administer the Group’s employee share scheme. This trust is consolidated as the substance of the  
relationship is that the trust is controlled by the Group.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
69  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
1
Summary of significant accounting policies (continued)  
c) Segment reporting  
(
Operating segments, as defined in note 2, are reported in a manner consistent with the internal reporting to the chief operating  
decision maker. The Chief Executive Officer is considered to be the chief operating decision maker.  
(d) Foreign currency translation  
i. Functional and presentation currency  
Items included in the financial statements of each of the Group’s entities are measured using the currency of the primary  
economic environment in which the entity operates (‘the functional currency’). The consolidated financial statements are  
presented in Australian dollars, which is CSL Limited’s functional and presentational currency.  
ii. Translation and balances  
Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates  
of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the  
translation at year end exchange rates of monetary assets and liabilities denominated in functional currencies are recognised  
in the statement of comprehensive income, except when deferred in equity as qualifying cash flow hedges and qualifying net  
investment hedges or are attributable to part of the net investment in a foreign operation.  
iii. Group companies  
The results of foreign subsidiaries are translated into Australian dollars at average exchange rates. Assets and liabilities of  
foreign subsidiaries are translated to Australian dollars at exchange rates prevailing at balance date. All resulting exchange  
differences are recognised in other comprehensive income and in the foreign currency translation reserve in equity.  
On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of  
borrowings and other financial instruments designated as hedges of such investments, are recognised in other comprehensive  
income and in the foreign currency translation reserve in equity. When a foreign operation is sold or any borrowings forming  
part of the net investment are repaid, a proportionate share of such exchange differences are recognised in the statement of  
comprehensive income, as part of the gain on sale or loss on sale where applicable.  
(e) Revenue recognition  
Revenue is recognised and measured at the fair value of the consideration received or receivable. The Group recognises revenue  
when: the amount of revenue can be reliably measured, it is probable that the future economic benefits will flow to the Group  
and the specific criteria have been met for each of the Group’s activities as described below.  
i. Sales revenue  
Sales revenue comprises revenue earned (net of returns, discounts and allowances) from the provision of products to buyers  
external to the Group. Sales revenue is recognised when the significant risks and rewards of ownership of the goods have  
passed to the buyer.  
ii. Interest income  
Interest income is recognised as it accrues (using the effective interest rate method).  
iii. Other revenue  
Other revenue is recognised as it accrues.  
iv. Dividend income  
Dividend income is recognised when the shareholder’s right to receive the payment is established.  
(f) Government grants  
Government grants are recognised at their fair value where there is reasonable assurance that the grant will be received and the  
Group will comply with all attached conditions. Government grants relating to an expense item are deferred and recognised  
in the statement of comprehensive income over the period necessary to match them with the expenses that they are intended  
to compensate. Government grants received for which there are no future related costs are recognised in the statement of  
comprehensive income immediately. Government grants relating to the purchase of property, plant and equipment are included  
in current and non-current liabilities as deferred income and are released to the statement of comprehensive income on a straight  
line basis over the expected useful lives of the related assets.  
(g) Borrowing costs  
Borrowing costs are expensed as incurred, except where they are directly attributable to the acquisition or construction of a  
qualifying asset in which case they are capitalised as part of the cost of that asset.  
70  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
1
Summary of significant accounting policies (continued)  
(h) Goods and Services Tax and other foreign equivalents (GST)  
Revenues, expenses and assets are recognised net of GST except where the amount of GST incurred is not recoverable  
from a taxation authority in which case it is recognised as part of an asset’s cost of acquisition or as part of the expense.  
Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST  
recoverable from, or payable to, taxation authorities is included in other receivables or payables in the balance sheet. Cash  
flows are presented in the cash flow statement on a gross basis. The GST component of cash flows arising from investing  
and financing activities that are recoverable from or payable to a taxation authority are presented as part of operating cash  
flows. Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, a taxation  
authority.  
(
i) Income tax  
The income tax expense or revenue for the period is the tax payable on the current period’s taxable income based on the  
applicable income tax rate for each jurisdiction adjusted for changes in deferred tax assets and liabilities attributable to  
temporary differences and to unused tax losses.  
Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of  
assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined  
using tax rates (and laws) that have been enacted or substantially enacted by the reporting date and are expected to apply  
when the related deferred income tax asset is realised or deferred income tax liability is settled.  
Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that  
future taxable amounts will be available to utilise those temporary differences and tax losses.  
Deferred tax assets and liabilities are not recognised for temporary differences between the carrying amount and tax bases  
of investments in controlled entities where the parent company is able to control the timing of the reversal of temporary  
differences and it is probable that the differences will not reverse in the foreseeable future.  
Deferred tax assets and liabilities are offset only if a legally enforceable right exists to set-off current tax assets against  
current tax liabilities and the deferred tax assets and deferred tax liabilities are related to the same taxable entity or group  
and the same taxation authority.  
Current and deferred tax balances attributable to amounts recognised in other comprehensive income or directly in equity  
are also recognised in other comprehensive income or in equity, respectively.  
CSL Ltd and its 100% owned Australian subsidiaries have formed a tax consolidated group effective from 1 July 2003.  
(
(
j) Cash, cash equivalents and bank overdrafts  
Cash and cash equivalents in the balance sheet comprise cash on hand, at call deposits with banks or financial institutions  
and investments in money market instruments with original maturities of three months or less that are readily convertible  
to known amounts of cash and which are subject to an insignificant risk of changes in value. In the balance sheet bank  
overdrafts are included within current interest bearing liabilities and borrowings. For the purposes of the cash flow  
statement, cash at the end of the financial year is net of bank overdraft amounts.  
k) Trade and other receivables  
Trade and other receivables are initially recorded at fair value and are generally due for settlement within 30 to 60 days  
from date of invoice. Collectability of trade and other receivables is reviewed on an ongoing basis at an operating unit level.  
Debts which are known to be uncollectible are written off when identified. An allowance for doubtful debts is recognised  
when there is objective evidence that the Group may not be able to fully recover all amounts due according to the original  
terms. The amount of the allowance recognised is the difference between the receivable’s carrying amount and the present  
value of estimated future cash flows that may ultimately be recovered. Cash flows relating to short term receivables are not  
discounted if the effect of discounting is immaterial. When a trade receivable for which a provision for impairment has been  
recognised becomes uncollectible in a subsequent period, it is written off against the provision.  
Other current receivables are recognised and carried at the nominal amount due. Non-current receivables are recognised  
and carried at amortised cost. They are non-interest bearing and have various repayment terms.  
(
l) Inventories  
Raw materials and stores, work in progress and finished goods are stated at the lower of cost and net realisable value.  
Cost includes direct material and labour and an appropriate proportion of variable and fixed overhead expenditure, the  
latter being allocated on the basis of normal operating capacity. Net realisable value is the estimated selling price in the  
ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
71  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
1
Summary of significant accounting policies (continued)  
m) Investments and other financial assets  
(
The Group’s financial assets have been classified into one of the three categories noted below. The classification depends on the purpose  
for which the investments were acquired. The Group determines the classification of its investments at initial recognition and re-evaluates  
this designation at each financial year end when allowed and appropriate.  
i. Financial assets at fair value through profit and loss  
Financial assets at fair value through profit and loss are financial assets held for trading. A financial asset is classified in this category  
if acquired principally for the purpose of selling in the short term. Derivatives are classified as held for trading unless they are  
designated as hedges. Financial assets at fair value through profit and loss are initially recognised at fair value and transaction costs  
are expensed in the statement of comprehensive income. After initial recognition, assets in this category are carried at fair value.  
Gains and losses on financial assets held for trading are recognised in the statement of comprehensive income when they arise.  
ii. Loans and receivables  
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active  
market. They are included in current assets, except for those with maturities greater than 12 months after the reporting date which  
are classified as non-current assets. Loans and receivables are carried at amortised cost using the effective interest rate method and  
are included in trade and other receivables in the balance sheet. Gains and losses are recognised in the statement of comprehensive  
income when the loans and receivables are derecognised or impaired.  
iii. Available for sale investments  
Available for sale investments, comprising principally marketable securities, are non-derivatives. They are included in non-current  
assets unless the Group intends to dispose of the investment within 12 months of the reporting date. Investments are designated as  
available for sale if they do not have fixed maturities and fixed or determinable payments and management intends to hold them for  
the medium to long term. Investments are initially recognised at fair value plus transaction costs. After initial recognition available  
for sale financial assets are measured at fair value with gains or losses being recognised as a separate component of equity until the  
investment is derecognised or determined to be impaired, at which time the cumulative gain or loss previously reported in equity is  
recognised in the statement of comprehensive income. A significant or prolonged decline in the fair value of an equity security below  
its cost is considered to be an indicator that the securities may be impaired.  
The fair values of investments that are actively traded in organised financial markets are determined by reference to quoted market  
bid prices at the close of business on the reporting date. For investments with no active market, fair values are determined using  
valuation techniques. Such techniques include: using recent arm’s length market transactions; reference to the current market value  
of another instrument that is substantially the same; discounted cash flow analysis; and option pricing models.  
Regular purchases and sales of financial assets are recognised on the date when the Group commits to purchase or sell the asset. Financial  
assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the  
Group has transferred substantially all the risks and rewards of ownership.  
The fair values of investments that are actively traded in organised financial markets are determined by reference to market prices. For  
investments that are not actively traded, fair values are determined using valuation techniques. These techniques include: using recent  
arm’s length transactions involving the same or substantially the same instruments as a guide to value, discounted cash flow analysis and  
various pricing models.  
The Group assesses at each balance date whether there is objective evidence that a financial asset or group of financial assets is impaired.  
(n) Business combinations  
The purchase method of accounting is used for all business combinations regardless of whether equity instruments or other assets are  
acquired. Cost is measured as the fair value of assets given, shares issued or liabilities incurred or assumed at the date of exchange. Where  
equity instruments are issued in a business combination, the fair value of the instruments is their published market price as at the date of  
the combination. Transaction costs arising on the issue of equity instruments are recognised directly in equity. All other transaction costs  
are expensed. Where settlement of any part of cash consideration is deferred, where material, the amounts payable in the future are  
discounted to their present value as at the date of the acquisition. The discount rate used is the entity’s incremental borrowing rate, being  
the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions.  
Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair  
values at the acquisition date. The excess of the cost of acquisition over the fair value of the identifiable net assets acquired is recognised  
as goodwill. If the cost of the acquisition is less than the identifiable net assets acquired, the difference is recognised immediately in the  
statement of comprehensive income, but only after a reassessment of the identification and measurement of the net assets acquired.  
72  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
1. Summary of significant accounting policies (continued)  
(o) Property, plant and equipment  
Land, buildings, capital work in progress and plant and equipment assets are recorded at historical cost less, where applicable,  
associated depreciation and any accumulated impairment losses. Land and capital work in progress assets are not depreciated.  
Historical cost includes expenditure that is directly attributable to the acquisition of an asset. Costs incurred subsequent to an asset’s  
acquisition, including the cost of replacement parts, are included in the asset’s carrying amount or recognised as a separate asset, as  
appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of  
the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repair and maintenance costs  
are charged to the statement of comprehensive income when incurred.  
Depreciable assets are depreciated using the straight line method to allocate their cost, net of residual values, over their estimated  
useful lives, as follows:  
Buildings  
Plant and equipment  
Leasehold improvements  
5 – 40 years  
3 – 15 years  
5 – 10 years  
Assets’ residual values and useful lives are reviewed and adjusted if appropriate at each reporting date. An asset’s carrying amount  
is written down immediately to its recoverable amount if its carrying amount is greater than its estimated recoverable amount. Items  
of property, plant and equipment are derecognised upon disposal or when no further economic benefits are expected from their  
use or disposal. Gains and losses on disposals of items of property, plant and equipment are determined by comparing proceeds  
with carrying amounts. Gains and losses are included in the statement of comprehensive income when realised.  
(
p) Impairment of assets  
Goodwill and other assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment  
or more frequently if events or changes in circumstances indicate that they may be impaired. Assets with finite lives are subject  
to amortisation and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount  
may not be recoverable. An impairment loss is recognised in the statement of comprehensive income for the amount by which the  
asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to  
sell and value in use. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately  
identifiable cash flows (cash generating units). Impairment losses recognised in respect of cash generating units are allocated first  
to reduce the carrying amount of any goodwill allocated to cash generating units, and then, to reduce the carrying amount of the  
other assets in the unit on a pro-rata basis.  
(q) Leasehold improvements  
The cost of improvements to leasehold properties is amortised over the unexpired period of the lease or the estimated useful life of  
the improvement whichever is the shorter.  
(r) Leases  
Leases of property, plant and equipment where the Group, as lessee, has substantially all the risks and rewards of ownership are  
classified as finance leases. Finance leases are capitalised at the lease’s inception at the fair value of the leased property or, if lower,  
the present value of the minimum lease payments. The corresponding rental obligations, net of finance charges, are included in  
interest bearing liabilities and borrowings. Each lease payment is allocated between the liability and finance cost. The finance cost  
is charged to the statement of comprehensive income over the lease period so as to produce a constant periodic rate of interest  
on the remaining balance of the liability for each period. The property, plant and equipment acquired under finance leases are  
depreciated over the shorter of the asset’s useful life and the lease term.  
Leases in which a significant portion of the risks and rewards of ownership are not transferred to the Group as lessee are classified  
as operating leases. Payments made under operating leases are charged to the statement of comprehensive income on a straight  
line basis over the period of the lease.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
73  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
1. Summary of significant accounting policies (continued)  
(s) Goodwill and intangibles  
i. Goodwill  
On acquisition of another entity, the identifiable net assets acquired (including contingent liabilities assumed) are measured at their  
fair value. The excess of the fair value of the purchase consideration plus incidental expenses, over the fair value of the identifiable  
net assets, is brought to account as goodwill. Goodwill acquired is allocated to each of the cash-generating units expected to  
benefit from the combination’s synergies. Goodwill is not amortised. Instead, following initial recognition, goodwill is measured at  
cost less any accumulated impairment losses.  
ii. Intangibles  
Intangible assets acquired separately or in a business combination are initially measured at cost. The cost of an intangible asset  
acquired in a business combination is its fair value as at the date of acquisition. Following initial recognition, intangible assets are  
carried at cost less any accumulated amortisation and any accumulated impairment losses. Internally generated intangible assets,  
excluding capitalised development costs, are not capitalised and expenditure is recognised in profit or loss in the year in which the  
expenditure is incurred.  
The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are amortised over  
the useful life and tested for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation  
period and the amortisation method for an intangible asset with a finite useful life is reviewed at least at each financial year-end.  
Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset  
are accounted for prospectively by changing the amortisation period or method, as appropriate, which is a change in accounting  
estimate.  
Intangible assets with indefinite useful lives are tested for impairment annually either individually or at the cash generating unit level.  
Such intangibles are not amortised. The useful life of an intangible asset with an indefinite life is reviewed each reporting period  
to determine whether indefinite life assessment continues to be supportable. If not, the change in the useful life assessment from  
indefinite to finite is accounted for as a change in an accounting estimate and is thus accounted for on a prospective basis.  
iii. IT development and software  
Costs incurred in developing products or systems and costs incurred in acquiring software and licences that will contribute to  
future period financial benefits through revenue generation and/or cost reduction are capitalised to software and systems. Costs  
capitalised include external direct costs of materials and service and direct payroll and payroll related costs of employees’ time spent  
on the project. Amortisation is calculated on a straight line basis over periods generally ranging from 3 to 10 years. IT development  
costs include only those costs directly attributable to the development phase and are only recognised following completion of  
technical feasibility and where the Group has the intention and ability to use the asset.  
iv. Research and development costs  
Research costs are expensed as incurred. An intangible asset arising from development expenditure on an internal project is  
recognised only when the Group can demonstrate: the technical feasibility of completing the intangible asset so that it will be  
available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic  
benefits, the availability of resources to complete the development and the ability to measure reliably the expenditure attributable  
to the intangible asset during its development. Following the initial recognition of the development expenditure, the cost model  
is applied requiring the asset to be carried at cost less any accumulated amortisation and accumulated impairment losses. Any  
development expenditure recognised is amortised over the period of expected benefit from the related project.  
(t) Trade and other payables  
Liabilities for trade and other payables represent liabilities for goods and services provided to the Group prior to the end of the financial  
year that are unpaid. Trade and other creditors are non-interest bearing and have various repayment terms but are usually paid within 30  
to 60 days of recognition.  
(u) Interest-bearing liabilities and borrowings  
Interest-bearing liabilities and borrowings are recognised initially at fair value net of transaction costs incurred. Subsequent to initial  
recognition, interest-bearing liabilities and borrowings are stated at amortised cost with any difference between the proceeds (net of  
transaction costs) and the redemption value recognised in the statement of comprehensive income over the period of borrowings using  
the effective interest method. Fees paid on the establishment of loan facilities that are yield related are included as part of the carrying  
amount of the loans and borrowings. Borrowings are classified as current liabilities unless the Group has an unconditional right to defer  
settlement of the liability for at least 12 months after the reporting date.  
74  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
1
Summary of significant accounting policies (continued)  
v) Derivative financial instruments  
(
The Group uses derivative financial instruments in the form of forward foreign currency contracts to hedge risks associated with  
foreign currency. Such derivative instruments are initially recognised at fair value on the date a derivative contract is entered into  
and are subsequently remeasured to their fair value. The gain or loss on re-measurement to fair value is recognised immediately in  
the statement of comprehensive income. The fair value of forward foreign exchange contracts is calculated by reference to current  
forward exchange rates for contracts with similar maturity profiles.  
The Group also has external loans payable that have been designated as a hedge of its investment in foreign subsidiaries (net  
investment hedge). Gains or losses on the hedging instruments relating to the effective portion of the hedge are recognised directly  
in equity while any gains or losses relating to the ineffective portion, if any, are recognised immediately in profit or loss.  
(w) Provisions  
Provisions are recognised when the Group has a present legal or constructive obligation arising from past transactions or events, it is  
probable that an outflow of resources will be required to settle the obligation and a reliable estimate can be made of the amount of  
the obligation. Provisions are not recognised for future operating losses.  
Provisions recognised reflect management’s best estimate of the expenditure required to settle the present obligation at the  
reporting date. Where the effect of the time value of money is material, provisions are determined by discounting the expected  
future cash flows required to settle the obligation at a pre-tax discount rate that reflects the current market assessments of the time  
value of money and the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of  
time is recognised as a borrowing cost.  
(
x) Employee benefits  
Liabilities for wages and salaries, including non-monetary benefits and annual leave, expected to be settled within 12 months of  
the reporting date are recognised in respect of employees’ services up to the end of the reporting period and are measured at the  
amounts expected to be paid when the liabilities are settled. The liability for annual leave is recognised in the current provision for  
employee benefits. All other short-term employee benefit obligations are presented as payables.  
The liability for long service leave is recognised in the provision for employee benefits and measured as the present value of expected  
future payments to be made in respect of services provided by employees up to the reporting date. Consideration is given to  
expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are  
discounted using market yields at the reporting date on national government bonds with terms to maturity and currency that match,  
as closely as possible, the estimated future cash outflows.  
(
y) Pension plans  
The Group contributes to defined benefit and defined contribution pension plans for the benefit of all employees. Defined benefit  
pension plans provide defined lump sum benefits based on years of service and final average salary. Defined contribution plans  
receive fixed contributions from the Group and the Group’s legal and constructive obligation is limited to these contributions.  
A liability or asset in respect of defined benefit pension plans is recognised in the balance sheet, and is measured as the present  
value of the defined benefit obligation at the reporting date less the fair value of the pension fund’s assets at that date and any  
unrecognised past service cost. The present value of the defined benefit obligation is based on expected future payments which arise  
from membership of the fund to the reporting date, calculated by independent actuaries using the projected unit credit method.  
Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service.  
Expected future payments are discounted using market yields at the reporting date on national government bonds with maturity and  
currency that match, as closely as possible, the estimated future cash outflows. Actuarial gains and losses arising from experience  
adjustments and changes in actuarial assumptions are recognised in retained earnings as incurred.  
Past service costs are recognised immediately in income, unless the changes to the pension fund are conditional on the employees  
remaining in service for a specified period of time (vesting period). In this case, the past service costs are amortised on a straight-line  
basis over the vesting period.  
Future taxes that are funded by the entity and are part of the provision of the existing benefit obligation are taken into account in  
measuring the net liability or asset.  
Contributions to defined contribution pension plans are recognised as an expense as they become payable.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
75  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
1
Summary of significant accounting policies (continued)  
(z) Share-based payment transactions  
i. Equity-settled transactions  
The Group provides benefits to its employees (including key management personnel) in the form of share-based payments, whereby  
employees render services in exchange for rights over shares (equity settled transactions). There are currently two plans in place to  
provide these benefits, namely the ‘Senior Executive Share Ownership Plan and Employee Performance Rights Plan’ and the ‘Global  
Employee Share Plan’.  
Under the ‘Senior Executive Share Ownership Plan and Employee Performance Rights Plan’, certain Group executives and employees  
are granted options or performance rights over CSL Limited shares which only vest if the Group and the individual achieve certain  
performance hurdles.  
Under the ‘Global Employee Share Plan’, all employees are granted the option to acquire discounted CSL Limited shares.  
The fair value of options or rights is recognised as an employee benefit expense with a corresponding increase in equity. The fair  
value is independently measured at grant date and recognised over the period during which the employees become unconditionally  
entitled to the options or rights. The fair value at grant date is independently determined using a combination of the Binomial and  
Black Scholes valuation methodologies, taking into account the terms and conditions upon which the options and rights were  
granted. The fair value of the options granted excludes the impact of any non-market vesting conditions. Non-market vesting  
conditions are included in assumptions about the number of options that are expected to vest.  
At each reporting date, the number of options and rights that are expected to vest is revised. The employee benefit expense  
recognised each period takes into account the most recent estimate of the number of options and rights that are expected to vest.  
No expense is recognised for options and rights that do not ultimately vest, except where vesting is conditional upon a market  
condition and that market condition is not met.  
ii. Cash-settled transactions  
The Group also provides benefits to its employees (including key management personnel) in the form of cash-settled share-  
based payments, whereby employees render services in exchange for cash, the amounts of which are determined by reference to  
movements in the price of the shares of CSL Limited.  
The ultimate cost of these cash-settled transactions will be equal to the actual cash paid to the employees, which will be the fair  
value at settlement date.  
The cumulative cost recognised until settlement is a liability and the periodic determination of this liability is as follows:  
(a) At each reporting date between grant and settlement, the fair value of the award is determined.  
(
b) During the vesting period, the liability recognised at each reporting date is the fair value of the award at that date multiplied by  
the expired portion of the vesting period.  
(c) From the end of the vesting period until settlement, the liability recognised is the full fair value of the liability at the reporting date.  
(d) All changes in the liability are recognised in employee benefits expense for the period.  
The fair value of the liability is determined by reference to the CSL Limited share price at reporting date, adjusted for the dividend  
yield and the number of days left in the vesting period.  
(aa) Contributed equity  
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares are shown in equity as a  
deduction, net of tax, from the proceeds. Where the Company reacquires its own shares, for example as a result of a share buy-back,  
those shares are cancelled. No gain or loss is recognised in the profit or loss and the consideration paid to acquire the shares, including  
any directly attributable transaction costs net of income taxes, is recognised directly as a reduction from equity.  
(
bb) Earnings per share  
Basic earnings per share is calculated by dividing the profit attributable to equity holders of the Parent Company by the weighted average  
number of ordinary shares outstanding during the financial year.  
Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after tax  
effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of  
additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.  
76  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
1
Summary of significant accounting policies (continued)  
cc) Dividends  
(
Provision is made for the amount of any dividend declared, being appropriately authorised and no longer at the discretion of the  
entity, on or before the end of the financial year but not distributed at balance date.  
(dd) New and revised standards and interpretations not yet adopted  
Certain new and revised accounting standards and interpretations have been published that are not mandatory for the June 2011  
reporting period. An assessment of the impact of these new standards and interpretations is set out below.  
New Standards and Amendments to Australian Accounting Standards: AASB 9, AASB 124, AASB 1054, AASB 2009-11,  
AASB 2009-12, AASB 2009-14, AASB 2010-2, AASB 2010-4, AASB 2010-5, AASB 2010-6, AASB 2010-7, AASB 2010-8,  
AASB 2011-1, AASB 2011-2, IFRS 10, IFRS 11, IFRS 12 and IFRS 13  
The amendments prescribe certain recognition, measurement and disclosure rules in respect of certain types of transactions, assets  
and liabilities. In many instances where the amendments are relevant to the preparation of the Group’s financial statements they  
generally clarify that the accounting policies historically adopted by the Group are now mandatory. On the date of their respective  
first time application, the amended standards are not expected to result in a material change to the manner in which the Group’s  
financial result is determined or upon the extent of disclosures included in future financial reports.  
(ee) Critical accounting estimates and judgements  
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the  
reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets,  
liabilities, contingent liabilities, revenue and expenses. Management bases its judgements and estimates on historical experience  
and on other various factors it believes to be reasonable under the circumstances, the result of which form the basis of the carrying  
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under  
different assumptions and conditions. The estimates and assumptions that have a significant risk of causing a material adjustment to  
the carrying amounts of assets and liabilities within subsequent financial years are discussed below.  
i. Testing goodwill and intangible assets for impairment  
On an annual basis, the Group determines whether goodwill and its indefinitely lived intangible assets are impaired in  
accordance with the accounting policy described in note 1(s). In the context of goodwill allocated to specific cash generating  
units, this requires an estimation of the recoverable amount of the cash generating units using a value in use discounted cash  
flow methodology. In the context of indefinite lived intangible assets, this requires an estimation of the discounted net cash  
inflows that may be generated through the use or sale of the intangible asset. The assumptions used in estimating the carrying  
amount of goodwill and indefinite lived intangibles are detailed in note 12.  
ii. Income taxes  
Judgements are required about the application of income tax legislation in jurisdictions in which the Group operates. These  
judgements and assumptions are subject to risk and uncertainty, hence there is a possibility that changes in circumstances will  
alter expectations, which may impact the carrying amount of deferred tax assets and deferred tax liabilities recognised on the  
balance sheet. In such circumstances an adjustment to the carrying value of a deferred tax item will result in a corresponding  
credit or charge to the statement of comprehensive income.  
iii. Trade and other receivables  
Government or Government backed entities, such as hospitals, often account for a significant proportion of the aggregate  
trade receivable balances attributable to the various countries in which the Group operates. In particular countries,most  
notably Spain, Greece, Italy and Portugal, there is some heightened uncertainty as to the timeframe in which trade receivables  
are likely to be recovered from Government and Government related entities and/or the amount likely to be recovered from  
them due to heightened concerns over sovereign risk. Accordingly, in applying the Group’s accounting policy in respect to  
trade and other receivables as set out in note 1(k), and particularly in respect to debts owed by Government and Government  
related entities in these countries, significant judgement is involved in first assessing whether or not trade or other receivable  
amounts are impaired and thereafter in assessing the extent of impairment.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
77  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
2
Segment Information  
Description of Segments  
Reportable segments are:  
•ꢀ CSLꢀBehringꢀ–ꢀmanufacturesꢀmarketsꢀandꢀdevelopsꢀplasmaꢀproducts.  
•ꢀ ꢀI ntellectualꢀPropertyꢀLicensingꢀ–ꢀrevenueꢀandꢀassociatedꢀexpensesꢀfromꢀtheꢀlicensingꢀofꢀIntellectualꢀPropertyꢀgeneratedꢀbyꢀtheꢀGroupꢀtoꢀ  
unrelated third parties.  
•ꢀ ꢀO therꢀHumanꢀHealthꢀ–ꢀcomprisesꢀCSLꢀBioplasmaꢀandꢀCSLꢀBiotherapies.ꢀTheseꢀbusinessesꢀmanufactureꢀandꢀdistributeꢀbiotherapeuticꢀ  
products and are disclosed in aggregate as they exhibit similar economic characteristics.  
Geographical areas of operation  
The Group operates predominantly in four specific geographic areas, namely Australia, the United States of America, Switzerland, and  
Germany. The rest of the Group’s operations are spread across many countries and are collectively disclosed as ‘Rest of World’ in note 2.  
Segment Accounting Policies  
Inter-segment sales are carried out on an arm’s length basis and reflect current market prices. Segment accounting policies are the same as  
the Group’s policies described in note 1. During the financial year, there were no changes in segment accounting policies.  
7
8
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
2
Segment information (continued)  
Intellectual  
Property Other Human  
Intersegment  
Elimination  
Consolidated  
Group  
CSL Behring  
011  
000  
Licensing  
2011  
Health  
2011  
2
2011  
$000  
2011  
$000  
$
$000  
$000  
Sales to external customers  
Inter-segment sales  
3,452,395  
116,947  
4,995  
-
-
735,159  
2,643  
-
(119,590)  
-
4,187,554  
-
Other revenue / other income (excl interest  
income)  
95,730  
4,797  
105,522  
Total segment revenue  
Interest income  
3,574,337  
95,730  
742,599  
(119,590)  
4,293,076  
28,354  
Unallocated revenue / income  
Consolidated revenue  
138  
4,321,568  
Segment EBIT  
1,061,726  
82,809  
71,685  
-
1,216,220  
(31,974)  
Unallocated revenue / income less  
unallocated costs  
Consolidated EBIT  
1,184,246  
28,354  
Interest income  
Finance costs  
(14,481)  
1,198,119  
(257,518)  
940,601  
Consolidated profit before tax  
Income tax expense  
Consolidated net profit after tax  
Amortisation  
26,811  
92,571  
-
-
10,730  
37,677  
-
-
-
37,541  
130,248  
Depreciation  
Segment EBITDA  
1,181,108  
82,809  
120,092  
1,384,009  
(31,974)  
Unallocated revenue / income less  
unallocated costs  
Unallocated depreciation and amortisation  
4,853  
Consolidated EBITDA  
1,356,888  
Segment assets  
4,172,616  
1,146,676  
16,534  
3,710  
911,861  
351,340  
(109,440)  
(109,440)  
4,991,571  
321,515  
Other unallocated assets  
Elimination of amounts between operating  
segments and unallocated  
(245,089)  
Total assets  
5,067,997  
Segment liabilities  
1,392,286  
276,440  
Other unallocated liabilities  
Elimination of amounts between operating  
segments and unallocated  
(245,089)  
Total liabilities  
1,423,637  
Other information - capital expenditure  
Property, plant and equipment  
122,618  
-
-
-
-
-
75,854  
-
-
-
-
198,472  
-
Payments for intellectual property  
Payments for software intangibles  
Total capital expenditure  
-
-
13,738  
136,356  
13,738  
212,210  
75,854  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
79  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
2
Segment information (continued)  
Intellectual  
Property  
Licensing  
Other Human  
Health  
Intersegment  
Elimination  
Consolidated  
Group  
CSL Behring  
010  
000  
2
$
2010  
$000  
2010  
$000  
2010  
$000  
2010  
$000  
Sales to external customers  
Inter-segment sales  
3,497,821  
126,966  
5,746  
-
-
958,000  
276  
-
(127,242)  
-
4,455,821  
-
Other revenue / other income (excl interest  
income)  
111,530  
8,303  
125,579  
Total segment revenue  
Interest income  
3,630,533  
111,530  
966,579  
(127,242)  
4,581,400  
40,485  
Unallocated revenue / income  
Consolidated revenue  
5,059  
4,626,944  
Segment EBIT  
1,130,546  
96,295  
160,473  
-
1,387,314  
(30,187)  
Unallocated revenue / income less  
unallocated costs  
Consolidated EBIT  
1,357,127  
40,485  
Interest income  
Finance costs  
(18,157)  
Consolidated profit before tax  
Income tax expense  
1,379,455  
(326,554)  
1,052,901  
Consolidated net profit after tax  
Amortisation  
26,708  
86,263  
-
-
4,180  
37,188  
-
-
-
30,888  
123,451  
Depreciation  
Segment EBITDA  
1,243,517  
96,295  
201,841  
1,541,653  
(30,187)  
Unallocated revenue / income less unallocated  
costs  
Unallocated depreciation and amortisation  
2,276  
Consolidated EBITDA  
1,513,742  
Segment assets  
4,288,442  
1,195,279  
23,029  
796,575  
722,224  
(76,771)  
(76,771)  
5,031,275  
1,325,883  
(646,114)  
Other unallocated assets  
Elimination of amounts between operating  
segments and unallocated  
Total assets  
5,711,044  
Segment liabilities  
4,181  
1,844,913  
297,051  
Other unallocated liabilities  
Elimination of amounts between operating  
segments and unallocated  
(646,114)  
Total liabilities  
1,495,850  
Other information - capital expenditure  
Property, plant and equipment  
163,511  
30,935  
20,991  
215,437  
-
-
-
-
80,777  
-
-
-
-
244,288  
30,935  
20,991  
296,214  
Payments for intellectual property  
Payments for software intangibles  
Total capital expenditure  
-
-
80,777  
8
0
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
2
Segment information (continued)  
Geographic areas  
Australia United States  
Switzerland  
Germany Rest of world  
Total  
June 2011  
$000  
$000  
$000  
$000  
$000  
$000  
External sales revenue  
527,892  
1,605,511  
156,843  
644,575  
1,252,733  
4,187,554  
2,122,337  
Property, plant, equipment and  
intangible assets  
478,272  
368,620  
1,008,203  
251,803  
15,439  
June 2010  
External sales revenue  
620,757  
454,473  
1,742,487  
445,479  
153,607  
992,360  
675,843  
251,638  
1,263,127  
19,402  
4,455,821  
2,163,352  
Property, plant, equipment and  
intangible assets  
Consolidated Group  
011  
000  
2
$
2010  
$000  
3
Revenue and eꢂpenses  
Revenue  
Sales revenue  
4,187,554  
4,455,821  
Other revenue  
Royalties and licence revenue  
Finance revenue  
95,730  
28,354  
111,530  
40,485  
Rent  
1,028  
1,003  
Other revenue  
8,902  
18,105  
Total other revenues  
Total revenue from continuing operations  
134,014  
4,321,568  
171,123  
4,626,944  
Finance revenue comprises:  
Interest income:  
Other persons and/or corporations  
28,354  
-
40,395  
90  
Key management personnel and other staff  
2
8,354  
40,485  
Finance costs  
Interest expense:  
Other persons and/or corporations  
Total finance costs  
14,481  
14,481  
18,157  
18,157  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
81  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
011  
2
2010  
$000  
Notes  
$000  
3
Revenue and eꢂpenses (continued)  
Depreciation and amortisation  
Depreciation and amortisation of fixed assets  
Building depreciation  
10  
10  
12,430  
114,715  
3,062  
12,302  
105,741  
3,445  
Plant and equipment depreciation  
Leased property, plant and equipment amortisation  
Leasehold improvements amortisation  
10  
10  
4,895  
4,239  
Total depreciation and amortisation of fixed assets  
135,102  
125,727  
Amortisation of intangibles  
Intellectual property  
12  
12  
22,749  
8,241  
23,433  
7,455  
Software  
Total amortisation of intangibles  
30,990  
30,888  
Impairment loss  
Intellectual property  
12  
6,550  
-
Total depreciation, amortisation and impairment expense  
172,642  
156,615  
Other expenses  
Write-down of inventory to net realisable value  
Doubtful debts  
50,567  
24,866  
1,279  
71,863  
10,823  
1,168  
Net loss on disposal of property, plant and equipment  
Net foreign exchange loss  
14,588  
10,312  
Lease payments and related expenses  
Rental expenses relating to operating leases  
31,918  
39,504  
Employee benefits expense  
Salaries and wages  
914,352  
20,315  
19,422  
14,488  
3,983  
975,321  
21,526  
19,901  
16,725  
-
Defined benefit plan expense  
Defined contribution plan expense  
Share based payments expense (LTI)  
Share based payments expense (EDIP)  
26(a)  
26(b)  
21  
14  
972,560  
1,033,473  
8
2
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
011  
2
2010  
$000  
Notes  
$000  
4
Income taꢂ eꢂpense  
Income taꢂ eꢂpense recognised in the statement of comprehensive income  
Current tax expense  
Current year  
261,858  
304,252  
Deferred tax expense  
Origination and reversal of temporary differences  
Tax losses recognised  
11  
4,549  
(50)  
34,253  
-
4
,499  
34,253  
(11,951)  
326,554  
Over provided in prior years  
Income tax expense  
(8,839)  
257,518  
Reconciliation between tax expense and pre-tax net profit  
The reconciliation between tax expense and the product of accounting profit before income  
tax multiplied by the Group’s applicable income tax rate is as follows:  
Accounting profit before income tax  
Income tax calculated at 30% (2010: 30%)  
Research and development  
1,198,119  
359,436  
(13,973)  
5,762  
1,379,455  
413,836  
(13,569)  
1,388  
Other non-deductible items  
Utilisation of tax losses/unrecognised deferred tax  
Revaluation of deferred tax balances  
Effects of different rates of tax on overseas income  
Over provision in prior year  
(50)  
-
-
58  
(84,818)  
(8,839)  
257,518  
(63,208)  
(11,951)  
326,554  
Income tax expense  
Income tax recognised directly in equity  
Deferred tax benefit  
Share based payments  
(3,508)  
-
1,699  
5,636  
7,335  
Capital raising costs  
Income tax benefit recognised in equity  
11  
(3,508)  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
83  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
011  
000  
2
$
2010  
$000  
5
Earnings Per Share  
Earnings used in calculating basic and dilutive earnings per share comprises:  
Profit attributable to ordinary shareholders  
940,601  
1,052,901  
umber of shares  
011  
2
2010  
Weighted average number of ordinary shares used in the calculation of basic earnings per share:  
540,530,188  
566,781,567  
Effect of dilutive securities:  
Employee options  
273,892  
1,002,133  
4,903  
444,613  
1,336,412  
312  
Employee performance rights  
Global employee share plan  
Adjusted weighted average number of ordinary shares used in the calculation of diluted  
earnings per share:  
541,811,116  
568,562,904  
Conversions, calls, subscription or issues after 30 June 2011  
Subsequent to 30 June 2011, no shares have been issued to employees as a result of the exercise of performance rights and performance  
options. There have been no other conversions to, calls of, or subscriptions for ordinary shares or issues of ordinary or potential ordinary  
shares since the reporting date and before the completion of this financial report.  
Options and performance rights  
Options and performance rights granted to employees are considered to be potential ordinary shares that have been included in the  
determination of diluted earnings per share to the extent to which they are dilutive. The options and rights have not been included in the  
determination of basic earnings per share.  
Consolidated Group  
2
011  
2010  
$000  
$
000  
6
Cash and cash equivalents  
Cash at bank and on hand  
Cash deposits  
294,883  
184,520  
257,756  
743,303  
479,403  
1,001,059  
Note 25(a) contains a reconciliation of the above figures to cash at the end of the financial year as shown in the statement of cash flows.  
8
4
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
$
011  
000  
2010  
$000  
7
Trade and other receivables  
Current  
Trade receivables  
734,366  
(22,891)  
827,078  
(25,615)  
801,463  
54,911  
Less: Provision for impairment loss (i)  
7
11,475  
67,084  
30,092  
Sundry receivables  
Prepayments  
26,628  
Carrying amount of current trade and other receivables*  
808,651  
883,002  
Non Current  
Related parties  
Loans to key management personnel – other executives**  
Loans to other employees  
-
1,093  
3,451  
4,544  
979  
2,499  
4,092  
7,570  
Long term deposits  
Carrying amount of non current trade and other receivables*  
*
The carrying amount disclosed above is a reasonable approximation of fair value. The maximum exposure to credit risk at the reporting  
date is the carrying amount of each class of receivable disclosed above. Refer to note 34 for more information on the risk management  
policy of the Group and the credit quality of trade receivables.  
**Further information relating to loans to key management personnel is set out in note 28.  
(
i) Past due but not impaired and impaired trade receivables  
As at 30 June 2011, the Group had current trade receivables which were impaired and had a nominal value of $22,891,265 (2010:  
25,614,775). These receivables have been provided for within the Group’s provisions for impairment loss. Amounts charged to the  
$
provision account are generally written off when there is no expectation of recovering additional cash. Movements in the provision for  
impairment loss are reconciled as follows:  
Opening balance at 1 July  
25,615  
(1,227)  
(1,497)  
22,891  
20,254  
8,693  
Additional allowance / (utilised)  
Currency translation differences  
Closing balance at 30 June  
(3,332)  
25,615  
Debts which are past due and not impaired are set out in the credit risk analysis in note 34.  
(
ii) Other receivables  
The other classes within trade and other receivables do not contain impaired or overdue receivable amounts and it is expected that all of  
these amounts will be received when due. Loans provided to key management personnel to purchase the company’s shares on the exercise  
of options are secured against those shares. The Group does not hold any collateral in respect to other receivable balances  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
85  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
$
011  
000  
2010  
$000  
8
Inventories  
Raw materials and stores – at cost  
Less: Allowance for diminution in value  
Raw materials and stores – net  
Work in progress – at cost  
290,763  
(5,489)  
300,107  
(11,306)  
288,801  
570,121  
(37,530)  
532,591  
653,012  
(19,788)  
633,224  
1,454,616  
285,274  
496,132  
(33,662)  
462,470  
733,612  
(25,361)  
708,251  
1,455,995  
Less: Allowance for diminution in value  
Work in progress – net  
Finished goods – at cost  
Less: Allowance for diminution in value  
Finished goods - net  
Total inventories at the lower of cost and net realisable value  
9
Other financial assets  
Current  
At fair value through the profit or loss:  
Managed financial assets (held for trading)  
Available-for-sale financial assets  
2,745  
15,248  
17,993  
479  
-
Total current other financial assets as at 30 June  
479  
Non-current  
At fair value through the profit or loss:  
Managed financial assets  
2,280  
2,280  
4,589  
4,589  
Total non-current other financial assets as at 30 June  
8
6
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
$
011  
000  
2010  
$000  
10 Property, Plant and Equipment  
Land at cost  
Opening balance 1 July  
Currency translation differences  
Closing balance 30 June  
Buildings at cost  
25,494  
(187)  
25,589  
(95)  
25,307  
25,494  
Opening balance 1 July  
Transferred from capital work in progress  
Other additions  
275,036  
15,886  
130  
266,756  
21,936  
509  
Disposals  
(410)  
(476)  
Transfers  
(327)  
-
Currency translation differences  
Closing balance 30 June  
Accumulated depreciation and impairment losses  
Opening balance 1 July  
Depreciation for the year  
Disposals  
(6,442)  
283,873  
(13,689)  
275,036  
66,411  
12,430  
(374)  
58,702  
12,302  
(236)  
Currency translation differences  
Closing balance 30 June  
Net book value of buildings  
Net book value of land and buildings  
Leasehold improvements at cost  
Opening balance 1 July  
Transferred from capital work in progress  
Other additions  
(1,734)  
76,733  
207,140  
232,447  
(4,357)  
66,411  
208,625  
234,119  
67,084  
14,975  
1,168  
67,479  
6,617  
900  
Disposals  
(5,721)  
503  
(5,952)  
-
Transfers  
Currency translation differences  
Closing balance 30 June  
Accumulated amortisation and impairment  
Opening balance 1 July  
Amortisation for the year  
Disposals  
(14,236)  
63,773  
(1,960)  
67,084  
26,863  
4,895  
(5,416)  
63  
29,611  
4,239  
(5,539)  
-
Transfers  
Currency translation differences  
Closing balance 30 June  
Net book value of leasehold improvements  
(6,371)  
20,034  
43,739  
(1,448)  
26,863  
40,221  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
87  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
011  
000  
2
$
2010  
$000  
10 Property, Plant and Equipment (continued)  
Plant and equipment at cost  
Opening balance 1 July  
1,405,733  
207,080  
26,958  
1,321,694  
218,655  
6,085  
Transferred from capital work in progress  
Other additions  
Disposals  
(34,874)  
(176)  
(28,638)  
-
Transfers  
Transfers to intangibles  
(1,852)  
-
Currency translation differences  
Closing balance 30 June  
(87,977)  
1,514,892  
(112,063)  
1,405,733  
Accumulated depreciation and impairment  
Opening balance 1 July  
738,258  
114,715  
(34,160)  
(63)  
725,632  
105,741  
(27,968)  
-
Depreciation for the year  
Disposals  
Transfers  
Currency translation differences  
Closing balance 30 June  
(56,695)  
762,055  
752,837  
(65,147)  
738,258  
667,475  
Net book value of plant and equipment  
Leased property, plant and equipment at cost  
Opening balance 1 July  
37,470  
1,051  
45,293  
1,478  
Other additions  
Disposals  
(1,350)  
(4,352)  
32,819  
(992)  
Currency translation differences  
Closing balance 30 June  
(8,309)  
37,470  
Accumulated amortisation and impairment  
Opening balance  
14,201  
3,062  
15,947  
3,445  
Amortisation for the year  
Disposals  
(817)  
(617)  
Currency translation differences  
Closing balance 30 June  
(2,078)  
14,368  
18,451  
(4,574)  
14,201  
23,269  
Net book value of leased property, plant and equipment  
Capital work in progress  
Opening balance 1 July  
242,755  
170,216  
(6)  
265,647  
236,794  
(65)  
Other additions  
Disposals  
Transferred to buildings at cost  
Transferred to plant and equipment at cost  
Transferred to leasehold improvements at cost  
Transfers to intangibles  
(15,886)  
(207,080)  
(14,975)  
(3,451)  
(21,936)  
(218,655)  
(6,617)  
-
Currency translation differences  
Closing balance 30 June  
(11,759)  
159,814  
1,207,288  
(12,413)  
242,755  
1,207,839  
Total net book value of property, plant and equipment  
8
8
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
$
011  
000  
2010  
$000  
11 Deferred taꢂ assets and liabilities  
Deferred tax asset  
174,206  
(122,202)  
52,004  
191,410  
(114,822)  
76,588  
Deferred tax liability  
Net deferred tax asset/(liability)  
Deferred tax balances reflect temporary differences attributable to:  
Amounts recognised in the statement of comprehensive income  
Trade and other receivables  
(4,286)  
69,899  
(63,869)  
(36,950)  
1,285  
(6,797)  
73,144  
(54,373)  
(29,482)  
(128)  
Inventories  
Property, plant and equipment  
Intangible assets  
Other assets  
Trade and other payables  
8,641  
7,385  
Interest bearing liabilities  
3,958  
4,152  
Other liabilities and provisions  
33,212  
15,311  
4,322  
39,769  
12,764  
5,979  
Retirement assets/(liabilities)  
Tax bases not in net assets – share based payments  
Recognised carry-forward tax losses  
14,854  
13,155  
65,568  
46,377  
Amounts recognised in equity  
Capital raising costs  
3,751  
1,876  
5,636  
5,384  
Share based payments  
5
,627  
11,020  
76,588  
Net deferred tax asset/(liability)  
52,004  
Movement in temporary differences during the year  
Opening balance  
76,588  
(4,549)  
(1,302)  
(3,508)  
(15,225)  
52,004  
119,034  
(34,253)  
2,402  
Credited/(charged) to profit before tax  
Credited/(charged) to other comprehensive income  
Credited/(charged) to equity  
7,335  
Currency translation difference  
(17,930)  
76,588  
Closing balance  
Unrecognised deferred tax assets  
Deferred tax assets have not been recognised in respect of the following items:  
Tax losses:  
Expiry date in less than 1 year  
-
107  
-
-
115  
-
Expiry date greater than 1 year but less than 5 years  
Expiry date greater than 5 years  
No expiry date  
759  
841  
956  
866  
Deferred tax assets have not been recognised in respect of these items because it is not probable that future taxable profit will be available for  
utilisation in the entities that have recorded these losses.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
89  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
011  
$000  
2
2010  
$000  
Notes  
12 Intangible Assets  
Carrying amounts  
Goodwill  
Opening balance at 1 July  
Currency translation differences  
Closing balance at 30 June  
Intellectual property  
722,040  
(9,370)  
712,670  
758,298  
(36,258)  
722,040  
Opening balance at 1 July  
Additions  
358,236  
367,965  
2,166  
-
-
Disposals  
(259)  
Currency translation differences  
Closing balance at 30 June  
Accumulated amortisation and impairment  
Opening balance at 1 July  
Amortisation for the year  
Current year impairment charge  
Amortisation written back on disposal  
Currency translation differences  
Closing balance at 30 June  
Net intellectual property  
(3,316)  
354,920  
(11,636)  
358,236  
171,575  
22,749  
6,550  
151,716  
23,433  
-
3
-
(259)  
(2,035)  
198,839  
156,081  
(3,315)  
171,575  
186,661  
Software  
Opening balance at 1 July  
Additions  
59,400  
549  
40,194  
20,991  
-
Disposals  
(1,900)  
6,768  
Transfers from intangible capital work in progress  
Currency translation differences  
Closing balance at 30 June  
Accumulated amortisation and impairment  
Opening balance at 1 July  
Amortisation for the year  
Currency translation differences  
Closing balance at 30 June  
Net Software  
-
(10,364)  
54,453  
(1,785)  
59,400  
12,588  
8,241  
5,258  
7,455  
(2,073)  
18,756  
35,697  
(125)  
12,588  
46,812  
Intangible capital work in progress  
Opening balance at 1 July  
Additions  
-
13,189  
(6,768)  
5,303  
-
-
Transfers to software intangibles  
Transfers from property, plant and equipment  
Currency translation differences  
Closing balance at 30 June  
Total net intangible assets as at 30 June  
-
-
(1,123)  
10,601  
915,049  
-
-
955,513  
The amortisation charge is recognised in general and administration expenses in the statement of comprehensive income.  
9
0
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
011  
000  
2
$
2010  
$000  
12 Intangible Assets (continued)  
Impairment tests for cash generating units containing goodwill  
For the purpose of impairment testing, goodwill is allocated to the business unit which  
represents the lowest level within the Group at which the goodwill is monitored for internal  
management purposes. The aggregate carrying amounts of goodwill allocated  
to each unit are as follows:  
CSL Behring  
700,587  
12,083  
709,957  
12,083  
CSL Biotherapies  
Closing balance of goodwill as at 30 June  
712,670  
722,040  
The impairment tests for these cash generating units are based on value in use calculations. These calculations use cash flow projections  
based on actual operating results and the three-year strategic business plan, after which a terminal value is calculated based on a business  
valuation multiple. The valuation multiple has been calculated based on independent external analyst views, long term government bond  
rates and the company’s pre-tax cost of debt. Projected cash flows have been discounted by using the implied pre-tax discount rate of  
10.3% (2010: 11.4%) associated with the business valuation multiple discussed above. Each unit’s recoverable amount exceeds the carrying  
value of its net assets, inclusive of goodwill. It is not considered a reasonable possibility for a change in assumptions to occur that would  
lead to a unit’s recoverable amount falling below the carrying value of each unit’s respective net assets.  
Consolidated Group  
2
011  
2010  
$000  
$
000  
13 Retirement benefit assets and liabilities  
Retirement benefit assets  
Non-current defined benefit plans (refer note 26)  
2,588  
4,967  
Retirement benefit liabilities  
Non-current defined benefit plans (refer note 26)  
113,924  
116,401  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
91  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
011  
000  
2
$
2010  
$000  
14 Trade and other payables  
Current  
Trade payables  
244,711  
248,795  
493,506  
210,180  
275,223  
485,403  
Accruals and other payables  
Carrying amount of current trade and other payables  
Non-current  
Share based payments (EDIP)  
3,983  
3,983  
-
-
Carrying amount of non-current trade and other payables  
15 Interest-bearing liabilities and borrowings  
Current  
Bank overdrafts – Unsecured  
Bank loans – Unsecured (a)  
Senior Unsecured Notes - Unsecured (b)  
Lease liability – Secured (c)  
584  
209,039  
13,697  
2,894  
6,554  
-
16,312  
3,118  
25,984  
226,214  
Non-current  
Bank loans - Unsecured  
Senior Unsecured Notes - Unsecured (b)  
Lease liability - Secured (c)  
-
196,984  
207,159  
32,076  
162,926  
27,104  
190,030  
436,219  
(a) This facility matures in March 2012. Interest on the facility is paid quarterly in arrears at a variable rate. As at the reporting date the Group  
had $41.4m in undrawn funds available under this facility.  
(
b) Represents US$105.4 million and Euro 58.3 million of Senior Unsecured Notes placed into the US Private Placement market. The notes  
have biannual repayments and mature in December 2012. The interest rate on the US$ notes is fixed at 5.30% and 5.90%. The interest  
rate on the Euro notes is fixed at 3.98% and 4.70%.  
(
c) Finance leases have an average lease term of 12 years (2010: 13 years). The weighted average discount rate implicit in the leases is 5.65%  
2010: 5.51%). The Group’s lease liabilities are secured by leased assets of $18.5 million (2010: $23.3 million). In the event of default, leased  
assets revert to the lessor.  
(
Note 34 has further information about the Group’s exposure to interest rate risk, foreign exchange risk and the fair value of financial assets  
and liabilities.  
92  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
011  
000  
2
$
2010  
$000  
16 Taꢂ liabilities  
Current income tax liability  
131,729  
176,809  
176,809  
131,729  
17 Provisions  
Current  
Employee benefits  
71,570  
74,532  
Restructuring  
Onerous contracts  
Other  
4,107  
11,034  
1,909  
6,458  
11,721  
2,986  
88,620  
95,697  
Non-current  
Employee benefits  
Other  
27,391  
1,079  
29,729  
1,195  
28,470  
30,924  
Restructuring  
A restructuring provision is recognised when the main features of the restructuring are planned. Restructuring plans must set out the  
businesses, locations and approximate number of employees affected and the expenditures that will be undertaken, together with  
an implementation timetable. There must be a demonstrable commitment and valid expectation that the restructuring plan will be  
implemented prior to a provision being recognised.  
Onerous contracts  
The provision recognised is based on the excess of the estimated cash flows to meet the unavoidable costs, over the estimated cash flows  
to be received in relation to certain contracts, having regard to the risks of the activities relating to the contracts.  
Discounting  
Where the effect of discounting is determined to be material to the provision, the net estimated cash flows are discounted using a pre-tax  
discount rate reflecting current market assessments of the time value of money and the risks specific to the liability.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
93  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
$
011  
000  
2010  
$000  
17 Provisions (continued)  
Movements in provisions  
Restructuring  
Opening balance  
Provided / (released)  
Payments made  
6,458  
1,790  
(4,141)  
-
7,757  
(474)  
-
Currency differences  
Closing balance  
(825)  
6,458  
4,107  
Onerous contracts  
Opening balance  
Currency differences  
Closing balance  
11,721  
(687)  
14,217  
(2,496)  
11,721  
11,034  
Surplus lease space  
Opening balance  
Payments made  
Currency differences  
Closing balance  
-
-
-
-
77  
(73)  
(4)  
-
Contingent consideration  
Opening balance  
Payments made  
Currency differences  
Closing balance  
-
-
-
-
26,247  
(28,769)  
2,522  
-
Other  
Opening balance  
Additional provision  
Payments made  
Currency differences  
Closing balance  
4,181  
(311)  
(784)  
(99)  
6,841  
1,719  
(1,481)  
(2,898)  
4,181  
2,987  
18 Deferred government grants  
Current deferred income  
995  
18,910  
19,905  
995  
10,605  
11,600  
Non-current deferred income  
Total deferred government grants  
19 Derivative financial instruments – current liabilities  
Forward Currency Contracts  
5,054  
1,991  
The Group has entered into forward currency contracts as an economic hedge against variations in the value of certain trade payable  
amounts due to currency fluctuations. All movements in the fair value of these forward currency contracts are recognised in the profit  
and loss when they occur.  
9
4
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
$
011  
000  
2010  
$000  
20 Contributed equity  
Ordinary shares issued and fully paid  
253,896  
1,139,228  
Ordinary shares have the right to receive dividends as declared and, in the event of winding up the company, to participate in the proceeds  
from the sale of all surplus assets in proportion to the number of and amounts paid up on shares held. Ordinary shares entitle their holder  
to one vote, either in person or proxy, at a meeting of the company.  
2011  
2010  
Number of  
Number of  
shares  
shares  
$000  
$000  
Movement in ordinary shares on issue  
Opening balance at 1 July  
549,692,886  
1,139,228  
599,239,428  
-
2,760,207  
Shares issued to parties other than CSL employees through  
participation in:  
-
Capital raising tax benefit  
-
-
9,341  
Shares issued to employees via:  
-
-
-
-
SESOP II (i)  
-
540,971  
-
9,569  
77,040  
253,154  
670  
4,432  
Performance Options (ii)  
Performance Rights (for nil consideration)  
GESP (iii)  
483,734  
-
539,006  
-
186,110  
5,099  
186,124  
5,162  
Share buy-back, inclusive of cost  
Closing balance  
(26,063,169)  
524,840,532  
(900,000)  
253,896  
(50,601,866)  
549,692,886  
(1,640,584)  
1,139,228  
Consolidated Group  
2
$
011  
000  
2010  
$000  
(
i) Options exercised under SESOP II as disclosed in note 27 were as follows:  
-
-
Nil (2010: 9,240 issued at $4.06)  
Nil (2010: 67,800 issued at $9.32)  
-
38  
-
-
632  
670  
(
(
ii) Options exercised under Performance Option plans as disclosed in note 27 were as follows  
-
-
534,707 issued at $17.48 (2010: 252,769 issued at $17.48)  
6,264 issued at $35.46 (2010: 385 issued at $35.46 )  
9,347  
222  
4,418  
14  
9,569  
4,432  
iii) Shares issued to employees under Global Employee Share Plan (GESP) as disclosed in  
note 27 were as follows:  
-
-
95,517 issued at $27.29 on 7 September 2010  
90,593 issued at $27.51 on 10 March 2011  
2,607  
2,492  
2,572  
2,590  
5,162  
5,099  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
95  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
$
011  
000  
2010  
$000  
21 Reserves  
Share based payments reserve  
99,494  
(520,216)  
(913)  
84,163  
(326,778)  
-
Foreign currency translation reserve  
Available-for-sale investments reserve  
Carrying value of reserves at 30 June  
(421,635)  
(242,615)  
Movements in reserves  
Share based payments reserve (i)  
Opening balance at 1 July  
84,163  
14,488  
843  
65,739  
16,725  
1,699  
Share based payments expense  
Deferred tax on share based payments  
Closing balance at 30 June  
99,494  
84,163  
Foreign currency translation reserve (ii)  
Opening balance at 1 July  
(326,778)  
(193,438)  
(520,216)  
(50,541)  
(276,237)  
(326,778)  
Net exchange gains / (losses) on translation of foreign subsidiaries, net of hedge  
Closing balance at 30 June  
Available-for-sale investments reserve (iii)  
Opening balance at 1 July  
-
-
-
-
Mark to market adjustment on available-for-sale financial assets  
Closing balance at 30 June  
(913)  
(913)  
Nature and purpose of reserves  
(
i) Share based payments reserve  
The share based payments reserve is used to recognise the fair value of options, performance rights and global employee share plan rights  
issued to employees.  
(
ii) Foreign currency translation reserve  
The foreign currency translation reserve is used to record exchange differences arising from the translation of the financial statements  
of foreign operations and exchange gains and losses arising on those foreign currency borrowings which are designated as hedging the  
Company’s net investment in foreign operations.  
(
iii) Available-for-sale investments reserve  
Changes in the fair value and exchange differences arising on translation of investments classified as available-for-sale financial assets are  
recognised in other comprehensive income, as described in note 1(m) and accumulated in a separate reserve within equity. Amounts are  
reclassified to profit and loss when the associated assets are sold or impaired.  
9
6
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
011  
$000  
2
2010  
$000  
Notes  
22 Retained earnings  
Opening balance at 1 July  
3,318,581  
940,601  
(435,882)  
(9,899)  
2,687,490  
1,052,901  
(429,477)  
5,265  
Net profit for the year  
Dividends  
23  
Actuarial gain/(loss) on defined benefit plans  
Deferred tax on actuarial gain/(loss) on defined benefit plans  
Closing balance at 30 June  
(1,302)  
2,402  
3,812,099  
3,318,581  
23 Dividends  
Dividends paid  
Dividends recognised in the current year by the Company are:  
Final ordinary dividend of 45 cents per share, franked to 11%, paid on 8 October 2010  
247,489  
188,393  
235,665  
(2010: 40 cents per share, unfranked)  
Interim ordinary dividend of 35 cents per share, unfranked, paid on 8 April 2011 (2010:  
5 cents per share, unfranked)  
193,812  
429,477  
3
435,882  
Dividends not recognised at year end  
In addition to the above dividends, since year end the directors have recommended  
the payment of a final dividend of 45 cents per share, franked to 2.00 cents per share  
(2010: ordinary dividend of 45 cents per share, franked to 5.28 cents per share). The  
final dividend is expected to be paid on 14 October 2011. Based on the number of  
shares on issue as at reporting date, the aggregate amount of the proposed dividend  
would be:  
236,178  
247,364  
The actual aggregate dividend amount paid out of profits will be dependent on the  
actual number of shares on issue at dividend record date.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
97  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
011  
$000  
2
2010  
$000  
Notes  
24 Equity  
Total equity at the beginning of the financial year  
Total comprehensive income for the period  
Movement in contributed equity  
4,215,194  
735,049  
5,462,895  
784,331  
20  
23  
21  
(885,332)  
(435,882)  
15,331  
(1,620,979)  
(429,477)  
18,424  
Dividends  
Movement in share based payments reserve  
Total equity at the end of the financial year  
3,644,360  
4,215,194  
25 Statement of Cash Flows  
(a) Reconciliation of cash and cash equivalents and non-cash financing and  
investing activities  
Cash at the end of the year is shown in the cash flow statement as:  
Cash at bank and on hand  
Cash deposits  
6
294,883  
184,520  
(584)  
257,756  
743,303  
(6,554)  
6
Bank overdrafts  
15  
478,819  
994,505  
(
b) Reconciliation of Profit after tax to Cash Flows from Operations  
Profit after tax  
940,601  
1,052,901  
Non-cash items in profit after tax  
Depreciation, amortisation and impairment charges  
172,642  
1,279  
913  
156,615  
1,168  
-
(Gain)/loss on disposal of property, plant and equipment  
Mark to market adjustment on available-for-sale investments  
Share based payments expense  
14,488  
16,725  
Changes in assets and liabilities:  
(
(
(
Increase)/decrease in trade and other receivables  
48,604  
(156,934)  
2,224  
(77,686)  
(74,383)  
(4,736)  
Increase)/decrease in inventories  
Increase)/decrease in retirement benefit assets  
Increase/decrease in net tax assets and liabilities  
Increase/(decrease) in trade and other payables  
Increase/(decrease) in provisions  
10,234  
146,732  
(28,482)  
(25,523)  
5,161  
25,440  
(40,059)  
(1,313)  
Increase/(decrease) in retirement benefit liabilities  
Net cash inflow from operating activities  
1,018,119  
1,168,492  
(c) Non cash financing activities  
Acquisition of plant and equipment by means of finance leases  
1,051  
1,478  
9
8
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
$
011  
000  
2010  
$000  
26 Employee benefits  
A reconciliation of the employee benefits recognised is as follows:  
Retirement benefit assets – non-current (note 13)  
2,588  
4,967  
Provision for employee benefits – current (note 17)  
Retirement benefit liabilities – non-current (note 13)  
Provision for employee benefits – non-current (note 17)  
71,570  
113,924  
27,391  
74,532  
116,401  
29,729  
212,885  
220,662  
The number of full time equivalents employed at 30 June  
10,411  
9,992  
(a) Defined benefit plans  
The Group sponsors a range of defined benefit pension plans that provide pension benefits for its worldwide employees upon  
retirement. Entities of the Group who operate the defined benefit plans contribute to the respective plans in accordance with the  
Trust Deeds, following the receipt of actuarial advice.  
Movements in the net liability/(asset) for defined benefit obligations recognised  
in the balance sheet  
Net liability/(asset) for defined benefit obligation:  
Opening balance  
111,434  
(16,917)  
(5,822)  
20,315  
9,899  
133,894  
(18,883)  
(3,126)  
21,526  
(5,265)  
368  
Contributions received  
Benefits paid  
Expense/(benefit) recognised in the statement of comprehensive income  
Actuarial (gains)/losses recognised in equity  
Other movements  
-
Currency translation differences  
Closing balance  
(7,573)  
111,336  
(17,080)  
111,434  
Net liability/(asset) for defined benefit obligation is reconciled to the balance sheet  
as follows:  
Retirement benefit assets – non-current (note 13)  
Retirement benefit liabilities – non-current (note 13)  
Net liability/(asset)  
(2,588)  
113,924  
111,336  
(4,967)  
116,401  
111,434  
Amounts for the current and previous periods are as follows:  
Consolidated Group  
2
$
011  
000  
2010  
$000  
2009  
$000  
Defined benefit obligation  
Plan assets  
492,194  
380,858  
(111,336)  
(12,857)  
3,657  
467,379  
355,945  
(111,434)  
(2,270)  
467,887  
333,993  
(133,894)  
(8,016)  
Surplus/(deficit)  
Experience adjustments on plan liabilities  
Experience adjustments on plan assets  
Actual return on plan assets  
7,535  
(46,040)  
(27,010)  
19,607  
24,643  
The Group has used the AASB 1 exemption and disclosed amounts under AASB 1.20A(p) above for each annual reporting period  
prospectively from the AIFRS transition date (1 July 2004).  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
99  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
$
011  
000  
2010  
$000  
26 Employee benefits (continued)  
(a) Defined benefit plans (continued)  
Changes in the present value of the defined benefit obligation are as follows:  
Opening balance  
467,379  
18,831  
17,433  
5,270  
467,887  
20,098  
18,536  
5,829  
Service cost  
Interest cost  
Contributions by members  
Actuarial (gains)/losses  
Benefits paid  
12,857  
(19,291)  
(973)  
2,270  
(14,467)  
(522)  
Other movements  
Currency translation differences  
Closing balance  
(9,312)  
492,194  
(32,252)  
467,379  
The present value of the defined benefit obligation comprises:  
Present value of wholly unfunded obligations  
Present value of funded obligations  
92,914  
98,474  
368,905  
467,379  
399,280  
492,194  
Changes in the fair value of plan assets are as follows:  
Opening balance  
355,945  
15,949  
3,657  
333,993  
17,108  
7,535  
Expected return on plan assets  
Actuarial gains/(losses) on plan assets  
Contributions by employer  
Contributions by members  
Benefits paid  
16,917  
5,270  
18,883  
5,829  
(15,448)  
(412)  
(11,341)  
(890)  
Other movements  
Currency translation differences  
Closing balance  
(1,020)  
380,858  
(15,172)  
355,945  
The major categories of plan assets as a percentage of total plan assets is as follows:  
Cash  
4.1%  
35.2%  
45.4%  
13.6%  
1.7%  
3.5%  
33.8%  
48.8%  
12.7%  
1.2%  
Equity instruments  
Debt instruments  
Property  
Other assets  
100.0%  
100.0%  
Expenses/(gains) recognised in the statement of comprehensive income are as follows:  
Current service costs  
18,831  
17,433  
(15,949)  
20,315  
20,098  
18,536  
(17,108)  
21,526  
Interest on obligation  
Expected return on assets  
Total included in employee benefits expense  
100  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
011  
000  
2
$
2010  
$000  
26 Employee benefits (continued)  
(a) Defined benefit plans (continued)  
The principal actuarial assumptions at the balance sheet date (expressed as weighted  
averages) are as follows:  
Discount rate  
3.7%  
3.7%  
2.3%  
0.3%  
4.0%  
3.8%  
2.3%  
0.4%  
1
Expected return on assets and expected long-term rate of return on assets  
Future salary increases  
Future pension increases  
1The expected long-term rate of return is based on the portfolio as a whole.  
Accrued  
benefit  
Plan surplus /  
(deficit)  
Plan assets1  
1
Surplus/(deficit) for each defined benefit plan on a funding basis  
$000  
$000  
$000  
Consolidated Group – June 2011  
CSL Pension Plan (Australia)  
35,401  
(32,813)  
(315,293)  
(51,175)  
(71,986)  
(1,557)  
(3,892)  
(184)  
2,588  
(13,563)  
(7,448)  
(71,986)  
(1,557)  
(3,892)  
(184)  
CSL Behring AG Pension Fund (Switzerland)  
CSL Behring Union Pension Plan (US UPP)  
CSL Behring GmbH Supplementary Pension Plan (Germany)  
CSL Pharma GmbH Pension Plan (Germany)  
CSL Behring KG Pension Plan (Germany)  
CSL Plasma GmbH Pension Plan (Germany)  
CSL Behring KK Retirement Allowance Plan (Japan)  
CSL Behring S.A. Pension Plan (France)  
CSL Behring S.p.A Pension Plan (Italy)  
301,730  
43,727  
-
-
-
-
-
-
-
(13,724)  
(312)  
(13,724)  
(312)  
(1,258)  
(492,194)  
(1,258)  
(111,336)  
380,858  
Consolidated Group – June 2010  
CSL Pension Plan (Australia)  
33,020  
(31,873)  
(274,395)  
(62,637)  
(78,409)  
(1,768)  
1,147  
3,820  
CSL Behring AG Pension Fund (Switzerland)  
CSL Behring Union Pension Plan (US UPP)  
CSL Behring GmbH Supplementary Pension Plan (Germany)  
CSL Pharma GmbH Pension Plan (Germany)  
CSL Behring KG Pension Plan (Germany)  
CSL Plasma GmbH Pension Plan (Germany)  
CSL Behring KK Retirement Allowance Plan (Japan)  
278,215  
44,710  
(17,927)  
(78,409)  
(1,768)  
(3,962)  
(111)  
-
-
-
-
-
(3,962)  
(111)  
(14,224)  
(467,379)  
(14,224)  
(111,434)  
355,945  
1Plan assets at net market value and accrued benefits have been calculated at 30 June, being the date of the most recent financial statements of the plans  
In addition to the above, CSL Behring GmbH employees are members of two multi-employer pension plans (“Penka 1” and “Penka  
2”) administered by an unrelated third party. CSL Behring and the employees make contributions to the plans and receive pension  
entitlements on retirement. Following a recent review of these arrangements CSL is aware that there is the potential for the employer  
to have to make additional contributions in the event that the multi-employer fund does not have sufficient assets to pay all benefits.  
There is insufficient information available for the scheme to be shown at the CSL Group level because the pension assets cannot be  
split between the participating companies. The company’s contributions are advised by the funds and are designed to cover expected  
liabilities based on actuarial assumptions. CSL Behring GmbH contribute 300% of the employee contribution to Penka 1 (2011: €3.9m,  
2010: €4.0m) and 100% of the employee contribution to Penka 2 (2011: €0.4m, 2010: €0.7m), neither of these contribution rates has  
changed since 2007. Contributions are expensed in the year in which they are made.  
(
b) Defined contribution plans  
The Group makes contributions to various defined contribution pension plans. The amounts recognised as an expense for the year  
ended 30 June 2011 was $19,422,000 (2010: $19,901,000).  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
101  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
$
011  
000  
2010  
$000  
27 Share based payments  
(a) Recognised share based payments expenses  
The expense recognised for employee services rendered during the year is as follows:  
Expense arising from equity-settled share-based payment transactions  
Expense arising from cash-settled share-based payment transactions  
14,488  
3,983  
16,725  
-
18,471  
16,725  
(
b) Share based payment schemes  
The Company operates the following schemes that entitles key management personnel and senior employees to purchase shares in the  
Company under and subject to certain conditions:  
Senior Executive Share Ownership Plan (SESOP II)  
The SESOP II plan was approved by special resolution at the annual general meeting of the Company on 20 November 1997. The plan  
governed the provision of share based long term incentives in the form of options issued between 1997 and 1 July 2003 inclusive. There  
have been no SESOP II options issued since July 2003. Other than those which lapsed, all SESOP II options vested in earlier financial years  
following the achievement of a 7% compound growth in earnings per share over their vesting period. All SESOP II options which were  
capable of vesting have now been exercised. The price payable on exercise of SESOP II options equalled the weighted average price over the  
5
days preceding the issue date of the options. Upon request, interest bearing loans were available to employees to fund the exercise of their  
SESOP II options. The terms and conditions associated with the provision of SESOP II loans are set out in note 28(b) and the remuneration  
report. At 30 June 2011, no loans remain outstanding.  
Employee Performance Rights Plan (the plan)  
The Employee Performance Rights Plan was approved by special resolution at the annual general meeting of the Company on  
16 October 2003.  
Share based long term incentives issued between October 2003 and April 2006  
The plan, as originally approved, governed the provision of share based long term incentives in the form of performance rights issued  
between 16 October 2003 and 6 April 2006 inclusive. Other than those which lapsed, all performance rights issued under the original plan  
vested prior to 30 June 2009. Vesting of the performance rights was contingent on the Company achieving a Total Shareholder Return (TSR)  
which was at or above the 50th percentile relative to the TSR of a peer group of companies comprising those entities within the ASX top 100  
index by market capitalisation (excluding companies with the GICS industry codes of commercial banks, oil and gas and metals and mining).  
The original plan provided for vesting of 50% of the rights if the Company was ranked at the 50th percentile of TSR performance and for  
100% of the rights to vest if the Company was placed at or above the 75th percentile. Relative TSR performance between the 50th and 75th  
percentile resulted in the proportion of performance rights that vested increasing on a straight-line basis. Vested performance rights which  
are exercised entitle the holder to one ordinary share for nil consideration.  
Share based long term incentives issued between May 2006 and October 2009  
The Employee Performance Rights Plan was amended with effect from October 2006. Under the amended plan, share based long  
term incentives issued between October 2006 and October 2009 comprise grants made to executives of both performance rights  
and performance options, each subject to a different performance hurdle. Each long-term incentive grant generally consisted of 50%  
performance rights and 50% performance options. Grants of performance rights and performance options were issued for nil consideration.  
The plan, as amended, retained the TSR performance hurdle and provided for 100% vesting of performance rights at the expiration of their  
vesting period if the Company’s TSR performance was at or above the 50th percentile on the relevant test date. Under the revised plan,  
performance options were subject to an earnings per share (EPS) performance hurdle. 10% compound EPS growth per annum is required  
for the performance options to vest at the expiration of their vesting period. EPS growth is measured from 30 June in the financial year  
preceding the grant of options until 30 June in the financial year prior to the relevant test date. Vested performance options entitle the  
holder to one ordinary share on payment of an exercise price equal to the volume weighted average CSL share price over the week up to and  
including the date of grant. Performance rights and performance options issued between October 2006 and October 2009 were issued for  
a term of seven years. A portion, namely 25%, of the number of instruments granted becomes exercisable, subject to satisfying the relevant  
performance hurdle, after the second anniversary of the date of grant. Again, subject to satisfying the relevant performance hurdle, further  
portions of 35% and 40% of the number of instruments granted become exercisable after the third and fourth anniversaries post date of  
grant, respectively. If the portion tested at the applicable anniversary meets the relevant performance hurdle, that portion of rights and  
options vest and become exercisable until the expiry date. If the portion tested fails to meet the performance hurdle the portion is carried  
over to the next anniversary and retested. After the fifth anniversary, any performance rights and performance options not vested lapse.  
Importantly, there is an individual employee hurdle requiring an executive to obtain for the financial year prior to exercise of the Performance  
Rights and Performance Options, a satisfactory (or equivalent) rating under the Company’s performance management system. The last grant  
of performance rights and options to be issued on these terms was in October in 2009.  
102  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
27 Share based payments (continued)  
(
b) Share based payment schemes (continued)  
Share based long term incentives issued in October 2010  
Changes were made to the terms and conditions and key characteristics of Performance Rights and Performance Options granted in  
October 2010 and the number of employees who received grants was reduced following the introduction of the Employee Deferred  
Incentive Plan. Employees receiving a grant under the Plan received 80% of their entitlement in Performance Rights and 20% in  
Performance Options. Subject to performance hurdles being satisfied vesting of 50% of the LTI award will occur after 3 years, with  
the remaining 50% vesting after the 4th anniversary of the award date. EPS and TSR measures are applied to both Performance Rights  
and Performance Options as detailed in the Remuneration Report.  
Company provided loans are not available to fund the exercise of performance options under the plan  
Global Employee Share Plan (GESP)  
The ‘Global Employee Share Plan’ (GESP) operates whereby employees make contributions from after tax salary up to a maximum of  
$3,000 per each six month contribution period. The employees receive the shares at a 15% discount to the applicable market rate, as  
quoted on the ASX on the first day or the last day of the six month contribution period, whichever is lower.  
Executive Deferred Incentive Plan (EDIP)  
On 1 October 2010, 518,750 phantom shares were granted to employees under the Executive Deferred Incentive Plan. This plan  
provides for a grant of phantom shares which will generate a cash payment to participants in three years time, provided they are still  
employed by the company and receive a satisfactory performance review over that period. The amount of the cash payment will be  
determined by reference to the CSL share price immediately before the three year anniversary.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
103  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
27 Share based payments (continued)  
(c) Outstanding share based payment equity instruments  
The number and exercise price for each share based payment scheme outstanding is presented as follows. All options and rights are settled  
by physical delivery of shares.  
Vested at  
Opening  
Balance  
Closing  
balance  
Exercise  
Price  
Expiry  
date  
30 June  
2011  
June 2011  
Options  
Granted  
Exercised  
Forfeited  
Lapsed  
(
by grant date)  
2
1
1
1
1
1
1
October 2006  
October 2007  
April 2008  
815,711  
660,140  
3,240  
-
534,707  
11,352  
58,356  
-
-
-
-
-
-
-
-
-
269,652  
595,520  
3,240  
$17.48  
$35.46  
$36.56  
$37.91  
$32.50  
$33.68  
$33.45  
2-Oct-13  
30-Sep-14  
31-Mar-15  
30-Sep-15  
31-Mar-16  
30-Sep-16  
30-Sep-17  
269,652  
-
6,264  
357,272  
-
-
810  
October 2008  
April 2009  
762,840  
13,840  
1,102,880  
-
-
-
78,600  
4,540  
36,560  
-
684,240  
9,300  
171,060  
-
-
-
-
October 2009  
October 2010  
-
-
1,066,320  
216,420  
2,844,692  
-
-
216,420  
216,420  
3
,358,651  
540,971  
189,408  
798,794  
Performance  
Rights  
(
by grant date)  
8 April 2004  
1 June 2004  
9 October 2004  
5 July 2005  
2
60,000  
8,400  
-
60,000  
8,400  
11,400  
45,000  
39,800  
45,000  
8,400  
186,633  
79,101  
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
31-Mar-11  
31-Mar-11  
25-Aug-11  
7-Jun-12  
-
2
-
-
-
2
20,900  
45,000  
106,750  
45,000  
8,400  
-
-
9,500  
-
9,500  
1
-
-
-
7
7
6
2
1
1
1
1
1
1
September 2005  
March 2006  
April 2006  
-
-
-
66,950  
-
7-Jun-12  
66,950  
-
20-Dec-12  
20-Dec-12  
2-Oct-13  
-
-
-
-
-
October 2006  
October 2007  
April 2008  
253,665  
216,285  
1,460  
-
4,080  
11,370  
-
62,952  
125,814  
1,460  
247,840  
3,440  
358,240  
284,420  
1,160,616  
62,952  
-
30-Sep-14  
31-Mar-15  
30-Sep-15  
31-Mar-16  
30-Sep-16  
30-Sep-17  
33,822  
-
876  
October 2008  
April 2009  
273,100  
5,120  
-
-
25,260  
1,680  
13,340  
-
-
-
-
-
-
October 2009  
October 2010  
371,580  
-
-
-
-
284,420  
284,420  
-
1
,415,660  
483,734  
55,730  
174,100  
GESP  
by grant date)  
(
1
1
1
March 2010  
95,517  
-
90,593  
92,645  
183,238  
95,517  
90,593  
-
-
-
-
-
-
-
-
-
-
-
$27.29  
$27.51  
$28.10  
31-Aug-10  
28-Feb-11  
31-Aug-11  
-
-
-
September 2010  
-
-
#
March 2011  
92,645  
92,645  
95,517  
186,110  
Total  
4,869,828  
684,078  
1,210,815  
245,138  
-
4,097,953  
972,894  
#
As noted above, the exercise price at which GESP plan shares are issued is calculated at a 15% discount to the lower of the ASX market price on the first and last  
dates of the contribution period. Accordingly the exercise price and the final number of shares issued is not yet known (and may differ from the assumptions and  
fair values disclosed below). The number of shares which may ultimately be issued based on entitlements granted on 1 March 2011 has been estimated based on  
information available as at 30 June 2011.  
The weighted average share price at the dates of exercise, by equity instrument type, is as follows:  
Options  
Performance Rights  
GESP  
$34.57  
$33.38  
$34.24  
104  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
27 Share based payments (continued)  
(c) Outstanding share based payment equity instruments (continued)  
The number and exercise price for each share based payment scheme outstanding is presented as follows. All options and rights are settled  
by physical delivery of shares.  
Vested at  
Opening  
Balance  
Closing  
balance  
Exercise  
Price  
Expiry  
date  
30 June  
2010  
June 2010  
Options  
Granted  
Exercised  
Forfeited  
Lapsed  
(
by grant date)  
2
1
2
1
1
1
1
1
3 July 2002*  
67,800  
9,240  
-
67,800  
-
-
-
-
-
-
-
-
-
-
-
-
-
$9.32  
$4.06  
23-Jul-09  
1-Jul-10  
-
July 2003  
-
9,240  
-
October 2006  
October 2007  
April 2008  
1,088,880  
688,920  
3,240  
-
252,769  
20,400  
28,395  
-
815,711  
660,140  
3,240  
$17.48  
$35.46  
$36.56  
$37.91  
$32.50  
$33.68  
2-Oct-13  
359,159  
-
385  
30-Sep-14  
31-Mar-15  
30-Sep-15  
31-Mar-16  
30-Sep-16  
164,960  
-
-
-
October 2008  
April 2009  
792,180  
15,380  
-
-
-
-
29,340  
1,540  
2,880  
82,555  
762,840  
13,840  
1,102,880  
3,358,651  
-
-
-
-
-
October 2009  
1,105,760  
1,105,760  
2
,665,640  
330,194  
524,119  
Performance  
Rights  
(
by grant date)  
5 December 2003  
8 April 2004  
1 June 2004  
9 October 2004  
5 July 2005  
1
5,400  
60,000  
8,400  
-
5,400  
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
60,000  
8,400  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
27-Oct-10  
31-Mar-11  
31-Mar-11  
25-Aug-11  
7-Jun-12  
-
60,000  
8,400  
20,900  
45,000  
106,750  
45,000  
8,400  
359,159  
26,970  
-
2
-
-
-
-
2
-
-
2
38,100  
165,000  
244,850  
157,500  
15,900  
363,600  
265,800  
1,460  
-
17,200  
120,000  
138,100  
112,500  
7,500  
100,851  
37,755  
-
-
20,900  
45,000  
106,750  
45,000  
8,400  
1
-
-
7
7
6
2
1
1
1
1
1
September 2005  
March 2006  
April 2006  
-
-
-
7-Jun-12  
-
20-Dec-12  
20-Dec-12  
2-Oct-13  
-
-
October 2006  
October 2007  
April 2008  
-
9,084  
11,760  
-
253,665  
216,285  
1,460  
-
30-Sep-14  
31-Mar-15  
30-Sep-15  
31-Mar-16  
30-Sep-16  
-
October 2008  
April 2009  
286,780  
5,680  
-
-
-
13,680  
560  
273,100  
5,120  
-
-
-
October 2009  
-
372,720  
372,720  
-
1,140  
36,224  
371,580  
1,415,660  
-
1
,618,470  
539,306  
680,579  
GESP  
by grant date)  
(
1
1
1
March 2009  
93,696  
-
92,428  
99,203  
191,631  
93,696  
92,428  
-
-
-
-
-
-
-
-
-
-
-
$27.45  
$28.02  
$27.69  
31-Aug-09  
28-Feb-10  
31-Aug-10  
-
-
-
September 2009  
March 2010  
-
-
99,203  
99,203  
93,696  
186,124  
Total  
4,377,806  
1,670,111  
1,055,624  
118,779  
-
4,873,514  
1,204,698  
*AASB 2 has not been applied to these options as they were issued before 7 November 2002.  
The weighted average share price at the dates of exercise, by equity instrument type, is as follows:  
Options  
Performance Rights  
GESP  
$32.36  
$34.32  
$34.84  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
105  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
27 Share based payments (continued)  
(d)Valuation assumptions and fair values of equity instruments granted  
Expected  
dividend  
yield  
Share  
Price  
Exercise  
Price  
Expected  
Life  
Risk free  
Fair Value1  
volatility  
2
assumption  
interest rate  
Performance Rights  
(
by grant date)  
6 October 2003  
5 December 2003  
8 April 2004  
1 June 2004  
9 October 2004  
5 July 2005  
1
$3.51  
$3.78  
$5.42  
$5.84  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
Nil  
37.0%  
37.0%  
35.0%  
34.0%  
34.0%  
27.0%  
27.0%  
27.0%  
27.0%  
27.0%  
27.0%  
27.0%  
29.0%  
29.0%  
29.0%  
32.0%  
32.0%  
32.0%  
33.0%  
33.0%  
33.0%  
33.0%  
33.0%  
33.0%  
33.0%  
33.0%  
33.0%  
30.0%  
30.0%  
4 years  
4 years  
4 years  
4 years  
4 years  
4 years  
4 years  
4 years  
4 years  
2 years  
3 years  
4 years  
2 years  
3 years  
4 years  
2 years  
3 years  
4 years  
2 years  
3 years  
4 years  
2 years  
3 years  
4 years  
2 years  
3 years  
4 years  
3 years  
4 years  
2.5%  
2.5%  
2.0%  
2.0%  
2.0%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
2.5%  
2.5%  
5.61%  
5.79%  
5.71%  
5.63%  
5.32%  
5.19%  
5.10%  
5.37%  
5.51%  
5.67%  
5.67%  
5.67%  
6.45%  
6.45%  
6.45%  
6.00%  
6.00%  
6.00%  
5.22%  
5.22%  
5.22%  
3.94%  
3.94%  
3.94%  
5.16%  
5.16%  
5.16%  
4.83%  
4.91%  
1
2
$5.05  
$7.64  
2
$4.78  
$7.24  
2
$6.90  
$9.60  
1
$8.17  
$11.63  
$11.58  
$17.75  
$17.80  
$18.01  
$18.01  
$18.01  
$35.93  
$35.93  
$35.93  
$36.56  
$36.56  
$36.56  
$38.75  
$38.75  
$38.75  
$32.10  
$32.10  
$32.10  
$33.44  
$33.44  
$33.44  
$32.94  
$32.94  
7
7
6
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
September 2005  
$8.13  
March 2006  
$14.53  
$14.32  
$14.20  
$13.32  
$12.47  
$28.65  
$26.78  
$25.20  
$30.27  
$29.06  
$27.57  
$33.30  
$31.72  
$30.15  
$27.55  
$26.55  
$25.50  
$28.91  
$27.72  
$26.31  
$26.59  
$26.23  
April 2006  
October 2006 – Tranche 1  
October 2006 – Tranche 2  
October 2006 – Tranche 3  
October 2007 – Tranche 1  
October 2007 – Tranche 2  
October 2007 – Tranche 3  
April 2008 – Tranche 1  
April 2008 – Tranche 2  
April 2008 – Tranche 3  
October 2008 – Tranche 1  
October 2008 – Tranche 2  
October 2008 – Tranche 3  
April 2009 – Tranche 1  
April 2009 – Tranche 2  
April 2009 – Tranche 3  
October 2009 – Tranche 1  
October 2009 – Tranche 2  
October 2009 – Tranche 3  
October 2010 – Tranche 1  
October 2010 – Tranche 2  
1
Options and rights granted are subject to a service condition. Option grants made between 2006 and 2009 are also subject to a non-market vesting condition  
based on earnings per share (EPS). Service conditions and non-market conditions are not taken into account in the determination of fair value at grant date.  
Contrastingly, grants of rights made between 2006 and 2009 are also subject to a market vesting condition based on total shareholder returns (TSR), a condition  
which is taken into account when the fair value of rights is determined. However as a result of the comprehensive review carried out on the PRP, both the  
October 2010 grants of Performance Rights and Options now consist of a market vesting condition TSR hurdle and a non market vesting condition EPS hurdle  
equally applied to each grant.  
2
The expected volatility is based on the historic volatility (calculated based on the remaining life assumption of each equity instrument), adjusted for any expected  
changes to future volatility due to publicly available information.  
106  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
27 Share based payments (continued)  
(d) Valuation assumptions and fair values of equity instruments granted (continued)  
Expected  
dividend  
yield  
Share  
Exercise  
Expected  
Life  
Risk free  
Fair Value1  
Price  
Price  
volatility  
2
assumption  
interest rate  
Options (by grant date)  
1
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
July 2003  
$1.53  
$5.71  
$4.03  
$18.01  
$18.01  
$18.01  
$35.93  
$35.93  
$35.93  
$36.56  
$36.56  
$36.56  
$38.75  
$38.75  
$38.75  
$32.10  
$32.10  
$32.10  
$33.44  
$33.44  
$33.44  
$32.94  
$32.94  
$4.06  
$17.48  
$17.48  
$17.48  
$35.46  
$35.46  
$35.46  
$36.23  
$36.23  
$36.23  
$37.91  
$37.91  
$37.91  
$32.50  
$32.50  
$32.50  
$33.68  
$33.68  
$33.68  
$33.45  
$33.45  
37.0%  
27.0%  
27.0%  
27.0%  
29.0%  
29.0%  
29.0%  
32.0%  
32.0%  
32.0%  
33.0%  
33.0%  
33.0%  
33.0%  
33.0%  
33.0%  
33.0%  
33.0%  
33.0%  
30.0%  
30.0%  
3–5 years  
2 years  
3 years  
4 years  
2 years  
3 years  
4 years  
2 years  
3 years  
4 years  
2 years  
3 years  
4 years  
2 years  
3 years  
4 years  
2 years  
3 years  
4 years  
3 years  
4 years  
2.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
1.5%  
2.5%  
2.5%  
5.60%  
5.67%  
5.67%  
5.67%  
6.45%  
6.45%  
6.45%  
6.00%  
6.00%  
6.00%  
5.22%  
5.22%  
5.22%  
3.94%  
3.94%  
3.94%  
5.16%  
5.16%  
5.16%  
4.83%  
4.91%  
October 2006 – Tranche 1  
October 2006 – Tranche 2  
October 2006 – Tranche 3  
October 2007 – Tranche 1  
October 2007 – Tranche 2  
October 2007 – Tranche 3  
April 2008 – Tranche 1  
April 2008 – Tranche 2  
April 2008 – Tranche 3  
October 2008 – Tranche 1  
October 2008 – Tranche 2  
October 2008 – Tranche 3  
April 2009 – Tranche 1  
April 2009 – Tranche 2  
April 2009 – Tranche 3  
October 2009 – Tranche 1  
October 2009 – Tranche 2  
October 2009 – Tranche 3  
October 2010 – Tranche 1  
October 2010 – Tranche 2  
$5.83  
$5.96  
$12.06  
$12.33  
$12.59  
$12.64  
$12.92  
$13.18  
$13.31  
$13.58  
$13.85  
$9.27  
$9.73  
$10.15  
$10.34  
$10.87  
$11.36  
$8.46  
$8.90  
GESP (by grant date)3  
1
1
1
1
1
1
1
March 2008  
$5.51  
$5.62  
$4.84  
$4.94  
$4.81  
$4.86  
$4.96  
$36.75  
$37.50  
$32.29  
$32.96  
$32.10  
$32.37  
$33.06  
$31.24  
$31.88  
$27.45  
$28.02  
$27.29  
$27.51  
$28.10  
32.0%  
33.0%  
33.0%  
33.0%  
30.0%  
30.0%  
30.0%  
6 months  
6 months  
6 months  
6 months  
6 months  
6 months  
6 months  
1.5%  
1.5%  
1.5%  
1.5%  
2.5%  
2.5%  
2.5%  
6.00%  
5.22%  
3.94%  
5.16%  
4.83%  
4.83%  
4.83%  
September 2008  
March 2009  
September 2009  
March 2010  
September 2010  
March 2011  
1
Options and rights granted are subject to a service condition. Options are also subject to a non-market vesting condition based on earnings per share. Service  
conditions and non-market conditions are not taken into account in the determination of fair value at grant date. Contrastingly, grants of rights are also subject  
to a market vesting condition based on total shareholder returns, a condition which is taken into account when the fair value of rights is determined.  
2
3
The expected volatility is based on the historic volatility (calculated based on the remaining life assumption of each equity instrument), adjusted for any  
expected changes to future volatility due to publicly available information.  
The fair value of GESP equity instruments is estimated based on the assumptions prevailing on the grant date. In accordance with the terms and conditions  
of the GESP plan, shares are issued at the lower of the ASX market price on the first and last dates of the contribution period.  
(e) Cash-settled EDIP  
The fair value of the cash-settled options is measured by reference to the CSL share price at reporting date, adjusted for the dividend yield  
and the number of days left in the vesting period.  
The following table lists the inputs to the models used during the year:  
Consolidated Group  
2
011  
2010  
Dividend yield (%)  
2.5%  
-
-
Fair value of grants at reporting date ($)  
$31.27  
(f) Recognised cash-settled share based payments liability  
The carrying amount of the liability relating to the cash-settled share-based payment at 30 June 2011 is $3,982,898 (2010: $Nil). No cash-  
settled awards vested during the period ended 30 June 2011 (2010: $Nil).  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
107  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
28 Key management personnel disclosures  
The following were key management personnel of the Group at any time during the 2011 and 2010 financial years and unless  
otherwise indicated they were key management personnel (KMP) during the whole of those financial years:  
Non-executive directors  
E A Alexander (Chairman)  
J Akehurst  
Executive directors  
B A McNamee (Chief Executive Officer & Managing Director)  
A M Cipa (Finance Director & KMP until 13 October 2010)  
P Turner (Executive Director & President, CSL Behring)  
Executives  
D W Anstice  
I A Renard  
M A Renshaw  
G Naylor (Chief Financial Officer, KMP since 1 January 2010)  
A Cuthbertson (Chief Scientific Officer)  
E Bailey (Company Secretary)  
J Shine  
D Simpson  
C O’Reilly (appointed 16 Feb 2011)  
G Boss (General Counsel)  
J Lever (Senior VP, Human Capital)  
M Sontrop (Executive VP, Operations CSL Behring, KMP since 1 July 2010 )  
J Davies (Executive VP, CSL Biotherapies)  
P Perreault (Executive VP, Commercial Operations, KMP since 1 July 2010,  
appointed President Designate, CSL Behring on 29 March 2011)  
K Etchberger (Executive VP, Plasma, Supply Chain and IT, KMP since 1 July 2010)  
(a) Total compensation for key management personnel  
Consolidated Group  
2
011  
$
2010  
$
Short term remuneration elements  
Salary and Fees  
10,781,388  
3,896,409  
105,117  
8,835,175  
3,658,903  
84,683  
Short term incentive cash bonus  
Non-monetary benefits  
Total of short term remuneration elements  
14,782,914  
12,578,761  
Post-employment elements  
Pension benefits  
853,925  
-
861,703  
-
Retirement benefits  
Total of post-employment elements  
853,925  
861,703  
Other long term elements  
Long service leave and equivalents  
Deferred cash incentive  
578,447  
679,833  
503,857  
630,000  
Total of other long term elements  
1,258,280  
1,133,857  
Share-based payments  
Equity settled performance rights  
Equity settled options  
2,730,748  
2,703,490  
324,680  
2,081,205  
2,525,615  
-
Cash settled options  
Total of share based payments  
5,758,918  
4,606,820  
Other remuneration elements  
Termination benefits  
500,523  
-
1
Total of all remuneration elements  
23,154,560  
19,181,141  
The basis upon which remuneration amounts have been determined is further described in the remuneration report included in  
section 18 of the Directors’ Report.  
1
This note discloses remuneration of individuals defined as KMP for the relevant period.  
108  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
28 Key management personnel disclosures (continued)  
(
b) Loans to key management personnel and their related parties (Group)  
Details regarding the aggregate of loans made, guaranteed or secured by any entity in the Group to key management  
personnel and their related parties, and the number of individuals in each group, are as follows:  
Opening  
balance  
Interest  
charged  
Closing  
balance  
Number in  
group  
$
$
$
$
2011  
2010  
2011  
2010  
2011  
2010  
978,950  
1,598,710  
-
-
-
-
3
-
Total for key management personnel  
Total for other related parties  
51,393  
978,950  
-
-
-
-
-
-
-
-
978,950  
1,598,710  
-
Total for key management personnel  
and their related parties  
51,393  
978,950  
3
Details regarding loans outstanding at the reporting date to key management personnel and their related parties at any time during the  
reporting period, are as follows:  
Highest  
Balance at  
Balance at  
owing in  
period  
Interest  
charged  
Interest not  
charged  
1
July 2010  
$
30 June 2011  
$
$
$
$
Key management Personnel  
G Naylor  
978,950  
-
978,950  
-
11,956  
Total  
978,950  
-
978,950  
-
11,956  
All of the loans relate to SESOP and SESOP II under which key management personnel were provided with loans to fund the exercise of  
options. SESOP was terminated by the Company and there are no longer any outstanding options under this plan. No grants of options  
have been made under SESOP II since July 2003.  
Loans to key management personnel relating to SESOP are interest free. Loans relating to SESOP II are charged interest at a concessional  
average rate of 2.5%. This is based on interest being charged equivalent to the after-tax cash amount of dividends on the underlying shares  
(excluding the impact of imputation and assuming a marginal income tax rate of 46.5%). The average commercial rate of interest during  
the year was 7.19% (2010: 6.89%).  
(c) Other key management personnel transactions with the company or its controlled entities  
The key management personnel and their related entities have the following transactions with entities within the Group that occur within  
a normal employee, customer or supplier relationship on terms and conditions no more favourable than those which it is reasonable to  
expect the entity would have adopted if dealing at arm’s length in similar circumstances:  
•ꢀ ꢀT heꢀGroupꢀhasꢀaꢀnumberꢀofꢀcontractualꢀrelationships,ꢀincludingꢀpropertyꢀleasesꢀandꢀcollaborativeꢀresearchꢀarrangements,ꢀwithꢀtheꢀ  
University of Melbourne of which Ms Elizabeth Alexander is the Chancellor and Dr Virginia Mansour (whose husband is Dr Brian  
McNamee) is a member of the Council.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
109  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
28 Key management personnel disclosures (continued)  
(d) Options over equity instruments granted as compensation  
The movement during the reporting period in the number of options over ordinary shares in the Company held directly,  
indirectly or beneficially, by each key management person, including their related parties, is as follows:  
Number  
Number  
Lapsed /  
Forfeited  
Balance at  
30 June  
2011  
Vested  
Vested and  
Unvested  
Key management  
person  
Balance at  
1 July 2010  
Number  
Granted  
Number  
during the exercisable at at 30 June  
Exercised  
year  
30 June 2011  
2011  
Executive Directors  
B A McNamee  
P Turner  
411,740  
131,216  
121,560  
46,420  
20,740  
-
158,760  
23,256  
58,140  
-
-
299,400  
128,700  
-
109,398  
42,081  
42,081  
65,304  
26,250  
-
234,096  
102,450  
-
A M Cipa  
63,420  
Other executives  
P Perreault  
G Naylor  
87,400  
75,160  
81,230  
74,620  
54,744  
62,296  
41,012  
19,420  
13,660  
1,174,058  
9,360  
14,720  
12,140  
8,300  
19,620  
-
77,140  
75,660  
68,980  
82,920  
56,520  
70,996  
47,872  
20,500  
18,740  
947,428  
22,400  
17,126  
23,434  
16,902  
14,809  
17,049  
12,033  
3,060  
17,051  
12,947  
14,866  
32,361  
9,700  
60,089  
62,713  
54,114  
50,559  
46,820  
51,127  
33,499  
18,613  
18,740  
732,820  
14,220  
-
A Cuthbertson  
J Davies  
24,390  
-
-
-
G Boss  
9,360  
7,584  
-
M Sontrop  
K Etchberger  
E Bailey  
8,700  
-
-
19,869  
14,373  
1,887  
6,860  
-
4,320  
-
-
5,400  
-
-
J Lever  
5,080  
-
-
Total  
147,080  
310,290  
63,420  
320,373  
214,608  
The assumptions inherent in the valuation of options granted to key management personnel, amongst others, during the financial year  
and the fair value of each option granted are set out in Note 27(d).  
No options have been granted since the end of the financial year. The options have been provided at no cost to the recipients.  
For further details, including the key terms and conditions, grant and exercise dates for options granted to executives, refer to note 27.  
110  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
28 Key management personnel disclosures (continued)  
(e) Performance rights over equity instruments granted as compensation  
The movement during the reporting period in the number of performance rights over ordinary shares in the Company held directly,  
indirectly or beneficially, by each key management person, including their related parties, is as follows:  
Number  
Balance  
at 1 July  
2010  
Number  
Lapsed /  
Forfeited  
Balance at  
30 June  
2011  
Vested  
Vested and  
Unvested  
Key management  
person  
Number  
Granted  
Number  
during the exercisable at at 30 June  
Exercised  
year  
30 June 2011  
2011  
Executive Directors  
B A McNamee  
P Turner  
119,240  
35,289  
61,020  
27,260  
-
61,356  
10,077  
-
-
118,904  
52,472  
-
27,189  
10,077  
10,077  
-
-
-
118,904  
52,472  
-
A M Cipa  
186,060  
172,668  
13,392  
Other executives  
P Perreault  
G Naylor  
20,846  
18,362  
23,480  
31,710  
14,767  
16,830  
10,972  
6,740  
12,300  
19,340  
15,960  
10,900  
12,300  
11,440  
9,000  
5,322  
3,702  
10,512  
-
-
27,824  
34,000  
28,928  
42,610  
23,764  
24,532  
17,092  
13,840  
10,300  
394,266  
5,322  
3,702  
5,772  
3,696  
3,303  
3,738  
2,880  
1,125  
-
-
27,824  
34,000  
28,928  
23,944  
23,764  
24,532  
17,092  
11,308  
10,300  
373,068  
-
-
A Cuthbertson  
J Davies  
-
-
-
18,666  
G Boss  
3,303  
3,738  
2,880  
-
-
-
M Sontrop  
K Etchberger  
E Bailey  
-
-
-
-
2,532  
-
7,100  
-
-
J Lever  
3,620  
6,680  
-
Total  
487,916  
193,300  
273,558  
13,392  
76,881  
21,198  
The assumptions inherent in the valuation of performance rights granted to key management personnel, amongst others, during the  
financial year and the fair value of each option granted are set out in Note 27(d).  
No performance rights have been granted since the end of the financial year. The performance rights have been provided at no cost to  
the recipients.  
Modification of terms of equity-settled share-based payment transactions  
During the reporting period there have been no changes to the terms pertaining to issues of options, performance options and  
performance rights which have been granted as compensation to a key management person in the prior periods and in the current period.  
(
f) Exercise of equity instruments granted as compensation  
During the reporting period, the following shares were issued on the exercise of options granted as compensation:  
3
0 June 2011  
30 June 2010  
Date Option  
Number of  
Paid per  
share  
Date Option  
Number of  
shares  
Paid per  
share  
Granted  
shares  
Granted  
$
$
B McNamee  
A M Cipa  
A Cuthbertson  
G Naylor  
2 October 2006  
2 October 2006  
2 October 2006  
2 October 2006  
2 October 2006  
2 October 2006  
2 October 2006  
2 October 2006  
158,760  
58,140  
24,390  
14,220  
4,320  
17.48  
17.48  
17.48  
17.48  
17.48  
17.48  
17.48  
17.48  
E Bailey  
Paul Perreault  
P Turner  
19,620  
23,256  
7,584  
2 October 2006  
2 October 2006  
2 October 2006  
20,349  
11,376  
12,744  
44,469  
17.48  
17.48  
17.48  
G Boss  
M Sontrop  
Total  
310,290  
There are no amounts unpaid on the shares issued as a result of the exercise of options.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
111  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
28 Key management personnel disclosures (continued)  
(f) Exercise of equity instruments granted as compensation (continued)  
During the reporting period, persons who were key management personnel were issued the following shares on the exercise of  
performance rights granted as compensation:  
3
0 June 2011  
30 June 2010  
Date Option  
Granted  
Number of  
shares  
Date Option  
Number of  
shares  
Granted  
A M Cipa  
31 March 2004  
60,000  
45,000  
45,000  
17,160  
5,508  
7,200  
3,312  
3,096  
2,226  
1,872  
1,008  
2,232  
1,470  
46,920  
14,436  
2,232  
1,071  
2,520  
1,218  
6,864  
3,213  
7
June 2005  
2
0 December 2005  
2
1
October 2006  
October 2007  
A Cuthbertson  
P Perreault  
K Etchberger  
G Naylor  
2 October 2006  
October 2007  
2 October 2006  
October 2007  
2 October 2006  
October 2007  
2 October 2006  
October 2007  
2 October 2006  
October 2007  
2 October 2006  
October 2007  
2 October 2006  
October 2007  
2 October 2006  
October 2007  
1
1
1
2 October 2006  
1 October 2007  
7 June 2005  
1,953  
1,050  
120,000  
112,500  
1,953  
765  
1
B McNamee  
G Boss  
1
20 December 2005  
2 October 2006  
1 October 2007  
2 October 2006  
1 October 2007  
2 October 2006  
1 October 2007  
25 August 2004  
1
M Sontrop  
P Turner  
2,205  
870  
1
6,006  
2,295  
4,200  
2,700  
256,497  
1
E Bailey  
7
June 2005  
Total  
273,558  
No amount is payable on the exercise of performance rights.  
112  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
2
8 Key management personnel disclosures (continued)  
(g) Key management personnel shareholdings  
Movements in the respective shareholdings of key management personnel during the year ended 30 June 2011 are set out below.  
Shares acquired  
on exercise of  
Shares acquired  
on exercise  
of options  
Balance at  
1 July 2010  
performance  
(Shares sold)/  
Purchased  
Balance at  
Movements in shares  
rights during year  
during year  
30 June 2011  
Non-Executive Directors  
E A Alexander  
J Akehurst  
28,911  
29,512  
6,346  
17,572  
6,777  
3,499  
2,959  
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1,548  
530  
659  
528  
526  
526  
526  
61  
30,459  
30,042  
7,005  
18,100  
7,303  
4,025  
3,485  
61  
D W Anstice  
I A Renard  
M A Renshaw  
J Shine  
D J Simpson  
C O’Reilly  
Executive Directors  
B A McNamee  
P Turner  
835,669  
160,569  
25,777  
61,356  
10,077  
158,760  
23,256  
58,140  
(220,116)  
(33,333)  
835,669  
160,569  
-
A M Cipa  
Executives  
P Perreault  
G Naylor  
172,668  
(256,585)  
1,910  
188,159  
54,553  
735  
5,322  
3,702  
10,512  
-
19,620  
(24,781)  
(104,782)  
(26,280)  
-
2,071  
101,299  
63,175  
735  
14,220  
A Cuthbertson  
J Davies  
24,390  
-
G Boss  
358  
3,303  
3,738  
2,880  
-
7,584  
(10,681)  
(3,548)  
-
564  
M Sontrop  
K Etchberger  
E Bailey  
22,674  
6,990  
2,222  
-
-
22,864  
9,870  
2,441  
-
-
4,320  
-
(4,101)  
-
J Lever  
-
Total  
1,395,192  
273,558  
310,290  
(679,303)  
1,299,737  
There have been no movements in shareholdings of key management personnel between 30 June 2011 and the date of this report.  
(
h) Cash Settled Options granted as compensation to Key management personnel  
During the year 41,800 phantom shares were granted to KMPs under the Executive Deferred Incentive Plan. This was done primarily  
to reduce the risk of loss of executives in roles that are: key to the delivery of operating or strategic objectives; manage critical  
activities; or undertake functions requiring skills that are in short supply and are actively sought in the market.  
For further details, including key terms and conditions, grant date and exercise dates regarding the EDIP, refer to Note 27 (b) and (e).  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
113  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
29 ꢀon key management personnel related party disclosure  
Ultimate Controlling Entity  
The ultimate controlling entity is CSL Limited.  
Identity of related parties  
The parent company has a related party relationship with its subsidiaries (see note 32) and with its key management personnel (see  
note 28).  
Other related party transactions  
The Parent Company entered into the following transactions during the year with related parties in the Group:  
Wholly owned subsidiaries  
ꢀLoansꢀwereꢀadvancedꢀandꢀrepaymentsꢀreceivedꢀonꢀtheꢀlongꢀtermꢀintercompanyꢀaccounts;  
ꢀInterestꢀwasꢀchargedꢀonꢀoutstandingꢀintercompanyꢀloanꢀaccountꢀbalances;  
ꢀSalesꢀandꢀpurchasesꢀofꢀproducts;  
ꢀLicensingꢀofꢀintellectualꢀproperty;  
ꢀProvisionꢀofꢀmarketingꢀservicesꢀbyꢀcontrolledꢀentities;ꢀ  
ꢀManagementꢀfeesꢀwereꢀreceivedꢀfromꢀaꢀcontrolledꢀentity;ꢀand  
ꢀManagementꢀfeesꢀwereꢀpaidꢀtoꢀaꢀcontrolledꢀentity.  
The sales, purchases and other services were undertaken on commercial terms and conditions.  
Payment for intercompany transactions is through intercompany loan accounts and may be subject to extended payment terms.  
Partly owned subsidiaries  
•ꢀNoꢀtransactionsꢀoccurredꢀduringꢀtheꢀyear.  
Amounts receivable from partly owned subsidiaries are set out in the note 7.  
Transactions with key management personnel and their related parties  
Disclosures relating to key management personnel are disclosed in note 28.  
Transactions with other related parties  
During the year, the parent and subsidiaries made contributions to defined benefit and contribution pension plans as disclosed in  
note 26.  
Ownership interests in related parties  
The ownership interests in related parties in the Group are disclosed in note 32. All transactions with subsidiaries have been eliminated  
on consolidation.  
Consolidated Group  
2
011  
$
2010  
$
30 Remuneration of Auditors  
During the year the following fees were paid or were payable for services provided by the  
auditor of the parent entity and its related practices:  
(a) Audit services  
Ernst & Young  
802,000  
2,137,336  
2,939,336  
770,800  
2,437,888  
3,208,688  
Ernst & Young related practices  
Total remuneration for audit services  
(
b) Other services  
Ernst & Young  
-
compliance and other services  
Ernst & Young related practices  
compliance and other services  
16,500  
209,421  
-
104,196  
120,696  
101,566  
310,987  
Total remuneration for non audit services  
Total remuneration for all services rendered  
3,060,032  
3,519,675  
114  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
$
011  
000  
2010  
$000  
31 Commitments and contingencies  
(a) Operating leases  
Commitments for minimum lease payments in relation to non cancellable operating leases  
are payable as follows:  
Not later than one year  
31,725  
91,385  
36,455  
105,343  
171,442  
313,240  
Later than one year but not later than five years  
Later than five years  
163,577  
286,687  
Operating leases entered into relate predominantly to leased land and rental properties. The leases have varying terms and renewal  
rights. Rental payments under the leases are predominantly fixed, but generally contain inflation escalation clauses. No operating lease  
contains restrictions on financing or other leasing activities.  
(
b) Finance leases  
Commitments in relation to finance leases are payable as follows:  
Not later than one year  
4,333  
13,925  
26,092  
44,350  
(14,352)  
29,998  
4,875  
16,921  
30,403  
52,199  
(17,005)  
35,194  
Later than one year but not later than five years  
Later than five years  
Total minimum lease payments  
Future finance charges  
Finance lease liability  
The present value of finance lease liabilities is as follows:  
Not later than one year  
2,894  
8,866  
3,118  
11,130  
20,946  
35,194  
Later than one year but not later than five years  
Later than five years  
18,238  
29,998  
Finance lease – current liability (refer note 15)  
2,894  
3,118  
32,076  
35,194  
Finance lease – non-current liability (refer note 15)  
27,104  
9,998  
2
Finance leases entered into relate predominantly to leased plant and equipment. The leases have varying terms but lease payments are  
generally fixed for the life of the agreement. In some instances, at the end of the lease term the Group has the option to purchase the  
equipment. No finance leases contain restrictions on financing or other leasing activities.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
115  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
$
011  
000  
2010  
$000  
31 Commitments and contingencies (continued)  
(c) Total lease liability  
Current  
Finance leases (refer note 15)  
2,894  
3,118  
Non-current  
Finance leases (refer note 15)  
27,104  
32,076  
35,194  
29,998  
(d) Capital commitments  
Capital expenditure contracted for at balance date but not provided for in the financial  
statements, payable:  
Not later than one year  
63,571  
14,044  
-
61,226  
23  
Later than one year but not later than five years  
Later than five years  
-
77,615  
61,249  
(e) Contingent assets and liabilities  
Guarantees  
The Group provides certain financial guarantees in the ordinary course of business. No liability has been recognised in relation to  
these guarantees as the fair value of the guarantees is immaterial.  
Service agreements  
The maximum contingent liability for benefits under service agreements, in the event of an involuntary redundancy, is between 3 to  
12 months. Agreements are held with key management personnel who take part in the management of Group entities. The  
maximum liability that could arise, for which no provisions are included in the financial statements is as follows:  
Service agreements  
8,324  
11,609  
Litigation  
The Group is involved in litigation in the U.S. claiming that the Group and a competitor, along with an industry trade association,  
conspired to restrict output and fix and raise prices of certain plasma-derived therapies in the U.S. The lawsuits, filed by  
representative plaintiffs, seek status to proceed as class actions on behalf of “all others similarly situated”. The Group believes  
the litigation is unsupported by fact and without merit and will robustly defend the claims.  
The Group is involved in other litigation in the ordinary course of business.  
The directors believe that future payment of a material amount in respect of litigation is remote. An estimate of the financial effect  
of this litigation cannot be calculated as it is not practicable at this stage. The Group has disclaimed liability for, and is vigorously  
defending, all current material claims and actions that have been made.  
116  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
32 Controlled Entities  
The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the  
accounting policy described in Note 1.  
Country of incorporation  
Percentage Owned  
2
011  
%
2010  
%
Company:  
CSL Limited  
Australia  
Subsidiaries of CSL Limited:  
CSL Employee Share Trust  
CSL Biotherapies Pty Ltd  
Cervax Pty Ltd  
Australia  
Australia  
Australia  
New Zealand  
Sweden  
Australia  
Australia  
Australia  
Australia  
Australia  
Denmark  
Switzerland  
Switzerland  
Germany  
England  
England  
USA  
100  
100  
74  
100  
100  
74  
CSL Biotherapies (NZ) Limited  
Iscotec AB  
100  
100  
100  
100  
100  
100  
100  
100  
100  
-
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
-
(a)  
(a)  
Zenyth Therapeutics Pty Ltd  
Zenyth Operations Pty Ltd  
Amrad Pty Ltd  
CSL International Pty Ltd  
CSL Finance Pty Ltd  
CSL Behring ApS  
(a)  
(a)  
(c)  
(a)  
(a)  
(a)  
CSL Behring AG  
CSL Behring (Switzerland) AG  
ZLB GmbH  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
100  
CSL UK Holdings Limited  
ZLB Bioplasma UK Limited  
CSLB Holdings Inc  
CSL Biotherapies Inc  
ZLB Bioplasma (Hong Kong) Limited  
CSL Behring LLC  
USA  
Hong Kong  
USA  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)  
(a)(b)  
(b)  
(a)  
(a)  
CSL Plasma Inc  
USA  
CSL Behring Canada Inc.  
Canada  
Brazil  
CSL Behring Brazil Comercio de Produtos Farmaceuticals Ltda  
CSL Behring KK  
Japan  
CSL Behring S.A. de C.V.  
CSL Behring S.A.  
Mexico  
France  
CSL Biotherapies GmbH  
Germany  
CSL Behring Foundation for Research and Advancement of Patient Health  
CSL Behring Verwaltungs GmbH  
USA  
Germany  
Germany  
Germany  
Germany  
Austria  
CSL Behring Beteiligungs GmbH & Co KG  
CSL Plasma GmbH  
CSL Behring GmbH  
CSL Behring GmbH  
CSL Behring S.A.  
Spain  
CSL Behring A.B.  
Sweden  
CSL Behring S.p.A.  
Italy  
CSL Behring N.V.  
Belgium  
CSL Behring B.V  
Netherlands  
Portugal  
Greece  
CSL Behring Lda  
CSL Behring MEPE  
CSL Biotherapies Asia Pacific Limited  
CSL (Shanghai) Biotherapies Consulting Ltd  
CSL Behring S.A.  
Hong Kong  
China  
Argentina  
Panama  
CSL Behring Panama S.A.  
CSL Behring s.r.o.  
Czech Republic  
England  
-
CSL Behring Holdings Ltd.  
CSL Behring UK Ltd.  
100  
100  
England  
(
a) Audited by affiliates of the Company auditors.  
b) CSL Behring Panama S.A. and CSL Behring s.r.o. were incorporated during the year.  
c) CSL Behring (Switzerland) AG was dissolved during the year  
(
(
CSL Limited  
Annual Report 2010-2011  
Financial Report  
117  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
33 Deed of Cross Guarantee  
On 22 October 2009, a deed of cross guarantee was executed between CSL Limited and some of its wholly owned entities, namely CSL  
International Pty Ltd, CSL Finance Pty Ltd, CSL Biotherapies Pty Ltd and Zenyth Therapeutics Pty Ltd. Under this deed, each company  
guarantees the debts of the others. By entering into the deed, these specific wholly owned entities have been relieved from the requirement  
to prepare a financial report and directors’ report under Class Order 98/1418 (as amended) issued by the Australian Securities and Investments  
Commission.  
The entities that are parties to the deed represent a ‘Closed Group’ for the purposes of the Class Order, and as there are no other parties  
to the Deed of Cross Guarantee that are controlled by CSL Limited they also represent the ‘Extended Closed Group’. In respect to the  
Closed Group comprising the aforementioned entities, set out below is a consolidated income statement and a summary of movements in  
consolidated retained profits for the year ended 30 June 2011 and a consolidated balance sheet as at that date.  
Income Statement  
Consolidated Group  
2
$
011  
000  
2010  
$000  
Continuing operations  
Sales revenue  
584,361  
(337,764)  
246,597  
110,141  
756,109  
25,252  
773,158  
(346,456)  
426,702  
125,681  
639,114  
38,436  
Cost of sales  
Gross profit  
Sundry revenues  
Dividend income  
Interest income  
Research and development expenses  
Selling and marketing expenses  
General and administration expenses  
Finance costs  
(153,238)  
(56,502)  
(74,467)  
(7,662)  
(198,168)  
(91,458)  
(73,557)  
(10,050)  
856,700  
(37,819)  
818,881  
Profit before income tax expense  
Income tax (expense) / benefit  
Profit for the year  
846,230  
(15,397)  
830,833  
118  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
2
011  
2010  
$000  
$000  
33 Deed of Cross Guarantee (continued)  
Balance sheet  
CURRENT ASSETS  
Cash and cash equivalent  
Trade and other receivables  
Inventories  
193,644  
96,392  
730,389  
81,757  
175,535  
465,571  
147,895  
960,041  
Total Current Assets  
NON-CURRENT ASSETS  
Trade and other receivables  
Other financial assets  
Property, plant and equipment  
Deferred tax assets  
9,356  
1,817,232  
454,132  
12,768  
11,791  
1,808,445  
421,155  
29,173  
Intangible assets  
24,140  
33,317  
Retirement benefit assets  
Total Non-Current assets  
TOTAL ASSETS  
2,588  
1,147  
2,320,216  
2,785,787  
2,305,028  
3,265,069  
CURRENT LIABILITIES  
Trade and other payables  
Interest-bearing liabilities and borrowings  
Current tax liabilities  
Provisions  
123,145  
11,336  
5,534  
112,178  
11,305  
4,558  
38,902  
995  
40,003  
995  
Deferred government grants  
Total Current Liabilities  
NON-CURRENT LIABILITIES  
Trade and other payables  
Interest-bearing liabilities and borrowings  
Deferred tax liabilities  
Provisions  
179,912  
169,039  
1,147  
117,065  
-
21  
144,314  
13,881  
7,694  
7,373  
Deferred government grants  
Total Non-Current Liabilities  
TOTAL LIABILITIES  
NET ASSETS  
18,910  
144,816  
324,728  
2,461,059  
10,605  
176,194  
345,233  
2,919,836  
EQUITY  
Contributed equity  
253,896  
116,316  
1,139,228  
84,134  
Reserves  
Retained earnings  
2,090,847  
2,461,059  
1,696,474  
2,919,836  
TOTAL EQUITY  
Summary of movements in consolidated retained earnings of the Closed Group  
Retained earnings at beginning of the financial year  
Net profit  
1,696,474  
830,833  
(578)  
1,306,523  
818,881  
547  
Actuarial gain / (loss) on defined benefit plans, net of tax  
Dividends provided for or paid  
(435,882)  
2,090,847  
(429,477)  
1,696,474  
Retained earnings at the end of the financial year  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
119  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
34 Financial Risk Management Objectives and Policies  
The Group’s principal financial instruments comprise receivables, payables, bank loans and overdrafts, unsecured notes, lease liabilities,  
available for sale assets and derivative instruments.  
The Group’s activities expose it to a variety of financial risks: market risk (including currency and interest rate risk), credit risk and liquidity risk.  
The Group’s policy is to use derivative financial instruments, such as foreign exchange contracts and interest rate swaps, to manage specifically  
identified risks as approved by the board of directors. The objective of the policy is to support the delivery of the Group’s financial targets  
whilst protecting future financial security. The accounting policy applied by the Group in respect to derivative financial instruments is outlined  
in note 1(v). Derivatives are exclusively used for hedging purposes, i.e. not as trading or other speculative instruments. The Group uses different  
methods to measure different types of risk to which it is exposed. These methods include sensitivity analysis in the case of interest rate and  
foreign exchange risks.  
Market Risk  
1. Foreign exchange risk  
The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures. Foreign exchange risk  
arises from future commercial transactions and recognised assets and liabilities denominated in a currency other than the entity’s functional  
currency and net investments in foreign operations. The Group’s Treasury risk management policy is to hedge contractual commitments  
denominated in a foreign currency.  
The Group enters into forward exchange contracts to buy and sell specified amounts of foreign currencies in the future at predetermined  
exchange rates. The objective is to match the contracts with committed future cash flows from sales and purchases in foreign currencies  
to protect the Group against exchange rate movements. Contracts to buy and sell foreign currencies are entered into from time to time to  
offset purchase and sale obligations in order to maintain a desired hedge position.  
The table below summarises by currency the Australian dollar value of forward exchange agreements at balance date. Foreign currency  
amounts are translated at rates prevailing at reporting date. Entities in the group enter into forward contracts to hedge foreign currency  
receivables from other entities within the Group. These receivables are eliminated on consolidation, however, the hedges are in place to  
protect the entities from movements in exchange rates that would give rise to a profit or loss impact.  
Average Eꢂchange Rate  
2011  
Buy  
2010  
Buy  
Sell  
Sell  
2011  
2010  
$000  
$000  
$000  
$000  
US Dollar  
months or less  
3
1.0737  
0.8928  
4.4104  
0.7472  
0.6673  
196.43  
86.38  
0.8510  
0.9220  
3.3478  
0.6901  
0.5655  
200.20  
75.47  
6.6258  
5.1957  
10.9505  
1.5412  
-
6,676  
(142,139)  
(31,322)  
(7,664)  
(321,081)  
(15,722)  
(2,622)  
(24,017)  
(12,694)  
(9,808)  
(46,502)  
(2,492)  
(310)  
23,064  
(148,046)  
(31,847)  
(10,962)  
(299,279)  
(23,334)  
(1,866)  
(23,911)  
(14,325)  
(8,108)  
(51,242)  
(649)  
Swiss Francs  
months or less  
3
310,898  
265,149  
Argentina Peso  
months or less  
3
-
-
Euro  
3
months or less  
337,735  
304,297  
Pounds Sterling  
3
months or less  
830  
2,811  
Hungarian Florint  
3
months or less  
-
-
Japanese Yen  
3
months or less  
445  
2,830  
Swedish Kroner  
3
months or less  
6.7818  
5.5239  
12.6347  
1.6855  
1.2924  
8.2828  
0.8860  
-
-
Danish Kroner  
3
months or less  
-
1,103  
Mexican Peso  
3
months or less  
3,360  
3,833  
Brazilian Real  
3
months or less  
-
-
-
-
New Zealand Dollar  
3
months or less  
-
-
-
Hong Kong Dollar  
3
months or less  
-
(809)  
-
Australian Dollar  
3
months or less  
0.7930  
18,930  
(61,692)  
26,742  
(16,260)  
678,874  
(678,874)  
629,829  
(629,829)  
120  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
34 Financial Risk Management Objectives and Policies (continued)  
The Group reduces its foreign exchange risk on net investments in foreign operations, by denominating external borrowings in currencies  
that match the currencies of its foreign investments.  
Included in Interest Bearing Liabilities (refer note 15) as at 30 June 2011, are Unsecured Notes amounting to US$105.4m (2010:  
US$58.8m) and EUR 58.3m (2010: EUR 60.7m) that are designated as a hedge of the Group’s investment in CSLB Holdings Inc and  
CSL Behring GmbH. A net foreign exchange gain of $18.6m (2010: gain of $23.2m) was recognised in equity on translation of these  
borrowings to Australian Dollars.  
There was no ineffectiveness recognised on this hedging during the year.  
2. Interest rate risk  
The Group is exposed to interest rate risk through primary financial assets and liabilities. In accordance with the Group entities  
approved risk management policies, derivative financial instruments such as interest rate swaps are used to hedge interest rate risk  
exposures. As at 30 June 2011, no derivative financial instruments hedging interest rate risk were outstanding (2010: Nil).  
The following tables summarise interest rate risk for financial assets and financial liabilities, the effective interest rates as at balance  
date and the periods in which they reprice.  
Fiꢂed interest rate maturing in  
Over  
1 year to  
5 years  
Non-  
interest  
bearing  
Average  
interest  
Rate  
Floating  
rate (a)  
1 year  
or less  
Over  
5 years  
Total  
$’000  
Consolidated Group –  
June 2011  
$’000  
$’000  
$’000  
$’000  
$’000  
%
Financial Assets  
Cash and cash equivalents  
Trade and other receivables  
Other financial assets  
479,403  
-
-
-
-
-
-
-
-
-
-
-
-
-
813,195  
20,273  
479,403  
813,195  
20,273  
2.5%  
-
-
-
-
479,403  
833,468  
1,312,871  
Financial Liabilities  
Trade and other payables  
Bank loans – unsecured  
Bank overdraft – unsecured  
Senior unsecured notes  
Lease liabilities  
-
-
-
-
497,489  
497,489  
209,039  
584  
-
0.6%  
2.5%  
5.3%  
5.7%  
-
209,039  
-
-
-
-
-
-
584  
-
-
-
-
-
13,697  
2,894  
-
162,926  
8,866  
-
-
18,238  
-
-
-
176,623  
29,998  
5,054  
Other financial liabilities  
5,054  
502,543  
2
09,623  
16,591  
171,792  
18,238  
918,787  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
121  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
34 Financial Risk Management Objectives and Policies (continued)  
Fiꢂed interest rate maturing in  
Over  
Non-  
interest  
bearing  
Average  
interest  
Rate  
Floating  
rate (a)  
1 year  
or less  
1 year to  
5 years  
Over  
5 years  
Total  
$’000  
Consolidated Group –  
June 2010  
$’000  
$’000  
$’000  
$’000  
$’000  
%
Financial Assets  
Cash and cash equivalents  
Trade and other receivables  
Other financial assets  
1,001,059  
-
-
-
-
-
-
-
-
-
-
-
-
-
890,572  
5,068  
1,001,059  
890,572  
5,068  
4.1%  
-
-
-
-
1,001,059  
895,640  
1,896,699  
Financial Liabilities  
Trade and other payables  
Bank loans – unsecured  
Bank overdraft – unsecured  
Senior unsecured notes  
Lease liabilities  
-
-
-
-
485,403  
485,403  
196,984  
6,554  
-
0.9%  
3.8%  
5.3%  
5.5%  
-
196,984  
-
-
-
-
-
-
6,554  
-
-
-
-
-
16,312  
3,118  
-
207,159  
11,130  
-
-
20,946  
-
-
-
223,471  
35,194  
1,991  
Other financial liabilities  
1,991  
487,394  
2
03,538  
19,430  
218,289  
20,946  
949,597  
(a) Floating interest rates represent the most recently determined rate applicable to the instrument at balance sheet date. All floating rate  
financial assets and liabilities mature within one year.  
Sensitivity analysis  
In managing interest rate and currency risks the Group aims to reduce the impact of short-term fluctuations on the Group’s earnings.  
However, over the longer-term, permanent changes in foreign exchange and interest rates would give rise to a Group statement of  
comprehensive income impact.  
At 30 June 2011 it is estimated that a general movement of one percentage point in the interest rates applicable to investments of cash  
and cash equivalents would have changed the Group’s profit after tax by approximately $3.3m. This calculation is based on applying a 1%  
movement to the total of the Group’s cash and cash equivalents at year end. All other financial asset amounts are subject to fixed rate and  
therefore not subject to interest rate movements in the ordinary course.  
At 30 June 2011 it is estimated that a general movement of one percentage point in the interest rates applicable to floating rate unsecured  
bank loans would have changed the Group’s profit after tax by approximately $1.5m. This calculation is based on applying a 1% movement to  
the total of the Group’s unsecured bank loans at year end. All other interest bearing debt amounts are subject to fixed rate and therefore not  
subject to interest rate movements in the ordinary course.  
It is estimated that a general movement of one percentage point in the value of the Australian Dollar against other currencies would change  
the Group’s profit after tax by approximately $10.3m for the year ended 30 June 2011 comprising $3.1m, $5.6m and $1.6m against the  
Euro, Swiss Franc and US Dollar respectively. This calculation is based on changing the actual exchange rate of Australian Dollars to all other  
currencies during the year by 1% and applying these adjusted rates to the translation of the foreign currency denominated financial statements  
of various Group entities.  
These sensitivity estimates may not apply in future years due to changes in the mix of profits derived in different currencies and in the Group’s  
net debt levels.  
Credit Risk  
Credit risk represents the extent of credit related losses that the Group may be subject to on amounts to be exchanged under financial  
instruments contracts or the amount receivable from trade and other debtors. Management has established policies to monitor and limit the  
exposure to credit risk on an on-going basis.  
Transactions involving derivative financial instruments are with counterparties with whom the Group has a signed netting agreement as well  
as sound credit ratings. Given their high credit ratings, management does not expect any counterparty to fail to meet its obligations. The  
Group’s policy is to only invest its cash and cash equivalent financial assets with financial institutions having a credit rating of at least ‘A’ or  
better, as assessed by independent rating agencies.  
The Group minimises the credit risks associated with trade and other debtors by undertaking transactions with a large number of customers in  
various countries.  
The maximum exposure to credit risk at balance date is the carrying amount, net of any provision for impairment, of each financial asset in the  
balance sheet.  
122  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
34 Financial Risk Management Objectives and Policies (continued)  
The credit quality of financial assets that are neither past due, nor impaired is as follows:  
Financial  
Buying  
Groups  
Institutions  
Governments  
$’000  
Hospitals  
$’000  
Other  
$’000  
Total  
$’000  
For the year ended  
0 June 2011  
3
$’000  
$’000  
Cash and cash equivalents  
Trade and other receivables  
Other financial assets  
479,403  
869  
-
121,483  
15,248  
-
229,915  
-
-
256,239  
-
-
204,689  
-
479,403  
813,195  
20,273  
5,025  
485,297  
136,731  
229,915  
256,239  
204,689  
1,312,871  
For the year ended  
3
0 June 2010  
Cash and cash equivalents  
Trade and other receivables  
Other financial assets  
1,001,059  
2,771  
-
-
-
328,467  
-
-
1,001,059  
890,572  
5,068  
52,652  
-
301,892  
-
204,790  
-
5,068  
1,008,898  
52,652  
301,892  
328,467  
204,790  
1,896,699  
The Group has not renegotiated any material collection/repayment terms of any financial assets in the current financial year.  
An analysis of trade receivables that are past due and, where required, the associated provision for impairment is as follows. All other  
financial assets are less than 30 days overdue.  
Trade receivables which are:  
Provision for  
Not impaired  
$’000  
Impaired  
$’000  
impairment  
For the year ended 30 June 2011  
$’000  
Trade and other receivables:  
current but not overdue  
515,213  
52,223  
56,686  
87,353  
-
-
less than 30 days overdue  
-
-
-
-
more than 30 but less than 90 days overdue  
more than 90 days overdue  
22,891  
22,891  
22,891  
22,891  
711,475  
For the year ended 30 June 2010  
Trade and other receivables:  
current but not overdue  
580,935  
40,405  
51,810  
128,313  
-
-
less than 30 days overdue  
-
-
-
-
more than 30 but less than 90 days overdue  
more than 90 days overdue  
25,615  
25,615  
25,615  
25,615  
801,463  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
123  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
34 Financial Risk Management Objectives and Policies (continued)  
Financial assets are considered impaired where there is objective evidence that the Group will not be able to collect all amounts due  
according to the original trade and other receivable terms. Factors considered when determining if an impairment exists include aging and  
timing of expected receipts and the credit worthiness of counterparties. A provision for impairment is created for the difference between  
the assets carrying amount and the present value of estimated future cash flows. The Group’s trading terms do not generally include the  
requirement for customers to provide collateral as security for financial assets.  
During the year CSL Behring MEPE received zero coupon government bonds issued by the Greek government in settlement of €53.0m of  
trade receivables. Prior to the recognition of the bonds as a financial asset, the group recorded a provision for doubtful debts equal to the  
difference between the nominal value of the bonds and their estimated market value. During the financial year, €33.7m of bonds were  
traded at discounts ranging between 10% and 50% of the nominal value of the bonds. The remaining bonds held by the Group at 30 June  
2011 have been classified as an Available-for-sale Financial Asset in the balance sheet and are carried at fair value. The difference between  
the fair value at balance date and the fair value on initial recognition of the bonds has been reflected in Other Comprehensive Income. The  
proceeds from the sale of bonds have been recognised in cash flows from operations.  
Funding and liquidity risk  
Funding and liquidity risk is the risk that CSL cannot meet its financial commitments as and when they fall due. One form of this risk is  
credit spread risk which is the risk that in refinancing its debt, CSL may be exposed to an increased credit spread (the credit spread is the  
margin that must be paid over the equivalent government or risk free rate or swap rate). Another form of this risk is liquidity risk which is  
the risk of not being able to refinance debt obligations or meet other cash outflow obligations at any reasonable cost when required.  
Liquidity and re-financing risks are not significant for the Group, as CSL has a prudent gearing level and strong cash flows. The focus on  
improving operational cash flow and maintaining a strong balance sheet mitigates refinancing and liquidity risks enabling the Group to  
actively manage its capital position.  
CSL’s objectives in managing its funding and liquidity risks include ensuring the Group can meet its financial commitments as and when  
they fall due, ensuring the Group has sufficient funds to achieve its working capital and investment objectives, ensuring that short-term  
liquidity, long-term liquidity and crisis liquidity requirements are effectively managed, minimising the cost of funding and maximising the  
return on any surplus funds through efficient cash management, and ensuring adequate flexibility in financing to balance short-term  
liquidity requirements and long-term core funding, and minimise refinancing risk.  
The below table shows the profile of financial liabilities:  
Maturing in  
Over 1 year  
1
year or less  
$’000  
to 5 years  
Over 5 years  
$’000  
Total  
$’000  
Consolidated Group – June 2011  
$’000  
Financial Liabilities  
Trade and other payables  
Bank loans – unsecured  
Bank overdraft – unsecured  
Senior unsecured notes  
Lease liabilities  
493,506  
209,039  
584  
3,983  
-
497,489  
209,039  
584  
-
-
-
-
13,697  
2,894  
162,926  
8,866  
-
-
18,238  
-
176,623  
29,998  
5,054  
Other financial liabilities  
5,054  
724,774  
175,775  
18,238  
918,787  
Consolidated Group – June 2010  
Financial Liabilities  
Trade and other payables  
Bank loans – unsecured  
Bank overdraft – unsecured  
Senior unsecured notes  
Lease liabilities  
485,403  
-
-
196,984  
-
-
485,403  
196,984  
6,554  
-
6,554  
16,312  
3,118  
1,991  
-
207,159  
11,130  
-
-
20,946  
-
223,471  
35,194  
1,991  
Other financial liabilities  
513,378  
415,273  
20,946  
949,597  
124  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
34 Financial Risk Management Objectives and Policies (continued)  
Fair values  
With the exception of certain of the Group’s financial liabilities as disclosed in the table below, the remainder of the Group’s financial assets and  
financial liabilities have a fair value equal to the carrying value of those assets and liabilities as shown in the Group’s balance sheet. There are no  
unrecognised gains or losses in respect to any financial asset or financial liability.  
Carrying  
amount  
Fair  
Carrying  
amount  
Fair  
Value  
Value  
2
011  
2011  
2010  
2010  
Consolidated Group  
$’000  
$’000  
$’000  
$’000  
Financial Liabilities  
Interest bearing liabilities and borrowings  
Unsecured bank loans  
209,039  
176,623  
209,039  
176,739  
196,984  
223,471  
196,886  
223,958  
Unsecured notes  
The following methods and assumptions were used to determine the net fair values of financial assets and liabilities:  
Trade and other receivables / payables  
The carrying value of trade and other receivables/payables with a remaining life of less than one year is deemed to reflect its fair value.  
Other financial assets – derivatives  
Forward exchange contracts are ‘marked to market’ using listed market prices.  
Other financial assets – available-for-sale financial assets  
Fair value is calculated using quoted prices in active markets.  
Other financial assets – other  
Fair value is estimated using valuation techniques including recent arm’s length transactions of like assets, discounted cash flow analysis and  
comparison to fair values of similar financial instruments.  
Interest bearing liabilities and borrowings  
Fair value is calculated based on the discounted expected future principal and interest cash flows.  
Interest bearing liabilities and borrowings – finance leases  
The fair value is estimated as the present value of future cash flows, discounted at market interest rates for homogeneous lease agreements.  
The estimated fair values reflect change in interest rates.  
Capital Risk Management  
The Group’s objectives when managing capital are to safeguard their ability to continue as a going concern whilst providing returns to  
shareholders and benefits to other stakeholders. The Group aims to maintain a capital structure which reflects the use of a prudent level of  
debt funding so as to reduce the Group’s cost of capital without adversely affecting either of their credit ratings.  
Each year the Directors determine the dividend taking into account factors such as liquidity and the availability of franking credits. The full  
year dividend, as disclosed in note 23, represents a payout ratio of 46% of Net Profit after Tax.  
During the 2011 financial year, the parent company completed a $900m buyback, in total 26,063,169 ordinary shares were purchased.  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
125  
CSL Limited and its Controlled Entities  
Notes to the Financial Statements continued  
For the Year Ended 30 June 2011  
Consolidated Group  
011  
000  
2
$
2010  
$000  
35 Information relating to CSL Limited (‘the parent entity’)  
(a) Summary financial information  
The individual financial statements for the parent entity show the following aggregate amounts:  
Current assets  
Total assets  
460,973  
2,299,084  
516,663  
2,288,354  
4,089,043  
1,805,821  
1,823,799  
Current liabilities  
Total liabilities  
544,413  
Issued capital  
253,896  
88,443  
1,139,228  
73,351  
Share based payments reserve  
Retained earnings  
1,412,332  
1,052,665  
2,265,244  
1
,754,671  
Profit or loss for the year  
794,879  
795,549  
759,431  
759,978  
Total comprehensive income  
(
b) Guarantees entered into by the parent entity  
The parent entity provides certain financial guarantees in the ordinary course of business. No liability has been recognised in relation to  
these guarantees as the fair value of the guarantees is immaterial. These guarantees are mainly related to debt facilities of the Group.  
In addition the parent entity provides guarantees to some subsidiaries in respect of certain receivables from other group companies.  
(c) Contingent liabilities of the parent entity  
The parent entity did not have any contingent liabilities as at 30 June 2011 or 30 June 2010. For information about guarantees given by  
the parent entity, please refer above.  
(
d) Contractual commitments for the acquisition of property, plant or equipment  
Capital expenditure contracted for at balance date but not provided for in the financial statements, payable:  
Not later than one year  
33,965  
23,793  
Later than one year but not later than five years  
-
-
-
-
Later than five years  
33,965  
23,793  
36 Subsequent events  
Other than as disclosed elsewhere in these statements, there are no matters or circumstances which have arisen since the end of the  
financial year which have significantly affected or may significantly affect the operations of the Group, results of those operations or the  
state of affairs of the Group in subsequent financial years.  
126  
CSL Limited and its Controlled Entities  
Directors’ Declaration  
1. In the opinion of the Directors:  
(a) the financial report, and the remuneration report included in the directors’ report of the company and of the  
Group are in accordance with the Corporations Act 2001, including:  
(i) giving a true and fair view of the company’s and Group’s financial position as at 30 June 2011 and of their  
performance for the year ended on that date;  
(ii) complying with Australian Accounting Standards and Corporations Regulations 2001; and  
(iii) complying with International Financial Reporting Standards as issued by the International Accounting Standards  
Board.  
(
b) there are reasonable grounds to believe that the company will be able to pay its debts as and when they become  
due and payable.  
2. This declaration has been made after receiving the declarations required to be made to the directors in accordance  
with section 295A of the Corporations Act 2001 for the financial period ended 30 June 2011.  
3
. In the opinion of the Directors, as at the date of this declaration, there are reasonable grounds to believe that the  
members of the Closed Group identified in note 33 will be able to meet any obligations or liabilities to which they are  
or may become subject, by virtue of the Deed of Cross Guarantee dated 28 June 2007.  
This declaration is made in accordance with a resolution of the directors.  
Elizabeth A Alexander  
Chairman  
Brian A McNamee  
Managing Director  
Melbourne  
17 August 2011  
CSL Limited  
Annual Report 2010-2011  
Financial Report  
127  
Independent Auditor’s Report  
Independent auditor’s report  
to the members of CSL Limited  
Report on the financial report  
We have audited the accompanying financial report of CSL Limited, which comprises the consolidated  
balance sheet as at 30 June 2011, the consolidated statement of comprehensive income, the  
consolidated statement of changes in equity and the consolidated cash flow statement for the year then  
ended, notes comprising a summary of significant accounting policies and other explanatory information,  
and the directors’ declaration of the consolidated entity comprising the company and the entities it  
controlled at the year’s end or from time to time during the financial year.  
Directors’ responsibility for the financial report  
The directors of the company are responsible for the preparation of the financial report that gives a true  
and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for  
such internal controls as the directors determine are necessary to enable the preparation of the financial  
report that is free from material misstatement, whether due to fraud or error. In Note 1, the directors also  
state, in accordance with Accounting Standard AASB 101 Presentation of Financial Statements, that the  
financial statements comply with International Financial Reporting Standards.  
Auditor’s responsibility  
Our responsibility is to express an opinion on the financial report based on our audit. We conducted our  
audit in accordance with Australian Auditing Standards. Those standards require that we comply with  
relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain  
reasonable assurance about whether the financial report is free from material misstatement.  
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in  
the financial report. The procedures selected depend on the auditor’s judgment, including the assessment  
of the risks of material misstatement of the financial report, whether due to fraud or error. In making  
those risk assessments, the auditor considers internal controls relevant to the entity’s preparation and  
fair presentation of the financial report in order to design audit procedures that are appropriate in the  
circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s  
internal controls. An audit also includes evaluating the appropriateness of accounting policies used and  
the reasonableness of accounting estimates made by the directors, as well as evaluating the overall  
presentation of the financial report.  
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for  
our audit opinion.  
Independence  
In conducting our audit we have complied with the independence requirements of the Corporations Act  
2001. We have given to the directors of the company a written Auditor’s Independence Declaration, a  
copy of which is included in the directors’ report.  
Liability limited by a scheme approved  
under Professional Standards Legislation  
128  
Independent Auditor’s Report  
Opinion  
In our opinion:  
a. the financial report of CSL Limited is in accordance with the Corporations Act 2001, including:  
i
giving a true and fair view of the consolidated entity’s financial position as at 30 June 2011  
and of its performance for the year ended on that date; and  
ii complying with Australian Accounting Standards and the Corporations Regulations 2001; and  
b. the financial report also complies with International Financial Reporting Standards as disclosed in  
Note 1.  
Report on the remuneration report  
We have audited the Remuneration Report included in Section 18 of the directors’ report for the  
year ended 30 June 2011. The directors of the company are responsible for the preparation and  
presentation of the Remuneration Report in accordance with section 300A of the Corporations Act  
2001. Our responsibility is to express an opinion on the Remuneration Report, based on our audit  
conducted in accordance with Australian Auditing Standards.  
Opinion  
In our opinion, the Remuneration Report of CSL Limited for the year ended 30 June 2011, complies  
with section 300A of the Corporations Act 2001.  
Glenn Carmody  
Partner  
Melbourne  
17 August 2011  
Designed and produced by  
Fidelis Design Associates, Melbourne.  
This report is printed on Impact, made with  
a carbon neutral manufacturing process,  
consisting of 100% certified post consumer  
waste fibre. It is FSC certified and has been  
made in a facility that operates under the  
ISO14001 Environmental Management  
System. It is printed by a ISO 14001EMS  
&
ISO 9001 quality management system  
certified printer, which holds Sustainability  
Victoria Wastewise Gold accreditation, is  
FSC Chain of Custody certified and printed  
on an ecologically rated printing press using  
a chemical recirculation system and  
vegetable based inks.  
Legalꢀnotice: This report is intended for  
global use. Some statements about products  
or procedures may differ from the licensed  
indications in specific countries. Therefore,  
always consult the country-specific product  
information, package leaflets or instructions  
for use. For more information, please contact  
a local CSL representative. This report covers  
CSL’s global operations, including subsidiaries,  
unless otherwise noted and a reference to CSL  
is a reference to CSL Limited and its related  
bodies corporate. The matters discussed in this  
report that are not historical facts are forward-  
looking statements, including statements  
with respect to future company compliance  
and performance. These statements involve  
numerous risks and uncertainties. Many factors  
could affect the company’s actual results,  
causing results to differ, possibly materially,  
from those expressed in the forward looking  
statements. These factors include actions of  
regulatory bodies and other governmental  
authorities; the effect of economic conditions;  
technological developments in the healthcare  
field; advances in environmental protection  
processes; and other factors. CSL disclaims  
any obligation to update any forward-looking  
statements.  
®
Brand names designated by a or a  
throughout this publication are trademarks  
either owned by and/or licensed to CSL or its  
affiliates. Not all brands mentioned have been  
approved in all countries served by CSL.  
CSL Limited ABN 99 051 588 348  
Corporate Directory  
Registered Head Office  
Share Registry  
Auditors  
CSL Limited  
Computershare ꢁnvestor  
Services ꢀty Limited  
Ernst & Young  
45 Poplar Road  
Ernst & Young Building  
8 Exhibition Street  
Melbourne  
Parkville  
Victoria 3052  
Australia  
Yarra Falls  
452 Johnston Street  
Abbotsford VIC 3067  
Victoria 3000  
Phone: +61 3 9389 1911  
Fax: +61 3 9389 1434  
GPO Box 2975  
Melbourne  
GPO Box 67  
Melbourne Victoria 3001  
Victoria 3001  
www.csl.com.au  
Phone: +61 3 9288 8000  
Fax: +61 3 8650 7777  
Enquiries within Australia: 1800 646 882  
Enquiries outside Australia: +61 3 9415 4178  
Investor enquiries facsimile: +61 3 9473 2500  
Website: www.investorcentre.com  
Further Information  
For further information about CSL and its  
operations, refer to Company announcements  
to the Australian Securities Exchange and our  
website:  
www.csl.com.au  


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission